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Abstract 
 
Muscle wasting and increased proteolysis is a major problem in chronic kidney disease (CKD). 
Exercise is potentially beneficial, but has been under-investigated in pre-dialysis CKD and could 
theoretically worsen acidosis through exercise-induced lactic acid generation. We therefore 
investigated effects of 6 months walking exercise with and without additional alkali therapy. 40 
patients were recruited (23 male and 17 female, median age 58, range 20-83, mean eGFR±SEM 
25.7±1.2ml/min/1.73m2). 20 undertook walking exercise at a Borg Rating of Perceived Exertion 
Rate (RPE) of 12-14 for at least 30 minutes, 5 times a week. The other 20 continued with normal 
physical activity (non-exercising controls). In addition to standard oral bicarbonate therapy 
(STD), 10 patients in each group were randomised to receive additional bicarbonate (XS). Blood 
and vastus lateralis muscle biopsies were drawn at baseline, one and six months. 18 exercisers 
(including 8 in XS group) and 14 controls (6 in XS group) completed the 6 month study.  
 
Exercise tolerance increased after 1 and 6 months in the exercisers, but not the controls, 
accompanied by a reduced acute lactate response in the XS, but not the STD exercising group. 
After 6 months of exercise, 9 intramuscular free amino acids showed striking depletion in the 
STD, but not XS bicarbonate group. This suggests an inhibition of active amino acid 
transporters, possibly the SNAT2 transporters that are inhibited by acidosis. Studies with 
cultured myotubes identified glucocorticoid as a possible mediator of acid’s inhibitory effect on 
SNAT2. 
The preservation of amino acid  concentrations in the XS exercising group was accompanied by 
strong suppression of ubiquitin E3-ligases MuRF-1 and MAFbx which activate proteolysis 
through the ubiquitin-proteasome pathway. However, other anabolic indicators (Protein Kinase B 
activation and suppression of the 14kDa actin fragment) were unaffected in the exercising XS 
group. Possibly because of this, overall suppression of myofibrillar proteolysis (3-methyl 
histidine excretion) and increased lean body mass (DEXA) were not observed in the exercising 
patients. As XS alkali had no effect in non-exercisers, it is concluded that alkali effects in the 
exercisers arose by countering exercise-induced acidosis.  
 
Sulphuric acid produced from the catabolism of sulphur-containing amino acids ingested in the 
diet is the main contributor to the daily titratable acid load and hence acidosis in CKD. In these 
patients the amount of sulphate excreted in urine over 24h varied widely between individuals. 
This directly correlated with 3-methyl histidine excretion suggesting that sulphate excretion may 
be a better clinical indicator of acidotic patients at long-term risk of cachexia than conventional 
measures such as venous bicarbonate. Studies with cultured myotubes confirmed that skeletal 
muscle is a source of sulphuric acid and showed that production of this acid is partly suppressed 
by L-Glutamine – a potential novel way to control acidosis in CKD.  
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1.1 Basic muscle physiology 
A skeletal muscle such as rectus femoris, is surrounded by a layer of fascia and contains fascicles 
(bundles of fibres). Muscle fibres are long, cylindrical, multinucleated cells that lie with their 
long axes in parallel surrounded by a membrane called the sacrolemma and by a thin sheath of 
fibrous tissue called the endomysium that divides muscle into individual myofibrils (Figure 1.1). 
The intracellular structure of a muscle fibre contains sarcoplasm, mitochondria, myoglobin, and 
the main contractile element of muscle, the myofibrils that vary in length from only a few 
millimetres to over 30cm laid end to end and are surrounded by an extensive sarcoplasmic 
reticulum (Maughan et al. 1997a; Silverthorn, 2001a) (Figure 1.2). A muscle can contain a 
thousand or more myofibrils (Silverthorn, 2001a) that are made up of a continuous series of 
sarcomeres (contractile units of muscle) and have a striated appearance that can be seen by light 
microscopy, comprising alternating light and dark bands caused by the arrangement of the 
myofilaments in each repeating sarcomere (demonstrated in Figure 1.2). The myofilaments 
overlap each other to a lesser or greater extent depending on whether the muscle is relaxed or 
contracted. The light band is represented in this diagram by the I band and comprises the thin 
filament actin and two regulatory proteins troponin and tropomyosin that all extend part way into 
the A band, the dark band. The A band contains the thick filament myosin and is the only 
filament to be found in the H zone (Maughan et al. 1997a; Silverthorn, 2001a). 
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Figure 1.1. Skeletal muscle anatomy. Described in the text in Section 1.1. 
Diagram copied from Maughan et al. (1997a), Pg 2.  
 
 
Figure 1.2. Muscle fibre ultrastructure 
Diagram copied from Maughan et al. (1997a), Pg2. 
 
Actin in its monomeric form is a globular protein (G-actin) and usually polymerizes to form long 
chains or filaments of fibrous actin (F-actin) and two F-actin molecules twist together to form a 
helix, creating the thin filaments. The myosin molecule has two globular heads, a neck with an 
elastic hinge region that allows the head to swivel around the point of attachment, and a tail 
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region. The globular head has ATPase activity and the ability to bind actin. Each myosin 
molecule comprises two heavy protein chains that intertwine to form a coiled tail, and a pair of 
heads protruding in opposite directions. The thick filaments are arranged so that the myosin 
heads are clustered at the ends and the middle portion (H zone) contains the myosin tails. The 
myosin molecules are anchored to the Z line by titin, acting to stabilise these filaments (Tortora 
and Grabowski, 1996a).  
 
1.2 Muscle contraction 
Individual muscle fibres are usually innervated by just one nerve that excites skeletal muscle 
through the release of acetylcholine across the motor end plate, ultimately causing the release of 
Ca2+ from the sarcoplasmic reticulum. Ca2+ is bound by troponin C, altering the troponin-
tropomyosin complex and thereby displacing tropomoysin from the actin binding site on the 
myosin molecule allowing crossbridge formation to occur. This binding of myosin to the actin 
molecule results in the myosin head changing from its activated configuration to its ‘cocked’ 
shape causing the myosin heads to pull on the thin filament and the filaments to slide past each 
other. This is known as the power stroke and releases ADP and inorganic phosphate (Pi) (from 
the prior hydrolysis or ATP) from the myosin head.  A new ATP molecule can then bind, 
reducing the affinity of myosin for actin binding and causing detachment of the crossbridge. The 
ATP is then hydrolysed, returning the myosin head to its activated state in which it is able to 
bind another actin molecule further along the filament. This cycle repeats many times in the 
presence of Ca2+. In the relaxed state, Ca2+ is sequestered from the sarcoplasm back into the 
sarcoplasmic reticulum via the ATP dependent calcium pump, returning the troponin-
tropomyosin complex to its inhibitory position blocking cross bridge formation (Tortora and 
Grabowski, 1996a). 
 
1.3 Muscle buffering systems 
During high intensity exercise, lactic acid produced by anaerobic glycolysis dissociates to lactate 
and H+ resulting in a fall in intracellular pH. Skeletal muscle has a large buffering capacity (βm) 
that reduces the rate of intracellular pH decrements therefore delaying fatigue. A high βm is 
associated with good sprinting performance and it appears it can be increased with training 
(Weston et al. 1997).  
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In humans, the main skeletal muscle buffering systems are; the bicarbonate buffer system , and 
intramuscular phosphates, protein bound Histidine and Histidine containing dipeptides 
(carnosine, anserine and balenine) which make up the non-bicarbonate system (Bishop et al. 
2009).  In humans there is no balenine in skeletal muscle and anserine is only found in very low 
concentrations and so the most important dipeptide in muscle buffering in humans is carnosine 
(Abe, 2000). 
 
Skeletal muscle cells have a high concentration of phosphate related compounds, which have a 
very high capacity of buffering H+ and contribute approximately 20% to the non-bicarbonate 
buffering system (Hultman and Sahlin, 1980). Proteins containing Histidine residues have been 
suggested to contribute about 30-70% to the total muscle buffering capacity (Abe, 2000; 
Hultman and Sahlin, 1980). The majority of protein involved in skeletal muscle buffering is 
soluble proteins with little involvement from contractile proteins (Abe, 2000). Histidine is the 
only amino acid that is capable of exerting a buffering function in the physiological pH, owing to 
the imidazole side ring found in Histidine residues. Imidazole groups are potent buffering 
constituents as they have a pK value that is close to physiological pH and so one of the two 
nitrogen molecules of this group can be protonated in the physiological pH range (Abe, 2000).  
 
It has been suggested that free Histidine contributes little to the βm as it is in low concentration 
in skeletal muscle (Parkhouse and McKenzie, 1984) and Histidine containing dipeptides might 
be more important due to their larger intramuscular concentration (Bergström et al. 1974). A role 
for carnosine was established by Smith in 1938 who demonstrated that the imidazole side ring 
had a pKa of 6.83, which made it a suitable buffer at physiological pH. Carnosine is a dipeptide 
that is synthesised in skeletal muscle from β-alanine and L-Histidine catalysed by carnosine 
synthase (Sale et al. 2010). A role for carnosine in intramuscular buffering was first 
demonstrated by early studies in fish (Abe, 2000) Whilst the intramuscular concentration of 
carnosine is lower in humans compared to other species, with reported values in the vastus 
lateralis of 16-20 mmol/kg dw (Harris et al. 1990) these concentrations do vary between fibre 
types and can be changed with training. Carnosine concentrations have been observed to be 
twice as high in type II fibres compared to type I (Harris et al. 1998) and Parkhouse and 
collegues (1985) found the vastus lateralis carnosine content was higher in sprinters and rowers 
than in marathon runners and untrained individuals and Suzuki et al. (2002) found a significant 
correlation between carnosine concentration and power output in a wingate test. Furthermore, 
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Hill et al. (2007) showed that 10 weeks of β-alanine supplementation resulted in an 80% increase 
in muscle carnosine and a significant improvement in cycling capacity at 110% peak power 
output. Taken together, this evidence suggests muscle carnosine might be an important factor in 
determining performance during high intensity exercise and plays an important role in skeletal 
muscle buffering capacity. 
 
1.4 Basic renal physiology 
1.4.1 Renal anatomy 
The two kidneys are located either side of the spine between the posterior wall of the abdominal 
cavity and the peritoneum at the level of the eleventh and twelfth ribs (Tortora and Grabowski, 
1996b). They are about 10cm long and 5cm wide, weigh approximately 150g, are bean shaped 
and are encased in a fibrous outer capsule called the renal capsule.  The interior of the kidney is 
arranged in two layers, the outer cortex and the inner medulla. The outer cortex contains the 
renal corpuscle (made up of the glomerulus surrounded by Bowman’s capsule), renal tubules, 
cortical collecting ducts and vasculature. The medulla contains pyramids of straight tubules 
(medullary pyramids). The apex of each pyramid forms a papilla, which drains urine into the 
minor calyx then the major calyx (Kriz and Elger, 2007) followed by the renal pelvis and finally 
the proximal ureter which transports urine to the bladder. 
 
Figure 1.3. Cross section through a kidney 
Figure copied from Kriz and Elger, (2007), Pg 1. 
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The nephron is the functional unit of the kidney and regulates salt and water balance through 
excretion and reabsorption. The nephron consists of the renal corpuscle (glomerulus and 
Bowman’s capsule), the proximal tubule, loop of Henle, distal convoluted tubule and the 
collecting duct. A healthy kidney usually contains approximately 1 million nephrons (Shirley et 
al. 2007). There are two types of nephron, which are classified according to the location of the 
renal corpuscle. Cortical nephrons have their renal corpuscle in the outer renal cortex and have 
very short loops of Henle. Juxtamedullary nephrons have their renal corpuscle in the medulla and 
have long loops of Henle that extend deep into the medulla (Lote, 1990). 
Renal blood flow is approximately 1200mL/min receiving approximately 20-25% of the cardiac 
output (Tortra and Grabowski, 1996b) and of this, 125-130mL of plasma is filtered into 
Bowman’s capsule every minute resulting in the production of primary urine. Blood flow to the 
kidney is usually through a single renal artery entering the kidney at the renal hilus. The renal 
artery branches to form interlobar arteries which enter the renal cortex and branch further into 
afferent arterioles. Each nephron receives blood through one afferent arteriole which divides to 
form the glomerulus (Lote, 1990). Here water and salts are filtered out of the capillary and into 
the lumen of the tubule, passing along the length of the nephron until, at the end, the remaining 
filtrate is excreted as urine. The blood leaves the glomerulus and passes into an efferent arteriole 
and passes into a network of peritubular capillaries and vasa recta which surround the renal 
tubules. Any filtrate that is reabsorbed from the lumen, returns to the circulation through these 
capillaries. Eventually these capillaries drain to the renal vein that leaves the kidney through the 
renal hilus. 
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Figure 1.4. Nephrons and the collecting duct of the kidney 
Figure copied from Kriz and Elger (2007), Pg 1. 
 
1.4.2 Function of the kidney 
The main function of the kidneys is to maintain homeostatic regulation of the water and ion 
content of the blood by balancing reabsorption and excretion of solutes to maintain fluid and 
electrolyte balance. They also serve in the regulation of osmolarity and acid-base balance, 
excretion of waste and foreign materials, and production and secretion of hormones.  
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1.4.3 Renal processes 
The three processes of the kidney are filtration, secretion and reabsorption. Filtration occurs at 
the renal corpuscle in the cortex of the kidney and the processes of reabsorption and secretion 
occur in the tubules. 
 
1.4.4 Glomerular filtration 
Filtration is a relatively non-specific process creating an ultrafiltrate of the plasma containing 
water and dissolved salts and is almost protein free. A normal glomerular filtration rate is 
125ml/min producing 180L/day of primary filtrate. Blood pressure forces water and small 
solutes out of the capillary through three barriers, the endothelial fenestrations, the basement 
membrane and the slit diaphragms of the podocytes (glomerular epithelial cells). The resulting 
solution enters Bowman’s capsule and becomes glomerular filtrate. The molecular size, along 
with shape and charge of the molecule, is the main determinant as to whether a molecule is 
filtered into Bowman’s capsule, or remains in the glomerular capillaries (Lote, 1990). 
 
1.4.5 Components of the glomerular filtration barrier 
The first of these barriers is the layer of flattened endothelial cells of the fenestrated glomerular 
capillaries. This fenestrated area covers 20-50% of the endothelial cell surface and allows high 
permeability to water and small solutes.  The filter allows the free movement of molecules up to 
a molecular weight of 7000Da and molecules up to a weight of 70000Da can be filtered. (Lote, 
1990) There is much controversy over the importance of this barrier in the selective filtration 
process due to uncertainty over the effective size of the fenestrae (Haraldsson et al. 2008). By 
microscopy these appear large enough to allow the filtration of serum albumin. However, recent 
evidence indicates that the fenestrae may be an important barrier, due to the cell coat that fills the 
fenestrae i.e the glycocalyx that contains negatively charged proteoglycans, glycosaminoglycans 
and plasma proteins that tend to repel plasma proteins (Haraldsson and Sörensson, 2004). The 
thick basement membrane of the glomerulus (GBM) is the second barrier to filtration and was 
formerly considered to be the most important barrier (Lote, 1990). It forms a continuous layer 
allowing filtration of molecules depending upon the molecules’ size, shape and charge. It lies in 
between the glomerular endothelium and the epithelial lining of Bowman’s capsule. It contains 
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collagen like protein and negatively charged proteoglycans (Silverthorn, 2001b). Recent findings 
suggest the GBM lacks charge selectively and is therefore not such an important contributor to 
selective filtration (Haraldsson and Sörensson, 2004). The final layer to the filtration barrier is 
the epithelium of Bowman’s capsule containing specialized epithelial cells called podocytes. The 
podocyte is now regarded as the most important barrier in maintaining selective permeability 
(Haraldsson and Sörensson, 2004), as failure of the podocyte is associated with proteinuria, 
initiation of progressive renal disease and the maintenance of progression to end stage renal 
failure (Pavenstädt et al. 2003). Podocytes have long foot-like processes projecting from the cell 
body called pedicels. These processes encircle the basement membrane of the glomerulus and 
processes of adjacent podocytes interdigitate, creating filtration slits that are bridged by the slit 
diaphragm. The slit diaphragm has recently been discovered to contain many specialised 
proteins, one of which is nephrin, and mutations in this protein have been found to give rise to 
severe proteinuria and congenital nephritic syndrome of the Finnish type (Kestila et al. 1998). 
The slit diaphragm and luminal membrane are covered by sialoglycoproteins giving the 
podocytes a strong negative charge and preventing the movement of medium sized molecules 
(Pavenstädt et al. 2003). 
 
1.4.6 Tubular reabsorption and secretion  
Approximately 180L of plasma are filtered each day and most of this volume is reabsorbed by 
processes which vary along the length of the nephron. Transport processes within the nephron 
includes simple and facilitated diffusion and primary or secondary active transport processes. 
Passive transport is allowed by the concentration gradient that is maintained by the Na+, K+-
ATPase pump on the basolateral membrane. 
 
The bulk of the filtered Na+, Cl-, K+ and HCO3- are reabsorbed at the proximal tubule facilitated 
by the microvilli on the apicial surface of the epithelial cells which create a large surface area for 
reabsorption. The concentration of Na+ in the filtrate is approximately 140mmol/l and is much 
lower in the cytosol of the epithelial cells favouring movement of Na+ from the tubule into the 
cell through open leak channels. Approximately 20% enters the peritubular interstitium via Na+ 
pumps on the basolateral membrane whilst the remaining re-enters the tubule via tight junctions 
(paracellular pathways) (Shirley et al. 2007). The secretion of H+ into the lumen plays an 
important role in the reabsorption of HCO3- (see Section 1.5 for more detail). The walls of the 
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proximal tubule are highly permeable to water and approximately 60% of the filtered water is 
reabsorbed here by diffusion due to the decrease in osmolarity in the tubular lumen following 
solute reabsorption. There is also near complete reabsorption of glucose, amino acids and low 
weight molecular proteins that were able to cross the glomerular barrier. This water reabsorption 
results in a concentration gradient down which Cl-, K+ and urea diffuse via paracellular 
pathways. Glucose and amino acids are co-transported with Na+ into the epithelial cell against 
their concentration gradient and diffuse into the peritubular interstitium. Small proteins enter the 
epithelial cell by endocytosis and are digested inside the cell and released as amino acids 
(Shirley et al. 2007). 
 
As the filtrate reaches the loop of Henle, the majority of the reabsorption of water and solutes has 
already taken place. Approximately 25% of the filtered water is reabsorbed in the thin 
descending limb, which is freely permeable to water, but relatively impermeable to Na+. Na+ is 
reabsorbed by the Na+-K+-2Cl- active transporter in the thin ascending limb that is impermeable 
to water. The U shape of the loop of Henle and the differences in the permeability of the limbs to 
water and Na+ are responsible for the countercurrent multiplier which generates the medullary 
osmotic gradient (Shirley et al. 2007). 
 
The distal nephron and collecting duct are responsible for the reabsorption of the remaining Na+ 
and K+ via active transport mechanisms in the principal cells. These sections of the nephron are 
permeable to water in the presence of vasopressin that increases permeability by the insertion of 
channels (aquaporins) into the apical membrane in response to substrate receptor binding, 
allowing the diffusion of water out of the tubule. Ca2+reabsorption here is regulated by 
parathyroid hormone (PTH) and vitamin D. The presence of PTH activates Ca2+ channels in the 
apical membrane and a Ca2+-ATPase pump on the basolateral membrane. The intercalated cells 
in the late distal tubule secrete H+ or HCO3- into the filtrate that becomes final urine (Shirley et 
al. 2007). 
 
 
1.5 Acid-base balance 
Acid-base balance or pH homeostasis is an essential regulatory process of the body maintaining 
H+ concentration at an acceptable level, which in a healthy individual, leads to an arterial plasma 
pH within the range 7.35-7.45 (Tortora and Grabowski, 1996c). A conventional western diet is 
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high in protein and sulphur amino acids that, when metabolised, produce sulphuric acid (Suliman 
et al. 1996) and result in the generation of 40-70mEq of H+ per day (Sebastian et al. 2002). This 
must be buffered, as deviations from the acceptable pH range would denature proteins and 
disrupt normal body processes (Silverthorn, 2001c). The body has three mechanisms by which to 
eliminate acid from the body: buffers in the blood that are able to respond very quickly to 
changes in pH, respiratory responses that deal with 75% of the generated acid, and finally, the 
renal system. The renal system is much slower that the other two, but is capable of dealing with 
any remaining disturbance to pH. The main focus here will be the role of the kidneys in 
maintaining acid-base balance. 
 
Non-volatile acid (acid produced from sources other than carbon dioxide, for example lactic acid 
and sulphuric acid), is not eliminated by the lungs and is buffered quickly in the blood by 
bicarbonate (HCO3-), producing water and carbon dioxide, the concentration of which does not 
change from the level set and maintained by respiratory control. The function of the kidney is to 
excrete titratable acid, to regenerate bicarbonate that is lost in this process, and to reabsorb the 
filtered load of HCO3- (Koeppen, 2009). 
 
The reabsorption of HCO3- occurs primarily in the proximal tubule, with the remainder being 
reabsorbed at the thick ascending loop of Henle and a small proportion by the colleting duct 
(Koeppen, 2009).  Filtered bicarbonate is unable to cross the apical membrane of the proximal 
tubular cell (PTC), so in order to be reabsorbed it combines with H+ which is secreted into the 
lumen by the apical Na+-H+ antiporter in exchange for a filtered Na+, to form carbonic acid 
(H2CO3). Carbonic anhydrase (CA) IV present in the brush border catalyses the dissociation of 
H2CO3 to H2O and CO2. These readily diffuse across the apical membrane into the tubular 
epithelial cell where, under the influence of CA II, CO2 is hydrated to produce HCO3- and H+. 
The H+ is secreted back into the lumen by the apical Na+-H+ antiporter repeating the cycle. Three 
molecules of HCO3- are transported out of the cell across the basolateral membrane with one 
molecule of Na+ via the Na+-HCO3- symporter. The low intracellular Na+ concentration in the 
proximal convoluted tubule (PCT) is maintained by the active Na+-K + ATPase sodium pump on 
the basolateral membrane that pumps 2K+ into the cell for every 3Na+ transported out of the cell. 
This sets up the concentration gradient between the cytosol and the tubular lumen that is utilised 
by the Na+-H+ antiporter on the apical membrane to bring 1 Na+ into the cell in exchange for 1  
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H+ secreted into the tubular lumen. The net result is the reabsorption of one HCO3- and one Na+ 
for every H+ secreted into the lumen (Silverthorn, 2001c; Koeppen, 2009). 
 
Although the reabsorption of the filtered load of HCO3- is an important process, it does not fully 
replace the HCO3- lost in the titration of acid, so new HCO3- must be generated through 
ammoniagenesis. This is the main mechanism by which the kidney regulates acid base balance, 
accounting for 90% for the acid excreted into the urine (Karim et al. 2005) and subsequent 
generation of HCO3-, a process that occurs in the PCT. Glutamine from the peritubular capillaries 
is deaminated to glutamate via glutaminase and then converted to α-ketoglutarate by glutamate 
dehydrogenase. Further catabolism of α-ketoglutarate results in the generation of two NH4+ and 
two HCO3- per molecule of glutamine. The new HCO3- exits the cell via the Na+- HCO3- 
symporter and enters the blood and NH4+ is secreted from the PTC via a Na+-H+ antiporter taking 
the place of H+ (Karim et al. 2005). Between 40-80% of the NH4+ is reabsorbed at the thick 
ascending loop of Henle via the Na+, K+(NH4+)2Cl- cotransporter, on which NH4+ is substituted 
for K+. NH4+ is also reabsorbed through movement along the paracellular pathway resulting in an 
accumulation of total ammonia (NH4+ and NH3) in the medullary interstitium. In order to 
successfully buffer H+, NH4+ must be excreted in the urine: if it returns to the blood, it will be 
metabolised by the liver to urea, generating H+. NH4+ is secreted back into the tubule at the 
collecting duct via NH4+-H+ antiporters and is excreted into the urine. The process of 
ammoniagenesis is up-regulated in metabolic acidosis resulting in a much larger ammonia 
excretion. This up-regulation is due to increased expression stimulated by acidosis of the 
mitochondrial enzymes glutaminase, glutamate dehydrogenase and cytosolic 
phosphoenolpyruvate carboxykinase (Karim et al. 2005). 
 
As the filtrate passes down the nephron, the reabsorption of water results in an increased 
concentration of the remaining HCO3-, which was not removed at the proximal tubule. The 
majority of this is reabsorbed at the thick ascending loop of Henle, by a similar process to that in 
the proximal tubule (Koeppen, 2009). The type A intercalated cells of the distal tubule reabsorb 
any remaining HCO3- in the form of CO2 and H2O as the result of H+ secretion into the tubule. 
These cells have a high concentration of CA converting CO2 into H+ and HCO3-, which leaves 
the cell via a HCO3-Cl- antiport exchanger on the basolateral membrane back into the blood and 
the remaining proton is secreted back into the lumen (Koeppen, 2009). Net acid excreted is equal 
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to the sum of titratable acid plus NH4+ excretion minus the loss of HCO3- in the urine. Free H+ 
accounts for very little of the excreted acid and is not included in this equation. 
 
 
1.6 Chronic Kidney Disease 
Normal kidney function is defined by a glomerular filtration rate (GFR) of approximately 
130ml/min for men and 120ml/min for women (Gul et al. 2007). Chronic Kidney Disease (CKD) 
is defined as kidney damage, or a reduction in GFR to <60ml/min for three months or more, 
irrespective of the initial cause (Kossi and Nahas, 2007) and is generally due to a reduction in the 
nephron number (Gul et al. 2007). CKD has been classified into five stages determined by GFR 
(Table 1.1) 
 
Table 1.1 Classification of Chronic Kidney Disease. Adapted from Kidney Disease Outcomes 
Quality Initiative (K/DOQI) guidelines (Kossi and Nahas, 2007). 
Stage Description Estimated GFR (ml/minute) Action 
1 Kidney damage , normal or increased GFR ≥90 
Diagnose and treat, 
slow progression 
2 Kidney damage with mild decrease in GFR 60-89 Estimate Progression 
3 Moderate decrease in GFR 30-59 Evaluate and treat complications 
4 Severe decline in GFR 15-29 Prepare for renal replacement therapy 
5 Kidney Failure or End Stage <15 Initiate renal replacement therapy 
 
The prevalence of CKD is increasing and it is now estimated that approximately 26 million 
Americans have been diagnosed with CKD, 13% of the population (Bronas, 2009). The 
prevalence of CKD is lower in the UK with an estimated 8.8% of the population suffering with 
symptomatic CKD (The Association of Public Health Observatories, 2009), but the number of 
patients reaching end stage renal failure increased by 4.4% from 2007-2008 (Farrington et al. 
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2008). The rise in prevalence is most likely due to an aging population and the type II diabetes 
mellitus epidemic that is occurring. The early stages of CKD are usually asymptomatic and for 
this reason it is not unusual that it remains undetected until progression occurs. The glomerular 
barrier prevents the filtration of high molecular weight proteins and any small proteins that are 
filtered are reabsorbed by the proximal tubule resulting in very small amounts of protein 
appearing in the urine. Detection of protein in the urine (proteinuria) is usually the first sign of 
CKD (D’Amico and Bazzi, 2003) indicating either damage to the glomerular barrier allowing 
filtration of larger protein molecules, or to the proximal tubules preventing the reabsorption of 
the smaller protein molecules. 
Hypertension, obesity, diabetes, hyperlipidaemia and smoking are all risk factors for 
development of CKD in the general population (Kossi and Nahas, 2007). Hypertension is one the 
main causes of progression of CKD, by the transference of systemic pressure to the glomerular 
capillary beds resulting in glomerular hypertension which causes glomerulosclerosis. Therefore 
blood pressure in these patients is kept under tight control to help slow this progression. The 
appearance of proteinuria (>500mg/day) is also associated with a faster progression to end stage 
renal failure which can be controlled by diet and angiotensin receptor blockers (Kossi and Nahas, 
2007). 
 
1.7 Metabolic acidosis 
Metabolic acidosis is reported in the majority of CKD patients when GFR declines to less than 
20-25% of normal i.e. CKD Stage 4 onwards. The degree of acidosis usually correlates with the 
severity of the renal failure (Kraut and Kurtz, 2005) and is the result of a reduced ability to 
excrete ammonia and titratable acids in the face of a reduced reabsorption and synthesis of 
bicarbonate (Cibulka and Racek, 2007). Metabolic acidosis is diagnosed when the plasma 
bicarbonate concentration decreases from the normal range of 24-30mmol/l to 12-22mmol/l. This 
decrease severely impairs the ability of the blood to buffer H+ quickly. As renal failure 
progresses to less than 15ml/minute there is an increase in anion gap acidosis due to a decrease 
in the excretion of non-volatile acid. This acidosis seen in advanced renal failure is termed 
uraemic metabolic acidosis (Cibulka and Racek, 2007). Metabolic acidosis has been identified as 
a uraemic toxin because correction results in the amelioration or elimination of many 
complications of CKD (Mitch, 2006), including a negative nitrogen balance and skeletal muscle 
wasting (Mitch, 2006; see Section 1.8), anorexia (Kovacic et al. 2003), bone disease (Lefebvre et 
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al. 1989), negative effects upon cardiac function including suppression of myocardial 
contractility (Marsiglia et al. 1973) and impaired peripheral vasoconstriction and dilation (Narins 
and Cohen, 1987). Sodium bicarbonate is a successful treatment of metabolic acidosis (Movilli et 
al. 2009), but is undesirable due to the associated sodium and water retention and possible 
exacerbation of hypertension (Kraut and Kurtz, 2005) in patients where blood pressure must be 
kept under tight control to help reduce progression of the renal disease. 
 
 
1.7.1 The source of the titratable acid load - sulphur metabolism 
The dominant contributor to the titratable (non-volatile) acid load, whose excretion fails in 
uraemic metabolic acidosis, is catabolism of the sulphur amino acids L-cysteine and L-
methionine. These are irreversibly metabolised primarily by the liver, and to a lesser extent by 
the kidneys and brain, to cysteinesulphinate (CSA) via the enzyme cysteine dioxygenase 
(Suliman et al. 1996; Stipanuk, 2004) (Figure 1.5). CSA can have two fates: it can either be 
converted to hypotaurine and ultimately taurine by decarboxylation, or by transamination to 
pyruvate and sulphate. Skeletal muscle also has the ability to convert cysteine to taurine and 
sulphuric acid (accounting for up to 10% of the whole body sulphate production (Ensuna et al. 
1993)), but here the mechanism is less clear because the activity of cysteine dioxygenase is very 
low in this tissue (Ensuna et al. 1993). The conversion of CSA to sulphate also results in the 
production of two moles of H+ per mole of cysteine or methionine and is therefore considered to 
be an acid generating branch of the pathway generating sulphuric acid (Stipanuk et al. 2006; 
Coloso and Stipanuk, 1989; Bella and Stipanuk, 1995). This branch generates most of the daily 
titratable acid load of around 40-70mEq of H+ each day in humans (Sebastian et al. 2002), and in 
individuals with renal impairment is a major contributor to uraemic metabolic acidosis (Cibulka 
and Racek, 2007). This acidosis is a significant clinical problem in CKD patients and an 
important contributor to the muscle wasting that is frequently seen in CKD (Mitch, 2006) (see 
Section 1.8.1). Cysteine is also used in the biosynthesis of glutathione, a key physiological 
antioxidant compound and so plays a role in both acid base balance and redox status (Métayer et 
al. 2008).  
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Figure 1.5. Simplified scheme showing pathways for the catabolism of L-methionine and L-
cysteine (adapted from Suliman et al. 1996).  
 
1.7.2 Plasma concentrations of sulphur amino acids and metabolites in CKD patients 
The metabolism of sulphate may be abnormal in CKD, because despite normal plasma 
methionine concentrations (Gulyassy et al. 1970; Condon and Asatoor, 1971), the concentrations 
of cysteine and homocysteine, a homologue of cysteine, both in the free and bound forms, are 
frequently seen to be raised in uraemic patients (Flűgel-Link et al. 1983; Robins et al. 1972). 
Plasma taurine levels, however, in non-dialysed and haemodialysis patients tend to be lower than 
those seen in healthy individuals (Alvestrand et al. 1982; Qureshi et al. 1989; Suliman et al. 
1996) and Bergström and colleagues (1989) reported that in CKD patients the muscle and plasma 
taurine concentrations were both reduced by the same margin, suggesting that this represents a 
true depletion of taurine from the cells rather than a decline in the cell/plasma concentration 
gradient. 
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The concentrations of CSA in the plasma have also been reported to be high (Suliman et al. 
1996) and it was speculated that low plasma taurine accompanied by these high levels of CSA 
represents a defect in the activity of cysteinesulphinate decarboxylase (CSAD), the rate limiting 
step in the conversion of CSA to taurine (Suliman et al. 1996).  This enzyme requires vitamin B6 
as a cofactor, of which CKD patients are commonly deficient (Kopple et al. 1981). However, 
patients in a number of studies by Suliman and colleagues (1999, 2001, 2002) were administered 
vitamin B6 supplements, and so the authors concluded that uraemia itself inhibits CSAD. 
Anorexia and malnutrition are frequently seen in these patients (Suliman et al. 2002) and it is 
likely that this results in a reduced taurine intake that, when coupled with a reduced synthesis 
from CSA as proposed by Suliman et al. (1996), causes these reduced plasma taurine levels. 
Taurine has many important cellular functions including stabilization of the membrane potential, 
antioxidant properties and a positive inotropic effect on the heart (Suliman et al. 2002; Schaffer 
et al. 2009) and depletion could possibly result in muscle fatigue and cardiovascular disease 
(Suliman et al. 2002), common co-morbidities in CKD patients (Nussbaum and Garcia, 2009; 
Pecoits-Filho et al. 2002). It is possible therefore that in CKD the flux through this pathway is 
diverted away from taurine and towards the generation of pyruvate and sulphuric acid (Figure 
1.5). 
 
1.8 Cachexia 
Cachexia is defined as the progressive loss of muscle mass and muscle protein associated with 
chronic disease (Tan and Fearon, 2008) and is frequently reported in many disease states such as 
uraemia, diabetes, sepsis and burn injury (Workeneh et al. 2006). (The skeletal muscle 
abnormalities observed in CKD are described in detail in Section 1.16.2). Cachexia is an 
important clinical problem as it is strongly associated with morbidity and mortality (Griffiths, 
1996) and even mild degrees of CKD are capable of stimulating proteolysis leading to cachexia 
(Wang et al. 2006). For a long time malnutrition was believed to be the primary cause of 
cachexia (Mitch, 1998), but there is now much evidence to suggest that this is not the case 
(Mitch, 2002) as nutritional therapy has little impact on nitrogen balance (Mak and Cheung, 
2006). The mechanisms causing muscle loss in uraemia are complicated and are likely to be 
multifactorial including acidosis, neuropathy, oxidative stress, hyperparathyroidism, protein 
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restriction, inflammation, anorexia and physical inactivity (Mak and Cheung, 2006; Johansen et 
al. 2003). This thesis will focus on the effects of metabolic acidosis and glucocorticoid. 
 
1.8.1 Metabolic acidosis and cachexia 
Early reports demonstrated that fasted acidotic rats exhibit an increase in urinary ammonia with 
no change in urea production (Hannaford et al. 1982), leading to the speculation that the nitrogen 
required for this increase in ammonia production came from skeletal muscle. May et al. (1986) 
were the first to demonstrate a direct association between acidosis and an increase in skeletal 
muscle proteolysis in rats. They rendered rats acidotic through ammonium chloride 
administration and assessed changes in protein synthesis in ex vivo incubated muscle by L-[U-
14C] phenylalanine incorporation into muscle and changes in protein degradation by the rate of 
tyrosine released into the media. An increase in the rate of muscle proteolysis was observed in 
the acidotic rats, with no corresponding changes in the rate of muscle protein synthesis. 
However, an acute inhibitory effect of acidosis on muscle protein synthesis (measured by [ring-
2H5] phenylalanine incorporation into muscle) has been demonstrated in humans rendered 
acidotic by ingestion of ammonium chloride (Kleger at al. 2001) and it has been suggested from 
in vitro cell culture work, that the primary effect of acidosis may be on protein synthesis, 
followed by a chronic (possibly compensatory or adaptive) effect on protein degradation (Evans 
et al. 2008). The protein catabolic effect of metabolic acidosis was later confirmed by May and 
colleagues in 1987 in rats with an induced renal failure and a more physiological degree of 
acidosis, as a criticism of the 1986 study by these authors was that the rats were subjected to a 
severe acidosis unlikely to be seen in CKD. Furthermore, this increase in proteolysis (measured 
by tyrosine release from the hindquarter) in acidotic rats could be prevented by the correction of 
acidosis using bicarbonate (May et al. 1987). Alkali therapy in the form of sodium bicarbonate is 
commonly used in CKD patients to correct acidosis and is associated with improvements in 
nitrogen balance (Reaich et al. 1993; Papadoyannakis et al. 1984), increases in body weight, 
decreases in morbidity (Szeto et al. 2003) and decreases in protein catabolism (Movilli et al. 
2009). Stein and colleagues (1997) administered either a high or low alkali dialysis fluid to 
peritoneal dialysis patients, achieving plasma bicarbonate concentrations of 23mmol/l in the low 
group and 27mmol/l in the high group. After one year, those patients who received the additional 
alkali had significant improvements in body weight and mid arm circumference (a measure of 
muscle mass) and fewer hospital admissions. Normal adults with an experimental acidosis 
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induced using oral ammonium chloride had increased whole body protein degradation 
(determined from the kinetics of infused L-[l-13C] Leucine) and amino acid oxidation (Reaich et 
al. 1992), confirming acidosis as an important catabolic factor. The mechanisms through which 
this occurs will be discussed in Section 1.13.   
Sodium bicarbonate has obvious positive effects on protein balance (Reaich et al. 1993), but how 
might this be occurring? It is well established that acidosis increases protein degradation through 
a stimulation of the ubiquitin proteasome system (Lecker et al. 2006). Animal studies have 
shown that acidosis induced by CKD in conjunction with glucocorticoids reduce insulin 
signalling (Bailey et al. 2006) resulting in an increase in the abundance of the 14kDa fragment - 
a marker of myofibrillar degradation. Sodium bicarbonate is unable to cross the muscle 
sarcolemma, but may act to reduce protein degradation by diffusing out of the plasma into the 
interstitial fluid, the environment to which the cell membrane is exposed, and thereby increasing 
interstitial pH and through effects on pH sensors on the skeletal muscle membrane, for example 
SNAT2, may possibly relieve the inhibition on insulin signalling reducing protein degradation 
rates. Indeed this has been shown in preliminary results by Bailey and colleagues (2006) in rats, 
but whether this is the case in humans is unclear.  
However, the effects of acidosis do not appear to occur exclusively through low pH. May et al. 
(1986) found there was no increase in proteolysis rates when the muscles from normal rats were 
incubated at pH 7.1 and the incubation of muscles from acidotic rats at pH 7.4 was unable to 
fully reverse the abnormal proteolysis rates. These authors concluded that there must be another 
signal required for the acceleration of muscle proteolysis. 
 
1.8.2 Glucocorticoids and cachexia 
Previous studies have demonstrated that glucocorticoids are capable of increasing protein 
degradation and inhibiting protein synthesis (Goldberg et al. 1980) and May et al. (1986) 
reported that metabolic acidosis was associated with an increase in glucocorticoid production. 
This led to the investigation of the possible contribution of glucocorticoids to the muscle wasting 
process. 
As previously described, May et al. (1986) found acidotic rats had increased rates of protein 
degradation. This observation was then extended to the effects of glucocorticoid on protein 
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degradation. They found these elevated rats of proteolysis were abolished if acidotic rats 
underwent an adrenalectomy (ADX) and were increased again following the administration of 
dexamethasone, suggesting that glucocorticoids are necessary for the increase in proteolysis seen 
in uraemia (May et al. 1986). This was later supported by the finding that ADX also prevents the 
increase in mRNA for ubiquitin and proteasome subunits (see Section 1.11.1) that was observed 
in intact acidotic rats, therefore preventing the activation of protein degradation pathways (Price 
et al. 1994), a response that was also restored by dexamethasone. Oxidation of branched chain 
amino acids (BCAA) may be a further mechanism by which acidosis causes a loss of muscle 
protein mass in CKD (Lofberg et al. 1997) (see Section 1.14) and May et al. (1996) reported that 
this increase in oxidation of BCAA, in particular Leucine, also requires glucocorticoids. There 
was no increase in oxidation of BCAA in ADX rats with acidosis, but treatment with 
dexamethasone significantly increased Leucine oxidation (May et al. 1996). This suggests that 
glucocorticoids appear to be required for the acidosis-induced muscle wasting, but on their own, 
are insufficient.  
Contrary to the effects following ADX, blockade of the glucocorticoid receptor using the specific 
antagonist RU38486 failed to block muscle wasting in acid loaded rats with intact kidneys 
(Pickering et al. 2003) at least partly because this drug impairs acid excretion and worsens 
acidosis. 
It is important to note that in CKD all the evidence above suggesting a role for glucocorticoids in 
the muscle wasting process have been performed using a rodent model and using 
pharmacological doses of dexamethasone. Therefore it is not known how applicable this research 
is to humans. 
This evidence for a catabolic role of glucocorticoids, in particular dexamethasone, when 
incombination with metabolic acidosis, is in contrast to its clinical effects and application in 
humans. Dexamethasone has anti-inflammatory properties and is used clinically to treat 
inflammatory and autoimmune conditions (Rhen and Cidlowski, 2005). In support of this, a 
recent study by Crossland and colleagues (2010) demonstrated that in rats with endotoxaemia, a 
low dose of dexamethasone reduced muscle protein loss, observed by a prevention of the 
reduction of the muscle protein:DNA ratio that was seen to fall in rats with endotoxaemia 
without dexamethasone. This effect of dexamethasone was seen to occur with a reduced mRNA 
expression of TNF-α and IL-6 in muscle, suggesting the anti-inflammatory properties of 
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dexamethasone resulted in the maintenance of muscle mass in a condition that is usually 
considered to be catabolic. 
These contrasting results may be explained by dose of dexamethasone that was used, with a 
much lower dose used by Crossland and colleagues (2010) compared to those described above. 
However, there is research to show that in catabolic conditions, the involvement of 
glucocorticoids include physiologically relevant levels of glucocorticoid (Du et al. 2005a). For 
example, in acidosis, adrenalectomy reduces stimulation of the ubiquitin proteasome system and 
therefore reduces protein degradation rates (May et al. 1986; Price et al. 1994). It therefore may 
be more likely that the differences in glucocorticoids effects are due to different disease 
conditions. Endotoxaemia, unlike CKD, is not usually associated with a chronic metabolic 
acidosis, so it may be possible that when glucocorticoids, even at a physiological dose, are 
combined with metabolic acidosis, the results are catabolic and not anabolic in nature as their use 
in other conditions may suggest. 
 
1.9 Protein turnover  
Skeletal muscle accounts for 40% of total body weight and 50% of total body protein (Griffiths, 
1996). Approximately 3.5 – 4.5 g of protein/kg is degraded and synthesised every day (Mitch 
and Goldberg, 1996) equating to the amount of protein contained in 1 – 1.5 kg of skeletal 
muscle. In order for nitrogen balance to be maintained, rates of protein synthesis and degradation 
must be very tightly controlled, any small discrepancy that occurs could over many weeks lead to 
a substantial loss of muscle mass; indeed such a discrepancy is thought to be the basis of 
cachexia. 
 
1.9.1 Methods to determine muscle protein synthesis and breakdown in vivo 
The gold standard method by which to investigate protein synthesis is to measure it directly 
using the incorporation of a stable isotope into muscle tissue.  Fractional protein synthesis rates 
can be measured using a continuous primed intravenous infusion of an amino acid that is not 
transaminated or oxidised in muscle, or an alternative approach is to administer the tracer as a 
flooding dose to quickly equilibriate the tracer in the intracellular and extracellular amino acid 
pools. Both methods are frequently used and presently there is no evidence to suggest the use of 
one method over the other. Commonly used tracers are, L- [l-13C] Leucine, L-[l-13C] α-
Ketoisocoporate and L-[2H5] Phenylalanine. Once a steady state is reached in the precursor pool, 
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muscle biopsies can be taken and analysed using GC-combustion-IRMS methodology 
(Wagenmakers, 1999; Smith et al. 2007) to determine tracer enrichment and therefore protein 
synthesis rates. However, this method does not provide any information on protein degradation 
rates. The Arterio-Venous (A-V) tracer dilution method using a two or three compartmental 
model, is commonly used and allows simultaneous measurements of protein synthesis and 
degradation to be made.  A tracer amino acid, for example [2H5] Phenylalanine is given by 
primed intravenous infusions and under steady state conditions samples of arterial and venous 
blood from catheters inserted into the femoral artery and vein are made. Net balance of the tracer 
amino acid is calculated by the concentration in the arterial blood minus the concentration in the 
venous blood multiplied by blood flow. Protein degradation rates are commonly calculated from 
the A-V dilution of the [2H5] Phenylalanine tracer. This method is invasive and technically 
demanding and should only be used in the certainty of the presence of steady state conditions 
(Kumar et al. 2009). This topic is discussed in detail in two reviews by Wagenmakers (1999) and 
Rennie (1999). 
 
For ease, several indirect measures of myofibrillar protein degradation are commonly used: 3-
Methyl Histidine (3-MH) excretion rates, accumulation of the 14kDa actin fragment and mRNA 
expression of components of the proteasome and E3 ligases such as MAFbx and MuRF-1. The 
use of 3-MH excretion as an index of the rate of myofibrillar proteolysis is based upon the 
presence of N-Methylated Histidine residues in actin and myosin heavy chain proteins (Nissen, 
1997). The cleavage of myofibrils releases 3-MH which, as it has no specific tRNA, cannot be 
re-used for protein synthesis and so is excreted into the urine (Welle, 1999). Thus the excretion 
rate of 3-MH over a 24h period provides an indication of the rate of myofibrillar degradation. 
There are a few inherent problems with this method; Actin is present in all cells, not only muscle 
cells, and although 3-MH excretion will primarily represent myofibrillar breakdown, a 
proportion will also result from non-myofibrillar proteins such as skin and intestine, which has a 
much higher rate of turnover than muscle. However, it has been quoted that in healthy 
individuals, muscle turnover represents the majority of 3-MH appearing in the urine, accounting 
for approximately 75% of the total 3-MH excretion (Ballard and Tomas, 1983). It is assumed 
that 3-MH appearing in the urine is from endogenous muscle proteolysis and not from exogenous 
sources. However, 3-MH derived from dietary protein will be absorbed and ultimately also 
excreted in the urine. For this reason, to ensure that 3-MH excreted is coming primarily from the 
degradation of myofibrillar proteins and is not influenced by dietary protein intake, individuals 
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are placed on meat-free diets for three days prior to the day on which the urine collection is made 
due to the slow clearance of 3-MH. In order to determine 3-MH excretion rate, the total volume 
of the 24 hour urine collection is recorded and a sample is taken, deproteinsed and 3-MH 
concentration measured using High performance liquid chromatography. This method is 
frequently used to assess protein breakdown rates, particularly in chronic disease states due to 
the relative ease of collecting a 24h urine sample compared to the more invasive methods such as 
stable isotopes, and the low cost in the collection and analysis of the sample. 
 
The degradation of the myofibrils results in the production of a small 14kDa actin fragment (this 
is discussed in more detail in Section 1.11.2) which is present in the insoluble fraction of the 
muscle lysates and is easily detected by western blotting. This method has been significantly 
correlated against measured rats of muscle protein degradation using stable isotope techniques 
(Workeneh et al. 2006). 
 
Degradation of myofibrils is performed primarily by the ubiquitin proteasome system. The 
mRNA expression of subunits of the proteasome and of E3 liageses which are considered to be 
the rate limiting step in protein degradation by the proteasome (Lecker et al. 2006) have been 
used as an indicator of the activity of this system. However, recent evidence from Greenhaff et 
al. (2008) has shown that in humans the expression of these E3 ligases at the mRNA level do not 
relate to the protein degradation rate measured using [2H5]Phenylalanine dilution technique. This 
suggests that when used in isolation, caution is required interpreting this data.  
 
 
1.10 Protein synthesis 
In contrast to protein degradation (Section 1.11 below), there is only one known pathway for 
protein synthesis. In this process, the genetic information in the chromosomes is first transcribed 
into RNA which, following processing to messenger RNA (mRNA), is then translated into the 
protein amino acid sequence in the cytosol. The process of translation can be separated into three 
stages, initiation, elongation and termination (Proud, 2006). Most of the control of protein 
synthesis occurs at the initiation step and in the signalling events preceding it. Before the mRNA 
sequence can be translated, it must first undergo pre-translational modifications. The sequence is 
capped on the 5’ end with a methylated guanosine derivative, 7-methylguanosine and a polyA 
tail is added at the 3’ end (Welle, 1999). 
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1.10.1 Translation initiation 
This process involves the assembly of the ribosomal complex at the initiation codon on the 
mRNA sequence. A methionyl initiator tRNA (Met-tRNAi) is in its peptidyl(P) site with its 
anticodon base-paired to the start codon (usually AUG) on the mRNA strand (Mitchell and 
Lorsch, 2008). This process requires the involvement of many non-ribosomal proteins, known as 
eukaryotic initiator factors (eIFs). The first step involves the delivery of the Met-tRNAi to the 
40S ribosomal subunit by the trimeric GTP-binding protein eIF2. eIF2 can only bind Met-tRNAi 
in the GTP-bound state, which is regulated by eIF2B, a guanine nucleotide exchange factor that 
replaces a GDP molecule on eIF2 with GTP and allows the formation of the eIF2·GTP·Met-
tRNAi ternary complex. This complex then binds to the 40S subunit in the absence of mRNA 
facilitated by eIF1A and eIF3 forming the 43S pre-initiation complex (Acker and Lorsch, 2008; 
Kapp and Lorsch, 2004). The GDP-GTP exchange process is an important regulatory step in 
translation initiation. The phosphorylation of eIF2’s α subunit by an eIF2 kinase (which can 
occur for example during severe amino acid depletion) prevents this exchange and therefore the 
binding of Met-tRNAi to the start codon (Proud, 2006). 
 
The next step in translation initiation is the recruitment of mRNA to the ribosome by the eIF4F 
complex which comprises the 3 eIF’s 4A, 4E and 4G (Merrick, 1992) and is regulated by the 4E 
binding protein 4E-BP1 (Figure 1.6). eIF4E is released from the inactive 4E-BP1·eIF4E complex 
by the phosphorylation of 4E-BP1 allowing it to bind to the scaffold protein eIF4G that makes 
additional contacts with eIF4A.  Together these three eIFs form the eIF4F complex that is 
assembled on the 5’ end of the mRNA strand (Kimball and Jefferson, 2006). eIF4A comprises a 
RNA helicase that unwinds secondary structures in the mRNA’s 5’ untranslated region, 
promoting ribosomal binding to the mRNA. eIF4E recognises and binds the 5’ cap on the mRNA 
sequence and in conjunction with eIF3 and the poly A binding protein, loads the mRNA onto the 
43S initiation complex (Kapp and Lorsch, 2004). This complex then starts scanning in the 5’ to 
3’ direction to find the AUG start codon. Upon the recognition of the start codon, eIF1 is 
released from the 43S complex resulting in the hydrolysis of GTP by eIF2 releasing Met-tRNAi  
into the P site of the 40S subunit. The remaining eIF’s dissociate from the complex and the 60S 
subunit is joined to the 40S, facilitated by eIF5B, resulting in formation of the 80S initiation 
complex and the elongation phase of translation can begin (Acker and Lorsch, 2008). 
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Figure 1.6. Schematic representation of the events of translation initiation. 
This figure has been adapted from information described in Proud, (2006); Kimball and 
Jefferson, (2006); Merrick, (1992); Acker and Lorsch, (2008). Initiation factors are shown 
schematically as individually labelled coloured circles or ellipses. 
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1.10.2 Elongation 
Elongation is the addition of amino acids to the growing polypeptide chain in a stepwise manner. 
The process requires only two elongation factors, eEF1A that delivers the charged tRNA 
molecules to the ribosome and eEF2 that promotes the translocation of the ribosome along the 
mRNA strand (Groppo and Richter, 2009). There are three stages to the elongation process that 
are repeated until a stop codon is encountered. These are the binding of aminoacyl-tRNA, 
peptidyl transfer and translocation. The ribosome contains three binding sites, the aminoacyl (A 
site), the peptidyl (P site) and exit (E site) (Noble and Song, 2008).  Elongation begins with a 
peptidyl tRNA in the P site of the ribosome next to an empty A site. The GTP-bound eEF1A 
delivers an aminoacyl-tRNA to the A site for decoding to take place. When a correct match is 
made between the mRNA codon and the tRNA anticodon, a conformational change occurs in the 
small ribosomal subunit catalysing the hydrolysis of GTP by eEF1A releasing the aminoacyl 
tRNA into the A site. Almost immediately, a peptide bond is formed between the peptidyl tRNA 
and the incoming amino acid catalysed by peptidyl transferase activity on the large ribosomal 
subunit. The ribosome is then moved forward three bases facilitated by eEF2 and the now 
deacylated tRNA is displaced into the E site, the peptidyl tRNA is translocated from the A site to 
the P site and the A site becomes empty once again. This cycle is repeated until one of the stop 
codons is encountered, UAA, UAG or UGA (Noble and Song, 2008). 
 
 
1.10.3 Termination 
Upon recognition of a stop codon in the A site, elongation is terminated. This process is 
mediated by two proteins; eukaryotic release factor 1 (eRF1) and eRF3. In the GTP-bound state, 
eRF1 recognises the stop codon and induces the hydrolysis of the final peptidyl tRNA bond to 
the polypeptide chain catalysed by peptidyl-transferase at the centre of the ribosome (Janzen and 
Geballe, 2004). This releases the completed polypeptide chain and disassembles the ribosomal 
complexes (Kapp and Lorsch, 2004). eRF3 is a GTPase protein whose activity requires both the 
80S ribosome and eRF1 and stimulates eRF1 activity in response to GTP hydrolysis 
(Zhouravleva et al. 1995). Unlike eRF1, the necessity for eRF3 in the termination of protein 
translation in unclear (Janzen and Geballe, 2004). 
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1.11 Major proteolytic systems in skeletal muscle 
Intracellular protein degradation is important as it allows for adaptation to occur in response to 
changing physiological circumstances and it is an essential quality control mechanism that 
removes misfolded and damaged proteins (Lecker et al. 1999). Skeletal muscle, like other tissue, 
contains three major proteolytic systems:  
• The lysosomal system: Together with the proteasome system, the lysosomes comprise 
one of the major intracellular proteolytic systems in mammalian cells (Zhao et al. 2007). 
Lysosomes are small spherical organelles containing proteases called cathepsins and have 
an acidic pH ranging from 3.5 – 6.5. This system is primarily involved in the digestion of 
organelles (especially mitochondria) (Scott and Klionsky, 1998) by autophagy, 
phagocytosis and endocytosis. The myofibrils are too large to be engulfed by lysosomes 
and skeletal muscle cells contain very few lysosomes and so it is unlikely that this system 
has a large role to play in the turnover of myofibrillar proteins (Goll et al. 2008). It has 
recently been shown that FOXO transcription factors are capable of activating cathepsin 
L (Mallinson et al. 2009). 
• The calcium dependent system that relies on the activity of calpains, a family of Ca2+- 
dependent cysteine proteases. This system controls the disassembly of tropomyosin and 
therefore plays an important role in muscle contraction and it has been discovered that in 
muscular dystrophy this system is up-regulated contributing to the loss of muscle mass 
(Carragher, 2006).  
• Finally, there is the cytosolic ATP-dependent pathway(s), of which the best described is 
the ATP-dependent ubiquitin-proteasome system (UPS), responsible for degrading actin 
and myosin following prior cleavage by caspase-3. This is quantitatively the most 
important system in skeletal muscle (Rock et al. 1994). The high rates of proteolysis seen 
in uraemia and other catabolic states have been attributed to the stimulation of the UPS 
following the observation that an increased expression of mRNAs encoding certain 
components of this system occurs (Mitch and Goldberg, 1996), and that blocking the 
proteasome using MG132 blocks the accelerated protein degradation that is seen in 
uraemia (Bailey et al. 1996). 
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1.11.1 Ubiquitin-proteasome pathway 
The ATP-dependent ubiquitin-proteasome pathway is a highly organised and complex cascade of 
enzymatic events in which, ubiquitin (ub) molecules are covalently linked to proteins marking 
them for degradation. The tagging of a protein with ub is a process that is coordinated by the 
activity of three enzymes E1, a ub- activating enzyme, E2, a ub- conjugating enzyme, and E3, a 
ub- ligase. The key enzyme is the E3 ligase, which provides the system with specificity. There 
are in the region of 1000 different E3 ligases, each recognising a different protein (Rajan and 
Mitch, 2008). 
 
Before ub can be conjugated to the target protein it must first be activated by the binding of 
ubiquitin activating enzyme E1 via a high energy thioester bond in an ATP-dependent process. 
Once activated, ub is then transferred to an E2 carrier protein followed by an E3 ub ligase which 
then covalently joins the ub molecule by an isopeptide bond to an ε-amino group of a lysine 
residue on the target protein. This process is then repeated and the C-terminal glycine of another 
ub molecule is linked to the lysine residue on the first until a chain of four or more ub molecules 
is made producing a polyubiquiniated protein. This can then be recognised and degraded by the 
26S proteasome (Lecker et al. 1999; Murton et al. 2008). 
 
The 26S proteasome is a large protein complex of approximately 50 subunits and is located in 
the nucleus and cytoplasm of all cells. It comprises a 20S catalytic core and two 19s regulatory 
sub units. The 19s “cap” protein complex, recognises and binds polyubiquitinated molecules, 
unfolds the protein to its primary structure and guides it into the catalytic core following the 
disassembly of the ub chain enabling the ub molecules to be recycled (Hasselgren, et al. 2002). 
The barrel shaped 20S subunit is made up of four stacked rings of proteins each containing 
approximately seven subunits around a central cavity (Goldberg et al. 1995). The subunits of the 
two inner rings have proteolytic sites that cleave the protein into peptides that are six to twelve 
amino acids in length (Mitch and Goldberg, 1996). These peptides are then degraded into 
individual amino acids by cytosolic exopeptidases (Debigaré and Price, 2003), (Figure 1.7). 
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Figure 1.7. Ubiquitin conjugation of a protein and its degradation by the ubiquitin 
proteasome system. 
This diagram depicts ubiquitination of a protein catalysed by E1, E2 and E3 ligases and 
subsequently degraded by the 26S proteasome into small peptides. This figure was adapted from 
the information in Debigaré and Price, (2003); Lecker et al. (1999); Murton et al. (2008). 
 
1.11.2 Degradation of myofibrillar proteins 
The majority of muscle protein (50-70%) exists as myofibrils and actomyosin complexes (Du et 
al. 2004), but the ubiquitin proteasome system is unable to degrade these large complexes 
(Solomon and Goldberg, 1996) so they must first be cleaved into smaller protein fragments by 
caspase-3, creating substrates that are rapidly degraded by the proteasome. This process leaves 
behind a characteristic “footprint”, a 14-kDa C-terminal fragment of actin that is found in the 
insoluble fraction of muscle (Du et al. 2004). The presence of this fragment has been seen to 
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increase in catabolic states and the level of this is closely related to the rate of protein 
degradation (Workeneh et al. 2006). In conjunction with other methods, this fragment can be 
used to detect changes in muscle proteolysis (Workeneh et al. 2006; Workeneh and Mitch, 
2010). 
 
1.11.3 Muscle Specific E3 Ligases and FOXO transcription factors 
Muscle contains two specific E3 ligases, muscle atrophy F box (MAFbx, also known as atrogin-
1) and muscle-specific RING finger-1 (MuRF-1) (Sandri et al. 2004, Bodine et al. 2001b) 
collectively called atrogins. The expression of these E3 ligases is controlled by the 
phosphorylation status of the forkhead box gene group O (FOXO) family of transcription factors. 
FOXO is phosphorylated by PKB rendering it inactive and inhibiting its transcriptional activity 
by confining it to the cytoplasm. A reduction in phosphorylation of FOXO by PKB results in 
their translocation to the nucleus where they increase the transcription of the two E3 ligases and 
thereby increasing protein degradation through the ubiquitin proteasome system. 
The expression of these ligases increases dramatically in many different catabolic states, 
including uraemia (Lecker et al. 2004). Bodine and colleagues (2001b) observed that in response 
to denervation, MAFbx or MuRF-1 knockout mice experienced a 56% and 36% slowing of 
muscle atrophy respectively in comparison to a wild type, identifying these genes as critical 
regulators of muscle atrophy. Subsequently, many research groups have used the mRNA 
expression of these E3 ligases as a marker of myofbrillar proteolysis. 
However, caution is required when interpreting this expression data from humans when 
measures of proteolysis have not been made, as recent evidence suggests that in healthy 
individuals the relative expression of MuRF-1 and MAFbx do not always correlate with 
measured protein degradation rates (Greenhaff et al. 2008). However, this study was carried out 
using healthy individuals and there are currently no studies of its kind in humans in a chronic 
disease state. It is possible that in healthy individuals, the increase in MuRF-1 and MAFbx 
mRNA expression is a side effect of an increase in FOXO activity, which has an involvement in 
muscle fuel selection. In the case of an individual in a chronic disease state characterized by 
muscle wasting, the increase in the mRNA expression of these E3 ligases may have 
physiological significance and correlate with measured rates of protein degradation. This has 
certainatly been shown in animal models. Wang and colleagues (2006) studied the influence of 
 32 
 
insulin resistance, a common feature of many catabolic diseases, on muscle atrophy using the 
db/db mouse model. They observed that these insulin resistance mice had reduced muscle mass 
and increased rates of muscle protein degradation as measured by tyrosine release into the media. 
Rosiglitazone, an insulin sensitizer, was administered to a group of the db/db mice, and resulted 
in an increase in muscle mass, and in PI3-K activity, and a reduction in muscle proteolysis rates. 
This was also seen with a significant reduction in the mRNA expression of MuRF-1 and MAFbx, 
consistent with the decline seen in muscle protein breakdown rates. A similar finding was 
reported by Crossland et al. (2008) who reported in a model of sepsis, a reduction in muscle 
protein:DNA ratio was seen with increases in the expression of MuRF-1 and MAFbx. However, 
these results are yet to be demonstrated in humans. 
 
Recent studies by Crossland et al. (2008, 2010) and Constantin et al. (2007) have highlighted a 
potential role for FOXO transcription factors in the generation of muscle insulin resistance by 
identification of another target, pyruvate dehydrogenase kinase 4 (PDK4). Activation of FOXO 
(reduced phosphorylation) results in an increase in transcription of PDK4 which phosphorylates 
and inactivates pyruvate dehydrogenase complex, preventing the conversion of pyruvate to 
acetyl-CoA and impairing carbohydrate oxidation. This suggests there is a common pathway that 
activates the loss of muscle protein and impairs muscle carbohydrate oxidation involving 
activation of the FOXO family of transcription factors. 
 
 
1.12 Insulin signalling pathway 
In human skeletal muscle, insulin and IGF-1 exert a major anti-catabolic effect preventing 
initiation of protein degradation (Goldspink, 2006). 
 
Insulin signalling propagates through three major pathways, Phosphatidylinositol 3 kinase (PI3-
K), MAPK (mitogen-activated protein kinase) and Cbl/CAP (Cbl-associated pathways). As this 
thesis focuses on the initiation of protein synthesis and signalling to protein degradation, only the 
PI3-K pathway will be discussed.  
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1.12.1 PI3-K pathway 
Insulin and IGF-1 signalling through the PI3-K pathway plays a key role in promoting muscle 
growth, repair and the maintenance of muscle mass (Goldspink, 2006). The insulin receptor has 
two α extracellular subunits and two transmembrane β subunits connected by disulphide bridges 
(Seino et al. 1989). Insulin binds to its receptor on the outside surface of the cell causing a 
conformational change that triggers tyrosine kinase activity on the β subunits and 
autophosphorylation of the β insulin receptor subunit at several tyrosine residues (Sykiotis and 
Papavassiliou, 2001). This activation of tyrosine kinase causes phosphorylation of insulin 
receptor substrates 1 and 2 (Sykiotis and Papavassiliou, 2001), which then act as a docking site 
for proteins containing Src-homology-2 (SH-2) domains including the p85 regulatory subunit of 
PI3-K. The binding of the SH-2 domain to the insulin receptor substrate – 1 (IRS-1) stimulates 
the activity of the P110 catalytic subunit of the PI3-K molecule resulting in the conversion of 
phosphatidylinositol 4,5-bisphosphate (PIP2) to PIP3 which is an important second messenger in 
the action of insulin. PIP3 recruits PDK1 (3-Phosphoinositide-dependent kinase 1) and protein 
kinase B (PKB, also known as Akt) to the plasma membrane where PKB becomes activated 
(Cohen, 2006). Downstream of PKB, but upstream of the mammalian target of rapamycin 
(mTOR) are the Tuberous Sclerosis Complex proteins (TSC), TSC1 also known as hamartin and 
TSC2, also known as tuberin. When present as a hetrodimer, the TSC1-TSC2 complex inhibits 
mTOR indirectly by converting a small G protein, ras homolog enriched in brain (rheb) from the 
active GTP-bound state into the inactive GDP-bound state (Corradetti and Guan, 2006; 
Jastrzebski et al. 2007; Frost et al. 2009). PKB phosphorylates TSC2 at Ser939 and Thr1462 
residues (Rosner et al. 2008) degrading the TSC1/TSC2 complex and therefore increasing the 
activity of rheb and ultimately mTOR. It has recently been shown that rheb up regulates the 
activity of mTOR via the association with FKBP38, a member of the FK506 binding protein 
family (FKBP) relieving FKB38’s inhibition on mTOR (Rosner et al. 2008). Downstream targets 
of mTOR are P70S6K and 4E-BP1, which are both regulators of the translational machinery (Hay 
and Sonenberg, 2004) and allows initiation of protein synthesis (Figure 1.8). 
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Figure 1.8. Schematic representation of the PI3-K/PKB pathway. 
This figure was adapted from the information cited in Cohen (2006); Sykiotis and Papavassilou 
(2001); Hay and Sonenberg (2004); Lizcano and Alessi (2002). 
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1.12.2 PI3-K 
PI3-K is a lipid kinase consisting of a p110 catalytic subunit and a p85 regulatory subunit that 
contains two SH2 domains that interact with the IRS proteins and is a key protein in the 
metabolic action of insulin. There are three classes of PI3-K, but the most likely form to be 
involved with insulin signalling is Class 1a (Shepherd et al. 1998) that is sensitive to activation 
by growth factors, but is not sensitive to amino acids. Upon IRS-1 phosphorylation, PI3-K is 
recruited to the membrane where it converts PIP2 to PIP3. Recent evidence shows PI3-K is an 
important regulator of proteolysis and suppressed activity of this kinase by acidosis has been 
implicated in the accelerated muscle protein degradation in CKD (Franch et al. 2004). The 
activation of mTOR complex 1 (mTORC1) by insulin appears to be mediated by P13-K as 
blockade using wortmannin inhibits the phosphorylation of 4E-BP1 and P70S6K which are 
downstream targets of mTORC1.  
 
 
1.12.3 Protein Kinase B (PKB) 
PKB is a serine/threonine phosphatidylinositol – regulated kinase and is a critical mediator of 
mTOR activity sitting at the crossroads between protein synthesis and degradation, and playing a 
central role in the regulation of glucose and protein metabolism, motility, and cell growth and 
survival (Fayard et al. 2005). There are three isoforms of PKB, α, β and γ. The most important 
isoform in muscle seems to be PKBβ which is also the dominant isoform in insulin responsive 
tissues (Kandel and Hay, 1999). In order to become fully activated, PKB must be phosphorylated 
on two sites, Ser473 and Thr308. Ser473 is phosphorylated first by rictor that is bound to the 
mammalian target of rapamycin complex 2  (mTORC2) and is required for the localisation of -
PKB to the membrane (Sarbassov et al. 2005). PKB contains a pleckstrin homology domain that 
binds to PIP3 with high affinity, exposing the Thr308 residue and allowing phosphorylation by 
PDK-1 (Cohen, 2006; Scheid et al. 2002). Once activated, PKB dissociates from the membrane 
and phosphorylates downstream targets such as TSC2 (Kimball, 2007) and AS160 (Sano et al. 
2003). The phosphorylation of AS160 results in the inactivation of its GTPase activity leading to 
the accumulation of GTP-bound Rab (a small G-protein required for vesicle trafficking) and 
promotes the translocation of GLUT-4 to the plasma membrane (Cartee and Funai, 2009; Thong 
et al. 2005). 
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1.12.4 Mammalian target of rapamycin (mTOR) 
The mammalian target of rapamycin is a 289kDa serine/theronine protein kinase that regulates 
many aspects of cell growth, notably the regulation of translation through the phosphorylation of 
P70S6K  and 4E-BP1 (Corradetti and Guan, 2006) and the phosphorylation of these two proteins 
is often used as a marker of mTOR activity (Hay and Sonenberg, 2004). mTOR exists in two 
complexes, mTORC1 and mTORC2. mTORC1 consists of three proteins, mTOR, MLST8 and 
raptor (regulatory associated protein of mTOR) and is involved in the control of translation and 
of cell growth in response to nutrients and growth factors. mTORC2 consists of mTOR, MLST8 
and rictor (rapamycin insensitive companion of mTOR) and is a rapamycin insensitive protein. It 
controls the actin cytoskeleton dynamics and the phosphorylation PKB on the Ser473 residues 
(Cohen, 2006; Um et al. 2006). It is raptor that binds mTORC1 to P70S6K and 4E-BP1 and 
facilitates their phosphorylation (Corradetti and Guan, 2006). mTOR is activated by growth 
factors and is also a nutrient sensing protein that is capable of being activated by amino acids 
(Hay and Sonenburg, 2004). Insulin and IGF-1 activate mTOR through the PI3-K/PKB 
signalling pathway, whilst amino acids possibly signal to mTOR through a type III PI3-K (a 
nutrient sensing isoform) that is not activated by insulin and does not phosphorylate PKB (as in 
traditional PI3-K signalling), but phosphorylates mTORC1 directly (Kimball, 2007; Evans et al. 
2008). 
 
If signalling through mTOR is inhibited using rapamycin, cell growth and protein accretion is 
inhibited. Bodine and colleagues (2001a), demonstrated that 14 days of overload of the plantaris 
muscles by removal of the synergists resulted in an increase in the size of the overloaded leg by 
45% compared to the control, however, this effect was abolished when rapamycin was 
administered demonstrating the powerful effect of mTOR signalling. 
 
Studies have shown that mTOR activity can also be negatively regulated by DNA damage 
responses protein 1 (REDD-1) that acts to restore the TSC1-TSC2 complex and subsequently 
inhibits rheb (DeYoung et al. 2008; Frost et al. 2009). Expression of this protein has been found 
to be increased under conditions of hypoxia (Brugarolas et al. 2004).  
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1.12.5 S6 kinases 
Mammalian cells contain two genes for S6 kinases, giving rise to S6K1 (also known as P70S6K) 
and S6K2. P70S6K was discovered much earlier and as much more is known about the function 
of this protein it will be discussed here in more detail than S6K2. Downstream targets of S6Ks 
are ribosomal protein S6 (rpS6) and eIF4B (Yang et al. 2008; Holz et al. 2005). 
 
The activity of P70S6k is regulated by mTORC1, specifically by Raptor (Corradetti and Guan, 
2006) and is phosphorylated in a sequential manner on a number of different residues, Ser411, 
Ser418, Thr421 and Ser424 by mTOR which then allows phosphorylation of Ser389 and Ser371 also 
by mTOR and finally allowing PDK1 to phosphorylate P70S6K on its Thr229 residue (Jastrzebski 
et al. 2007). In the inactive form, P70S6K along with 4E-BP1 are bound to eIF3, part of the pre-
initiation complex and, following stimulation by growth factors and nutrients, both P70S6K and 
4E-BP1 are phosphorylated by mTORC1 causing their dissociation from this complex 
(Corradetti and Guan, 2006). 
 
The importance of S6K as a growth effecter became apparent when the gene for P70S6K was 
successfully knocked out (Shima et al. 1998). These knockout mice are 20% smaller at birth, 
glucose intolerant and have low insulin levels due to a reduction in β cell volume. It was 
observed that there was an increase in S6K2 expression, but this was unable to reverse the 
growth defect caused by this genotype. Interestingly, the transcription of the 5’ terminal 
oligopyrimidine (5’ TOP) mRNA’s (see Section 1.12.6) was intact indicating that the low birth 
size was not due to a decrease in the translational machinery (Shima et al. 1998). Those mice 
null for the P70S6K gene also had a muscle atrophy phenotype despite no alteration in 
phosphorylation of PKB or 4E-BP1, indicating that P70S6K plays a key role in IGF-1 induced 
skeletal muscle hypertrophy (Um et al. 2006) 
 
 
1.12.6 Ribosomal protein S6 (RpS6) 
RpS6 is a component of the 40S subunit of the ribosome and is phosphorylated on five residues, 
Ser235, Ser236, Ser240, Ser244 and Ser247 by ribosomal protein S6 kinase (rpS6K) (Ruvinsky et al. 
2005). Evidence from knockout mice show both P70S6K and S6K2 are required for the activation 
of rpS6, but predominantly S6K2 is required (Pende et al. 2004). Despite its discovery many 
years ago, the precise biological function of rpS6 remains obscure (Proud, 2007). However, the 
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phosphorylation of rpS6 correlates with protein synthesis rates and phosphorylated rpS6 is found 
at the mRNA binding site of 40S ribosomes, so it probably has a significant translational 
function. It has been suggested that rpS6 is involved in the translational control of the 5’TOP 
mRNA’s that encode proteins associated with the assembly of the translational machinery 
(Ruvinsky et al. 2005). However, as described above, P70S6K-/- mice have no defects in the 
translation of these mRNA’s indicating that rpS6 phosphorylation is not required for this (Shima 
et al. 1998) and in fact these mice did not display any translation related phenotype. In support of 
these findings by Shima and colleagues (1998), rpS6-/- mice have a reduction in cell size, but not 
body size and a defective glucose homeostasis, but normal rates of protein synthesis (Ruvinsky, 
2005). 
 
 
1.12.7 Eukaryotic Initiation Factor 4E- Binding Protein 1 (4E-BP1) 
The efficiency of mRNA binding to the 40S ribosome depends upon the availability of 
eukaryotic initiation factor 4e (eIF-4E) (see Section 1.10.1 above). When signalling through the 
PI3-K pathway is low and therefore anabolic signalling to protein synthesis is low, eIF4E is 
bound to 4E-BP1 sequestering it away from other initiation factors. However, when demand for 
protein synthesis increases, 4E-BP1 is hyper-phosphorylated. This dissociates the eIF4E:4E-BP1 
complex thereby releasing eIF4E. Once released, eIF4E can bind with eIF4G and eIF4A creating 
the initiation complex eIF4F and allowing cap-dependent mRNA translation initiation (Shah et 
al. 2000). 4E-BP1 is phosphorylated at many sites by mTORC1 stimulated by growth factors and 
nutrients. In humans these are Thr37, Thr46, Ser65, Thr70, Ser83 (Bai and Jiang, 2010), with the 
first four being of particular importance, and upon phosphorylation of Ser65, eIF4E is released 
from its complex with 4E-BP1 (Hay and Sonenberg, 2004). 
 
 
1.12.8 Activation of PKB/mTOR in relation to protein synthesis in humans 
Results from studies using cell culture and small mammals suggest that insulin activates mTOR 
and up-regulates protein synthesis rates (Kimball et al. 1994; Biolo et al. 1995).  However, there 
is evidence to suggest that there is some dissociation between insulin signalling and protein 
synthesis rates in humans.  Greenhaff et al. (2008) investigated the effect of insulin on muscle 
protein synthesis and breakdown rates and changes in phosphorylation of anabolic signalling 
proteins in the presence of a continuous supply of amino acids in healthy human subjects. Four 
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insulin concentrations were used, 5, 30, 70 and 180 mU/l that were maintained using the insulin 
clamp technique. They observed that with an increasing plasma insulin concentration there was a 
dose-response effect on the phosphorylation status of PKB and P70S6K and that the 
phosphorylation of mTOR and 4E-BP1 was increased when plasma insulin concentrations were 
increased from 5 to 30 uM/l, but no further changes were seen when insulin concentrations were 
increased to 70 and 180 uM/l. However, these changes in phosphorylation status was seen to 
occur with no corresponding change in muscle protein synthesis rates measured from [l-13C] 
Leucine incorporation into the quadriceps muscle. Glover et al. (2008) investigated the effect of 
14 days unilateral knee immobilization on muscle protein synthesis rates in the quadriceps 
muscle. They found immobilization did result in decreased rates of protein synthesis compared to 
the non-immobilized leg and this was unable to be restored by amino acid infusion. The changes 
in phosphorylation status of PKB, mTOR and P70SK6 were not easily interpreted and as 
Greenhaff et al. (2008) had observed previously, didn’t follow the changes in protein synthesis 
rates. This discrepancy in muscle protein synthesis rates and phosphorylation status of proteins 
thought to be important in anabolic signalling has also been demonstrated by de Boar and 
colleagues (2007) who also reported that lower leg immobilization resulted in reduced rates of 
myofibrillar protein synthesis with no corresponding changes in the phosphorylation of any of 
the proteins in the PI3-K pathway.  Finally, Wilkinson et al. (2008) compared the effects of 10 
weeks of resistance or endurance training on muscle protein synthesis rates and activation of the 
signalling proteins in the PKB/mTOR pathway. They observed that resistance exercise training 
lead to a significantly greater increase in resting muscle protein synthesis rates compared to 
endurance exercise, which was associated with changes in mitochondrial protein synthesis rates. 
This increase in muscle protein synthesis was also seen to occur with no obvious change in the 
phosphorylation of the regulatory proteins involved in translation initiation. These studies 
suggest that this pathway may be more complex in humans than has previously been described in 
rodents and that using the phosphorylation status of these proteins alone may cause misleading 
conclusions on the rates of protein turnover in humans and so caution may be required when 
interpreting this data. 
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1.13 The coupling of insulin signalling, glucocorticoid and activation of the 
ubiquitin-proteasome system in metabolic acidosis 
 In early experiments in which rats with intact kidneys were subjected to metabolic acidosis, an 
increase in skeletal muscle protein degradation was observed (May et al. 1986). However, 
depletion of ATP from the muscle abolished this effect demonstrating that the acceleration of 
muscle wasting was via a pathway that consumed energy (Mitch et al. 1994), i.e. the ubiquitin 
proteasome system, that is now accepted as a major contributor to mscle wasting in acidosis and 
uraemia (Lecker et al. 2006). Evidence from uraemic patients has shown that there is an increase 
in the expression of mRNA encoding ubiquitin and some proteasome subunits in CKD (Mitch 
and Goldberg, 1996), and correction of acidosis by sodium bicarbonate results in a decrease in 
the expression of ubiquitin (Pickering et al. 2003). As discussed in Section 1.11.3 changes in 
expression of the E3 ligases MuRF-1 and MAFbx have been used to infer changes in proteolysis. 
To date, only one study has investigated the effect of CKD on MuRF-1 and MAFbx. Lecker et 
al. (2004) found by Northern blot that the expression of MuRF-1 and MAFbx was increased in 
uraemic rats, but as protein degradation was not measured directly, we are unable to conclude if 
this change in expression conferred an increase in protein degradation.  
It was aslo discussed in Section 1.8.2, that under conditions of catabolic stress, glucocorticoids 
may exert a permissive effect for the catabolic action of acidosis in vivo. This possible catabolic 
action of glucocorticoids also appears to be primarily through activation of the ubiquitin 
proteasome pathway. Bodine et al. (2001b) observed that dexamethasone administered to normal 
rats resulted in a 10-fold increase in expression of both MuRF-1 and MAFbx. This was also seen 
in vitro by Sandri et al. (2004), an effect that was rapidly suppressed by insulin. However, the 
MAFbx promoter lacks a glucocorticoid response element (GRE) and so the action of 
glucocorticoid on this ligase must be indirect and is most likely to be through expression of the 
transcription factor FOXO that controls expression of both MuRF-1 and MAFbx (Sandri et al. 
2004).  MuRF-1 on the other hand, does have a GRE upstream of the promoter so it appears this 
E3 ligase is directly activated by glucocorticoids and FOXO-1 synergistically (Waddell et al. 
2008). Expression of FOXO-1 and FOXO-3 have been seen to be raised in myotubes in response 
to glucocorticoids in vitro (Imae et al. 2003) and led to the conclusion that glucocorticoids 
activate a transcriptional programme thought to be responsible for activating muscle atrophy 
(Schakman et al. 2008).  
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Glucocorticoids have also been shown to reduce protein synthesis rates. Shah et al. (2000) 
demonstrated that L6 myotubes incubated with dexamethasone have a reduced phosphorylation 
of 4E-BP1 and P70S6K, ultimately resulting in a reduction in protein synthesis. A study by Wang 
and colleagues (2006) found an enhanced REDD-1 expression following dexamethasone 
administration in vivo, an effect that has been blocked using RU38486 in vitro (Shah et al. 2002) 
resulting in an increase in phosphorylation of these downstream targets of mTOR, suggesting 
that glucocorticoids exert their effects upon protein synthesis via regulation of mTOR activity. 
However, as discussed earlier (see Section 1.8.2) these studies use relatively high doses of 
glucocorticoids, and in light of the study by Crossland et al. (2010) who found a low dose of 
dexamethasone was actually able to suppress muscle protein degradation induced by 
endotoxaemia, the applicability of this data to humans where glucocorticoid concentrations are 
much lower, is questionable. However, as endotoxaemia is not characterized by acidosis, it is 
possible that in when combination with acidosis, the effect of glucocorticoids is catabolic and not 
anabolic, but much more data is needed before firm conclusions can be drawn. 
 
In CKD, metabolic acidosis blunts the action of insulin even in non-diabetic patients. This effect 
is not just the result of lower insulin or IGF-1 concentration, as it has been reported that uraemia 
and acidosis are typically associated with normal or high insulin levels (Defronzo et al. 1981).  
 
This insulin resistance appears not to result from a defect of the insulin receptor (Cecchin et al. 
1988) and has therefore been attributed to post-receptor defects, possibly through a decrease in 
signalling through the PI3-K/PKB pathway, an impairment of which has been observed during 
atrophy (Bodine et al. 2001a). In a study by Bailey et al. (2006), it was demonstrated that the 
muscles of acidotic CKD rats had abnormalities in the IRS-1-associated PI3-K activity that were 
accompanied by a reduction in the phosphorylation of PKB, leading to activation of the 
transcription factor FOXO. This PKB inhibition also activated caspase-3 which is known to lead 
to the initial cleavage of the myofibrils prior to degradation by the UPS (Du et al. 2004) and 
generates the characteristic 14kDa actin cleavage fragment (Section 1.11.2) which has been 
found to be higher in the muscle of maintenance haemodialysis patients than in healthy controls 
(Workeneh et al. 2006). There was also an increase in the activity of IRS-2 to compensate for the 
decrease in IRS-1-associated PI3-K activity, but this was unable to prevent the decrease in PKB 
phosphorylation (Bailey et al. 2006). In addition to this, as previously described in Section 
1.11.3, activation of FOXO and therefore PDK4 may also have a role to play in the impairment 
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of muscle carbonhydrate oxidation and therefore in the generation of insulin resistance in CKD 
(Constantin et al. 2007; Crossland et al. 2010). However, to date, there is no data to support this 
speculation. 
 
The defect in the IRS-1-associated PI3-K activity during metabolic acidosis may arise partly 
from the secondary increase in glucocorticoid secretion during acidosis (May et al. 1986, 
Pickering et al. 2003). In rats, a pharmacological dose of dexamethasone results in a reduced 
content of both IRS-1 and PI3-K in muscle and a reduced IRS-1 associated PI3-K activity (Saad 
et al. 1993).  Hu et al. (2009) discovered that endogenous glucocorticoids bind to the 
glucocorticoid receptor which then competes with IRS-1 for PI3-K binding, further reducing 
IRS-1-associated PI3-K activity and PKB phosphorylation, thus promoting atrophy. This 
mechanism has yet to be confirmed in humans, and the direct effect upon protein degradation 
rates would need to be determined in light of the suggestion of a dissociation between anabolic 
signalling and protein turnover in humans (Greenhaff et al. 2008). 
 
 
1.14 Depletion of intramuscular amino acids 
It is well established that branched chain amino acids (BCAA), in particular Leucine, are 
anabolic in muscle, capable of stimulating muscle protein synthesis (Rennie et al. 2006). Under 
conditions of catabolic stress, depletion of these BCAA could potentially be a limiting factor for 
protein synthesis (Bergström et al. 1990). Therefore, the depletion of intramuscular amino aicds 
is thought to be an important early step in the muscle wasting process and abnormalities have 
been reported in both muscle and plasma amino acid concentrations and in the distribution of 
amino acids between cells and extracellular fluid in CKD patients compared to healthy 
individuals (Bergström et al. 1990). Early studies of patients with untreated chronic uraemia 
reported low intramuscular concentrations of threonine, lysine, arginine, valine and taurine with 
low plasma concentrations of leucine, lysine, phenylalanine and again, taurine (Bergström et al. 
1990; Alvestrand et al. 1982; Bergström et al. 1989). It appears that some, but not all of these 
abnormalities can be corrected with nutrition (Alvestrand et al. 1978). However, it has also been 
observed that rats with chronic renal failure exhibit a similar pattern of amino acid depletion 
despite the same food intake as control rats (Haines et al. 1989) indicating that is not a result of 
malnutrition, but of factors relating to uraemia. 
 43 
 
Once the patients began haemodialysis, depletion of intramuscular valine and serine was still 
observed and the muscle/plasma concentration gradients for glycine, citrulline and arginine were 
low (Bergström et al. 1990). A strong positive correlation was also observed between the 
intramuscular valine concentration and the pre-dialysis plasma bicarbonate concentration in these 
haemodialysis patients, suggesting that metabolic acidosis may have a role in intramuscular 
amino acid depletion (Bergström et al. 1990). This was confirmed in a later study by rigorous 
correction of metabolic acidosis by use of high bicarbonate haemodialysis fluid which 
significantly increased the intramuscular concentrations of alanine, isoleucine, leucine and 
valine; and increased the muscle/plasma amino acid concentration gradients for these amino 
acids as well as arginine, asparagine, glycine, serine and histidine (Lofberg et al. 1997).  These 
changes were accompanied by a statistically significant fall in the plasma concentrations of 
glutamine, glycine and histidine. These effects on concentration gradients were observed in 
fasted patients, thus eliminating transient disturbances to amino acid concentrations caused by 
amino acid intake from the most recent meal. This implies that the active transport mechanisms 
responsible for pumping amino acids into the muscle cells, and for maintaining the intracellular 
concentrations higher than in extracellular fluid, are impaired in metabolic acidosis. 
 
1.15 The SNAT/slc38 amino acid transporters 
The System N and A Neutral Amino Acid Transporters (SNATs) are members of the slc38 gene 
family and are sub-divided into System A and System N transporters according to their substrate 
specificities (i.e. the solutes that they carry). System A has three isoforms, SNATs 1, 2 and 4, 
and System N has two isoforms, SNATs 3 and 5 (Mackenzie and Erickson, 2004). 
 
System A transporters were originally described in the 1960s  as sodium-dependent transporters 
that carry small zwitterionic (neutral) amino acids into the cell along with one Na+ cation that 
binds to the transporter first (Mackenzie and Erickson, 2004). This is a secondary active process 
utilising the Na+ gradient set up by the Na+,K+-ATPase pump (Palii et al. 2006). The property of 
System A transporters distinguishing them from the System N transporters is the ability to 
transport N-Methylamino acids, for example, α-Methylaminoisubyrate acid (MeAIB) (Yao et al. 
2000), and the uptake of this synthetic amino acid is often used as a measure of System A 
transport activity (McGivan and Pastor-Anglada 1994). System A’s naturally occurring 
substrates include alanine, asparagine, cysteine, glutamine, glycine, methionine and serine. In 
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contrast System N only carries glutamine, histidine and asparagine (Mackenzie and Erickson, 
2004). System A is regulated by environmental conditions, for example, it is up-regulated by 
insulin and amino acid starvation (Yao et al. 2000), is activated by exercise (King et al. 1994) 
and, of particular relevance to amino acid abnormalities in metabolic acidosis, it is  strongly 
inhibited by low pH (Mackenzie and Erickson, 2004).  
 
The only SNAT transporter that is strongly expressed in skeletal muscle is SNAT2 (Mackenzie 
and Erickson, 2004) so, for the purposes of this thesis, System A activity in muscle will be 
regarded as a consequence of the SNAT2 transporter. 
 
 
1.15.1 The SNAT2 amino acid transporter 
SNAT2 is widely expressed in mammalian tissue and is found in skeletal muscle, brain, adrenal 
glands, liver, kidney, lungs and skin (Mackenzie and Erickson, 2004) and appears to be the most 
highly regulated isoform in response to endocrine and nutrient stimuli (Baird et al. 2006, 
McDowell et al. 1998). SNAT2 directly accumulates amino acids, for example L-Glutamine, 
inside the cell, maintaining an intracellular L-Glutamine concentration that is approximately 10 
times greater than in the extracellular fluid (Mittendorfer et al. 2001). As with System A 
transporters in general (Section 1.15), the activity of this transporter is up-regulated in response 
to insulin (McDowell et al. 1998) and amino acid starvation (Mackenzie and Erickson, 2004) and 
is suppressed when the external pH falls, over the physiologically relevant range (pH 7.8 – 7.0) 
(Baird et al. 2006). 
 
This suppressed activity by low pH was initially thought to be caused by H+ directly competing 
with Na+ for the cation binding site (Chaudhry et al. 2002). However, more recently, mutation of 
the c-terminal histidine residue of SNAT2 has been shown to blunt the pH sensitivity, suggesting 
that this terminal histidine has functional effects in the sensing of H+, as it does in other 
membrane proteins (Zong et al. 2001; Uchiyama et al. 2003). Baird and colleagues (2006) found 
that reducing the extracellular pH resulted in a reduced affinity for Na+ binding to SNAT2, and 
pre-treatment of the cells with the histidine specific reagent DEPC reduced the pH sensitivity, 
leading to the conclusion that extracellular H+ affects SNAT2 transport activity by interacting 
with one or more conserved histidine residues which indirectly affect allosteric binding of Na+. 
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As well as being readily detectable at the plasma membrane (Hyde et al. 2002), SNAT2 is also 
reported to be present in intracellular membranes and is translocated to the plasma membrane in 
response to insulin in a manner similar to GLUT4 translocation (Hyde et al. 2001, 2002; 
Hatanaka et al. 2006). However, there is no evidence that internalisation of SNAT2 has any role 
in the reduction of its activity in response to low pH. 
 
 
1.15.2 SNAT2, amino acid depletion and suppression of protein synthesis 
As discussed in Section 1.14, intramuscular amino acid depletion may be an early contributor to 
cachexia (Bergström et al. 1990), but the precise mechanism of this depletion in vivo is not well 
defined. 
 
Previous work from our laboratory using cultured L6-G8C5 myotubes has suggested a role for 
SNAT2 in the regulation of intramuscular amino acid content and signalling through mTOR to 
protein synthesis (Evans et al. 2007). Inhibition or silencing of the SNAT2 transporter resulted in 
reduction of the intracellular concentration of a number of amino acids, notably L-Glutamine and 
the overall pattern of amino acid depletion was similar to the amino acid depletion observed in 
the muscles of acidotic CKD patients (Bergrstöm et al. 1990; Lofberg et al. 1997). A number of 
these depleted amino acids are not carried on SNAT2, for example, L-Leucine. This suggests 
that SNAT2 and the System L amino acid transporter (that is capable of transporting L-Leucine) 
are coupled, with System L exchanging the intracellular amino acids accumulated by SNAT2 for 
extracellular L-Leucine. The depletion of intracellular amino acids observed on inhibition or 
gene silencing of SNAT2 was accompanied by impaired signalling through mTOR, implying 
that SNAT2 has a role in the regulation of mTOR through the widely documented effect of free 
amino acids on this kinase (Kimball et al. 1999). 
 
 
1.15.3 SNAT2 and Proteolysis 
Further results from this laboratory have shown that silencing of SNAT2 using small interfering 
RNAs (SiRNA) stimulates proteolysis rates in L6-G8C5 myotubes, accompanied by an 
impairment in the activation of PI3-K and PKB in the presence of insulin (Evans et al. 2008).  
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The resemblance between these effects of SNAT2 silencing in myotubes in vitro and the effects 
of metabolic acidosis on skeletal muscle in vivo suggests that, owing to its sensitivity to pH, 
SNAT2 may have a functionally significant role in the control of protein synthesis and 
degradation in uraemic metabolic acidosis. The activity of System A transporters has been 
reported to be low in the skeletal muscle of rats with acute uraemia incubated ex vivo (Maroni et 
al. 1990); and the activity in skeletal muscle of CKD patients (assessed by measuring uptake of 
11C-MeAIB by positron emission tomography) is also reported to be low (Asola et al. 2001), but 
it is important to emphasise that there is no direct evidence yet for SNAT2 mediating the effects 
of acidosis in vivo.   
 
 
1.16 Exercise in CKD patients 
Recent published guidelines by the UK National Institute for Health and Clinical Excellence 
(NICE) gave the recommendation that CKD patients “should be encouraged to take exercise” 
(NHS, 2008), but there are currently no specific exercise guidelines for this population, unlike 
cardiac and pulmonary populations. However, exercise in CKD populations is an area that is 
gaining in popularity and momentum and the first sessions were dedicated to it at a recent 
congress (World Congress of Nephrology, Milan, 2009). There is a growing body of research in 
this area that will hopefully lead to the implementation of exercise programmes for these 
patients. 
 
CKD patients have a number of biochemical abnormalities such as reduced insulin sensitivity 
and glucose tolerance (Goldberg et al. 1983, 1986), hypertension (Johansen, 2005) and 
dyslipidemia (Bronas, 2009). These, and an abnormal internal milieu, contribute to a vastly 
increased risk of cardiovascular events, which is the biggest cause of mortality in these patients 
and poses a significant challenge to clinicians (Bronas, 2009). In the healthy population, exercise 
helps to reduce risk factors for CKD and so exercise in this population may also help to reduce 
mortality and increase quality of life. As in the healthy population, sedentary behaviour carries 
with it an increased risk of all-cause mortality. O’Hare et al. (2003) observed 2,837 patients for a 
one year period and showed that the sedentary patients had a 62% greater risk of mortality than 
those patients who were more active. The majority of research into exercise implementation has 
focused on the dialysis population and has shown significant benefits (Kouidi et al. 1998; Kopple 
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et al. 2007; Koufaki, et al. 2002), but there has been very little research performed using the pre-
dialysis population.  
 
1.16.1 Exercise tolerance and capacity in CKD patients 
Patients on dialysis are extremely inactive compared to their healthy counterparts (Johansen et al. 
2000) and Painter et al. (2000) reported that 59% of HD patients participated in no physical 
exercise at all. This may be the result of a lack of encouragement to do so by their doctors or 
nurses (Johansen et al. 2003), an increase in co-morbidity as the disease progresses, a general 
feeling of being unwell, depression or cardiac dysfunction (Kouidi et al. 1998). This reduced 
exercise capacity is further compounded by anaemia (Painter, 2005), which it appears cannot be 
improved with exercise (Zabetakis et al. 1982; Painter et al. 1986).  
 
Many early studies reported that CKD patients have a reduced VO2peak compared to the healthy 
population (Barnea et al, 1980) and this has been reported to be up to 60% less (Painter, 2005) 
ranging from 17.0 mL/kg/min to 28.6 mL/kg/min (Kouidi et al. 1998; Lundin et al. 1981). Many 
studies have shown that with aerobic exercise, CKD patients can improve their VO2peak, with 
improvements ranging from 17% (Hagberg et al. 1983) up to 43% (Konstantinidou et al. 2002) 
and even improvements of 70% after one year of cycle ergometer exercise (Kouidi et al. 2004).  
A few studies have reported no improvement in VO2peak (Carney et al. 1983; Akiba et al. 1995) 
and this can probably be attributed to a low exercise intensity and a short duration of the exercise 
training period. Correction of anaemia with recombinant human erythropoietin (rHuEPO) results 
in a very small improvement in VO2peak (Painter and Moore, 1994) suggesting that this is not the 
main cause of a limited exercise capacity. 
 
 
1.16.2 Muscular abnormalities in CKD patients 
CKD patients exhibit severe muscular atrophy that appears to affect type II fibres more than type 
I (Kouidi et al. 1998). Many abnormalities are present at the ultra structural level, for example,   
swollen mitochondria, disappearance of the cristae and reduced matrix density (Kouidi et al. 
1998). Electron microscopy has shown Z-band degeneration, myofilament loss and accumulation 
of intracellular glycogen (Diesel et al. 1993) and fibre splitting, internalized nuclei and moth-
eaten fibres by light microscopy (Diesel et al. 1993). This atrophy has also been seen in non-
locomotor muscles demonstrating that these changes are unlikely to be caused purely by disuse, 
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and are probably due to uraemia (Sakkas et al. 2003). As well as the abnormalities in 
mitochondrial structure described above, these patients also exhibit dysfunctional intramuscular 
energy metabolism (Johansen et al. 2005), but the cause of this is currently unknown. Following 
a bout of exercise, there is a slowing in the recovery of phosphocreatinine (PCr) (Kemp et al. 
2004) and a reduced PCr level and pH and a higher Pi/ PCr ratio (Johansen et al. 2005), 
indicating their ability to recover from a bout of exercise is grossly impaired. In principle, 
exercise in CKD patients may worsen pre-existing metabolic acidosis through exercise-induced 
lactic acid generation and this may explain the abnormally prolonged and severe intramuscular 
acidification observed in these patients following exercise (Johansen et al. 2005).   
 
Several studies have reported an improvement in these muscular abnormalities with exercise 
training in haemodialysis patients. Kouidi et al. (1998) saw an increase in the fibre cross 
sectional area for type I by on average 25.9%, and 23.7% for type II following a six month 
mixed exercise programme, and similar changes were seen by Sakkas et al. (2003). A 
regeneration of degraded fibres and an improved architecture was observed following exercise 
training (Kouidi et al. 1998; Sakkas et al. 2003). The mitochondria were of a normal shape and 
size with normal orientation of the cristae (Kouidi et al. 1998), and there was an increased 
capillary content of the muscle (Sakkas et al. 2003). This suggests that skeletal muscles of CKD 
patients are able to respond to exercise training in the same way as a healthy individual, but 
whether they are able to adapt to the same extent is unknown. 
 
CKD patients generally have a reduced muscular strength compared to healthy controls 
(Johansen et al. 2003), but this can also be improved with resistance exercise training. Castaneda 
et al. (2001) saw a 32% increase in muscle strength in pre-dialysis patients following a 12 week 
programme compared to a 13% reduction in strength in the non-exercising CKD control group. 
Headley et al. (2002) conducted a 12 week resistance exercise programme in haemodialysis 
patients and saw an improvement in peak torque of the leg extensors and an improvement in 
several physical functioning tests, with no adverse event reported in either study. Muscle wasting 
and weakness are well established predictors of increased mortality (Kosmadakis et al. 2010) and 
so any improvement in these parameters may lead to a reduced mortality risk. 
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1.16.3 Cardiac Function 
It is extremely important for renal patients to maintain good blood pressure control, as 
hypertension can accelerate progression of kidney disease. A study by Miller and colleagues 
(2002) was designed solely to examine the effect of an intradialytic exercise programme on 
blood pressure. They reported that after six months of cycling exercise there was no significant 
change in blood pressure compared to the control patients, but patients were taking on average 
36% less antihypertensive medications, an annual saving that the authors calculated was 
US$885/patient. An improvement in blood pressure has also been reported by Boyce et al. 
(1997) following four months of exercise training; an improvement that was reversed by two 
months of detraining. 
 
 
1.17 Signalling events in response to exercise and training adaptations 
Resistance exercise training is mainly associated with muscle hypertrophy and an increase in 
strength and power. Endurance exercise training on the other hand is associated with adaptations 
that lead to an increase in oxidative capacity, resulting in a slower rate of muscle glycogen and 
blood glucose utilisation, an increased reliance upon fatty acid oxidation and a reduction in 
lactate production during submaximal exercise (Hollosky and Coyle, 1984). These adaptations 
include: increases in stroke volume and cardiac output resulting in a reduced heart rate, increased 
capillarisation and importantly, an increase in mitochondrial content (mitochondrial biogenesis) 
(Hood, 2009). Mitochondrial content can be doubled within six weeks of endurance training, but 
due to their short half life, repeated exercise is required to maintain these increased levels 
(Zierath and Hawley, 2004). The diverse adaptations to training that occur with endurance and 
resistance training result from different molecular events in the hours following the exercise 
bout. 
 
A bout of resistance exercise results in an increase in protein synthesis rates that can be 
maintained for up to 48 hours (Phillips et al. 1997). This increase in protein synthesis is thought 
to be brought about through an increase in signalling through the PI3-K/PKB pathway (Baar, 
2006; Nader, 2006). A single bout of resistance exercise can increase the activity of PI3-K 
(Hernandez et al. 2000) and increase PKB phosphorylation  (Nader and Esser, 2001) and P70S6K 
phosphorylation (Baar and Esser, 1999; Koopman et al. 2006) resulting in rpS6 and 4E-BP1 
activation, but only in the post-prandial state (Koopman et al. 2006; Witard et al. 2009). If 
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resistance exercise is performed in the fasted state, it appears that this increase in protein 
synthesis is suppressed due to AMPK activation, an important energy sensor that reduces the 
phosphorylation of 4E-BP1 (Dreyer et al. 2006). 
 
Endurance exercise, on the other hand, is not usually associated with hypertrophy and large 
increases in protein synthesis rates, but primarily with an increase in mitochondrial biogenesis 
and therefore mitochondrial content (Holloszy and Coyle, 1984). This adaptation requires the 
activation of a different pattern of signalling events. The long exercise duration results in an 
increase in the AMP:ATP ratio that activates AMPK, inhibiting ATP-consuming pathways and 
increasing carbohydrate and fatty acid oxidation (Wackerhage, 2006; Hawley, 2009). Exercise 
also results in calcium release from the sarcoplasmic reticulum, increasing intramuscular calcium 
concentrations (Wackerhage, 2006) that activate calmodulin-activated kinase (CamK). CamK 
and AMPK allow myocyte-enhancing factor 2 (MEF2) to bind to the proliferator-activated 
receptor γ coactivator 1α (PGC-1α). PGC-1α then increases the expression of nuclear respiratory 
factors 1 and 2 (NRF-1,2) that bind to promoters and activate transcription of genes encoding 
mitochondrial respiratory chain proteins (Kelly and Scarpulla, 2004).  NRF-1 also regulates the 
expression of mitochondrial transcription factor A (Tfam) that binds to mitochondrial DNA and 
induces mitochondrial biogenesis (Baar, 2006; Wackerhage, 2006; Hawley, 2009). 
 
There is some evidence that moderate intensity (75% VO2Max) endurance exercise can increase 
phosphorylation of mTOR that remains above basal for two hours after exercise (Mascher et al. 
2007). An increase in phosphorylation of PKB was seen one and two hours after exercise which 
returned to baseline after three hours. This delay in PKB phosphorylation suggests that mTOR is 
activated by PKB, but also by an alternative mechanism. There was, however, no signalling 
downstream of mTOR to P70S6K (Coffey et al. 2006), suggesting another role for mTOR 
activation following endurance exercise. There is currently a lack of agreement on the effect of 
endurance exercise upon PKB phosphorylation. Some studies report no change (Widegren et al. 
1998), but others do show an increase (Sakamoto et al. 2004). It is likely that this discrepancy 
arises from differences in the intensity and duration of exercise and in participant characteristics.    
 
As well as an increase in mTOR phosphorylation, Mascher et al. (2007) also reported a 
dephosphorylation of eukaryotic elongation factor 2 (eEF2), that is activated by eEF2 kinase 
(eEF2k), following one hour of exercise at 75% VO2Max that occurred with a lack of P70S6K 
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activation. It is thought that insulin acting through mTOR may inactivate eEF2 kinase thus 
dephosphorylating eEF2 that in its phosphorylated state serves to inhibit elongation, the major 
energy consuming step of protein synthesis (Proud et al. 2001).  
 
However, recent evidence from two other studies that concomitantly measured protein synthesis 
rates and the phosphorylation status of some of the proteins in the PI3-K/PKB pathway suggest 
that this pathway may be a little more complicated in humans than previously thought. 
Wilkinson et al. (2008) showed that an acute bout of single-legged endurance exercise was 
associated with an increase in the phosphorylation of PKB, mTOR and P70S6K, but this was seen 
without any changes in myofibrillar protein synthesis rates. Likewise, Greenhaff et al. (2008) 
saw that in healthy human subjects, a stepwise increase in plasma insulin concentrations resulted 
in stepwise increases in the phosphorylation of PKB and P70S6K, but this was also seen with no 
changes in muscle protein synthesis rates. These results suggest that using the phosphorylation 
status of proteins such as these described above as markers of protein turnover in muscle, may be 
an oversimplification.  
 
1.17.1 Exercise signalling in CKD 
There is very little information regarding signalling events following exercise in CKD and the 
only studies that have been performed were in rodents. Wang and colleagues (2009) found that 
as previously reported (Bailey et al. 2006), the skeletal muscles from CKD mice (subjected to 
partial nephrectomy) had a reduced phosphorylation of PKB. However, they reported that two 
weeks of treadmill running or two weeks of muscle overload were able to correct this defect, 
returning phosphorylation levels back to those seen in the sham-operated control mice. This was 
accompanied by an increase in phosphorylation (and hence inactivation) of the FOXO 
transcription factors in both modes of exercise and ultimately a suppression of muscle protein 
breakdown, as evidenced by a reduced level of the 14kDa actin fragment in the muscle. Muscle 
overload was able to increase phosphorylation of mTOR and its downstream target P70S6K and 
reverse the CKD-induced suppression of protein synthesis. Treadmill running, however, was 
unable to increase the phosphorylation of these downstream targets despite a small increase in 
PKB phosphorylation, and only small increases in protein synthesis rates were seen, which is 
consistent with results from healthy humans undergoing endurance training (Coffey et al. 2006).  
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Chen and colleagues (2008) observed that rats (both with surgically induced CKD and sham-
operated controls) were able to activate PKB and P70S6K to the same extent in muscle following 
muscle overload, which was also accompanied by a decrease in the accumulation of the 14kDa 
actin fragment in both groups and hence a decrease in myofibrillar degradation. This evidence 
suggests that overload can overcome the signalling defects that are present in uraemic muscle 
and can effectively activate the PI3-K/PKB pathway. 
 
 
 
1.18 Cell stretch in vitro  
Muscle protein synthesis is modulated by mechanical activity (Hornberger et al. 2006), but the 
mechanisms by which this occurs are only recently becoming understood. What is well known 
however, is that as discussed above in Section 1.12.1 myocyte growth is regulated by mTOR 
through activation of downstream substrates. Mechanically overloading a muscle results in 
hypertrophy and underloading leads to atrophy (Goldberg et al. 1975) suggesting that tension 
may be playing a role in muscle growth (Hornberger et al. 2006). Administration of rapamycin to 
rats with overloaded plantaris muscles prevents the occurrence of hypertrophy (Bodine et al. 
2001a) suggesting a role for mTOR in mechanically induced hypertrophy.  
 
In contrast, passive stretch may be exerting effects via a different mechanism. Vandenburg 
(1987) demonstrated that cyclic stretch applied to myotubes in vitro resulted in an increase in 
protein synthesis rates and an accumulation of cellular protein with a decrease in protein 
degradation. This has been confirmed in vivo by Hornberger and colleagues (2006) who 
observed that muscles from mice incubated and subjected to passive intermittent stretch ex vivo 
had increased the rates of protein synthesis, an effect that was completely blocked by rapamycin. 
They also saw an increase in the phosphorylation of P70S6K, without any change in PKB 
phosphorylation, suggesting that the increase in protein synthesis that is seen following passive 
stretch occurs via a PI3-K independent mechanism.  
 
However, more recent measurements in vitro suggest that the timing of the measurements of 
protein synthesis rate may be critical:  Atherton and colleagues (2009) found an inhibition of 
protein synthesis in cultured myotubes during cyclic stretch, in accordance with the inhibition of 
protein synthesis that is seen during (but not following) exercise in vivo. Following stretch in 
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vitro they found an increase in mTOR, P70S6K and 4E-BP1, but not PKB phosphorylation 
accompanied by an increase in protein synthesis rates (Atherton et al. 2009) supporting the 
earlier results of Hornberger et al. (2006). 
 
 
1.19 Limitations of exercise performance 
The factors limiting exercise performance in healthy individuals are a complicated and multi-
factorial set of process that depends on the duration and intensity of the exercise bout. As this 
thesis is primarily concerned with muscle metabolism, only fatigue originating in the skeletal 
muscle will be discussed here. 
 
During short duration high intensity exercise, ATP is replenished by the hydrolysis of 
intramuscular PCr stores, and through anaerobic glycolysis which results in the production of 
lactate. High intensity anaerobic exercise sees a rapid decline in the ATP and PCr concentration 
of the type II muscle fibres: following a 30 second maximal sprint, concentrations of ATP and 
PCr fall by approximately 40% and 70% respectively (Cheetham et al. 1986). This results in a 
reduced rate of glycolysis after approximately 20 seconds (Soderlund et al. 1992) and an 
accumulation of ADP resulting in a reduction in force production and ultimately, fatigue. Lactate 
production is also associated with the accumulation of H+ (causing acidosis) which is a 
commonly cited cause of fatigue. However, recent studies have shown that reduced pH may have 
little effect on muscle contraction and therefore fatigue at physiological temperatures (Wiseman 
et al. 1996; Westerblad et al. 1997) and so fatigue must result from another product of anaerobic 
glycolysis. Inorganic phosphate produced during the breakdown of PCr has been shown to 
inhibit force generation in human muscle (Wilson et al. 1988) possibly by interfering with cross 
bridge formation or disruption of calcium handling and sensitivity (Westerblad et al. 2002; Allen 
et al. 2008), and is now a candidate for one of the main causes of muscular fatigue (Westerblad 
et al. 2002).  
 
Fatigue during prolonged exercise in temperate conditions is mainly due to muscle glycogen 
depletion and a fall in muscle carbohydrate (CHO) oxidation rates (Sherman et al. 1983; Tsintzas 
et al. 1996). At fatigue, muscle glycogen concentrations have been found to be nearly depleted 
(Bergström et al. 1967) and the ingestion of CHO both before and during the exercise bout 
(Sherman et al. 1991; Coyle et al. 1986), improves performance. Muscle glycogen depletion 
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results in a reduced rate of ATP resynthesis, an increase in ADP and Pi concentrations, a 
decrease in the intermediates of the TCA cycle and therefore reduced oxidative ATP resynthesis 
(Maughan et al. 1997b). 
 
Limitations to exercise in CKD patients appear to stem primarily from the muscular 
abnormalities described in Section 1.16.2 as CKD patients frequently attribute the early 
termination of exercise to muscle fatigue (McMahon et al. 1999; Lundin et al. 1987). CKD 
patients have defective mitochondrial energy metabolism, there is an accelerated rate of decline 
of PCr stores during exercise (Durozard et al. 1993) and a slower recovery following exercise 
(Reviewed in Kosmadakis et al. 2010), but the precise mechanism for this defect is currently 
unknown. Biopsy studies performed in haemodialysis patients have also shown fibre type 
grouping, which suggests denervation and subsequent re-innervation. However, central 
activation of motor units has been found to be normal (Johansen et al. 2003). It is possible that 
acidosis has a greater role to play in the development of fatigue in these patients. Nishida et al. 
(1991) observed using 31-P NMR that there was a greater decline in sarcosolic pH during 
aerobic exercise in CKD patients compared to healthy controls and a slower rate of its recovery, 
an observation that has been confirmed by other groups (Durozard et al. 1993; Kemp et al. 
2004). Earlier studies have reported that an imposed mild metabolic acidosis by either NH4Cl 
administration or through diet manipulation was sufficient to reduce exercise capacity in healthy 
individuals during high intensity exercise (Jones et al. 1977; Greenhaff et al. 1987) and it was 
suggested that acidosis may have directly caused the early fatigue possibly by reducing the rate 
of glycolysis. However, the exact role acidosis played in the development of fatigue is unclear as 
it was later demonstrated that the acute correction of diet induced metabolic acidosis by 
bicarbonate supplementation failed to have an effect on time to exhaustion (Ball et al. 1996). It 
may be that under conditions of chronic metabolic acidosis, such as that in CKD, the role that 
acidosis plays in fatigue is significantly greater than when it is merely transient. CKD patients 
also appear to have a reduced ability to increase muscle blood flow during submaximal and 
maximal exercise compared to controls (Bradley et al. 1990) coupled with anaemia further 
reducing these patients ability to exercise. 
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1.20 Unanswered Questions and Aims 
Muscle wasting is a clinically significant problem in CKD patients which appears to be partly 
caused by a combination of metabolic acidosis and glucocorticoids. The correction of acidosis by 
sodium bicarbonate therapy has been shown to improve nitrogen balance and morbidity in these 
patients. Exercise has also been shown to provide benefits to patients receiving haemodialysis 
therapy, but there is little information in the literature regarding potential benefits of exercise to 
skeletal muscle in the pre-dialysis population, nor is it known whether combining correction of 
acidosis with exercise would yield additional benefits. CKD is associated with impaired insulin 
signalling that in uraemic rat models has been shown to lead to the suppression of protein 
synthesis and the stimulation of protein degradation. It is not known if insulin signalling is 
suppressed in human CKD patients, or if this signalling has a tight relationship to protein 
synthesis and degradation, which has been shown in animal models, but seems to be more 
doubtful in healthy humans. If there is impairment in insulin signalling, it is not known if this 
can also be overcome using exercise and what effect this would have on protein turnover. 
The acid load that CKD patients fail to excrete, leading to uraemic metabolic acidosis, arises 
largely from catabolism of the sulphur amino acid cysteine to sulphuric acid. The concentration 
of some of these sulphur metabolites is abnormal in uraemia, and there may be a defect in the 
activity of the enzyme CSAD resulting in a greater proportion of the flux from cysteine being 
metabolised to sulphuric acid rather than to taurine, thus adding to the burden of metabolic 
acidosis in these patients. However, few direct measurements of the flux from cysteine to 
sulphuric acid and taurine have been reported in CKD patients and the relative excretion rates of 
these metabolites of cysteine oxidation would shed more light on this. 
Results from animal models have shown that glucocorticoids when in combination with 
metabolic acidosis, may have a role in the muscle wasting process that is commonly seen in 
uraemia via activation of the ubiquitin proteasome system. A functionally significant role for the 
pH-sensitive neutral amino acid transporter SNAT2 has also been identified in mediating the 
effects of acidosis on protein synthesis and degradation in a culture model of skeletal muscle in 
vitro. Whether a combined effect of acid and glucocorticoids upon SNAT2 might contribute to 
the synergism between acidosis and glucocorticoid in muscle wasting is currently unknown. 
The specific hypothesises of this project were therefore: 
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In Chapter 3: 
• It was hypothesised that six months of walking exercise would increase LBM (as measured 
by DEXA) compared to the control group. This would be associated with increased basal 
insulin signalling (increased phosphorylation of PKB, P70S6K and 4E-BP1) suggesting and 
increase in muscle protein synthesis rates, and a reduction in MuRF-1 and MAFbx mRNA 
expression, reduced levels of 14kDa fragment, reduced 3-MH excretion rates and an increase 
in muscle protein:DNA ratio, indicating reduced rates of myofibrillar proteolysis.  
• The effects of exercise and additional acidosis correction using sodium bicarbonate in these 
patients would be additive.  
 
In Chapter 4: 
• It was hypothesised that CKD patients would excrete more sulphuric acid and less taurine 
than healthy individuals and that the sulphate excretion (and hence sulphuric acid production) 
would vary widely between individuals, but correlate with myofibrillar protein degradation, 
thus possibly allowing identification of those patients who may be high acid producers and 
therefore may be at a greater risk of muscle wasting. 
• Exercise and bicarbonate supplementation would reduce sulphuric acid production in CKD 
patients. 
 
In Chapter 5 
• It was hypothesised that glutamine would reduce sulphuric acid production in vitro. 
• Glucocorticoids, like acidosis, would reduce the transport activity of SNAT2.  
• Passive and cyclical stretch would increase mRNA expression and transport activity rates of 
SNAT2. 
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Chapter 2 
 
General Methods 
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All the methods described in this chapter are used in more than one experimental chapter. 
 
Note: For convenience, throughout this thesis all microcentrifuge speeds are quoted in rpm 
because all centrifuges used have approximately the same rotor radius of 7cm. All other 
centrifuge speeds have been quoted as the maximum g force generated at the outer edge of the 
rotor. 
2.1 Blood sampling, handling and analysis 
Venous blood samples, approximately 7ml, were collected for studies described in Chapters 3 
and 4. Samples were taken from a superficial antecubital vein, drawn into a dry syringe and 
dispensed into a tube containing either the anticoagulant K2 EDTA or lithium heparin, depending 
upon its intended analytical use. Arterial blood samples were also taken during the study 
described in Chapter 3 at each time point prior to the muscle biopsy, this data is also presented in 
Chapter 4. A 3ml sample was taken from the brachial artery following the administration of 1% 
lignocaine, drawn into a blood gas syringe containing heparin and taken to the Pathology 
Department at the Leicester General Hospital for analysis of arterial pH and bicarbonate.  
 
2.2 Urine sampling and handling 
Consenting patients and healthy volunteers underwent a diet free from animal protein for 4 days 
and collected a 24h urine sample on the final day of the diet. The urine volume was measured 
and aliquots were stored at -20oC prior to assay for sulphate, and amino acid derivatives by High 
Performance Liquid Chromatography (HPLC) as described below. 
 
2.3 Measurement of amino acids and their derivatives by high performance 
liquid chromatography 
Muscle and plasma samples were analysed for their full amino acid profiles.  Urine samples were 
analysed for the derivatives of sulphur amino acid catabolism, cysteinesulphinic acid (CSA) and 
taurine and for the myofibrillar catabolite 3-Methyl Histidine (3-MH).  
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2.3.1 Preparation of muscle samples for amino acid analysis 
Approximately 2mg (dw) muscle was homogenised (T8.01 Netzgerät, IKA, Germany) in 0.3M 
PCA (400µl) containing 1mM Norvaline as an internal standard and incubated on ice for 30 
minutes. The samples were centrifuged in a microcentrifuge at 13,000rpm for 15 minutes at 4°C. 
The resulting supernatant was stored on ice and the pellet was retained for determination of total 
DNA concentration (see Chapter 3.2.7.2). An equal volume of freon-trioctylamine (78% v/v 
1,1,2-trichlorotrifluoroethane, 22% v/v trioctylamine) was added to the supernatant and vortexed 
for 1 minute. The tubes were centrifuged briefly (for approximately 10 seconds at 13,000rpm) 
resulting in the formation of three phases. Approximately 80% of the top (aqueous) phase was 
taken off and filtered through a 0.45 microfilter into a glass HPLC vial. 
 
2.3.2 Preparation of the plasma and urine samples for amino acid analysis 
Plasma (500µl) was deproteinsed using 12M PCA (12.5µl) containing 40mM Norvaline as an 
internal standard. Urine (1ml) was deproteinsed using 12M PCA (25µl) containing 40mM 
Norvaline. The tubes were vortexed for 1 minute and incubated on ice for 30 minutes. From this 
point, the method of amino acid extraction from plasma and urine was the same as described 
above for muscle, with the exception that the pellets formed following centrifugation were 
discarded.  
 
2.3.3 Amino acid separation by reverse-phase HPLC 
Amino acid master standard was made fresh daily and comprised 25µl Agilent amino acid 
standard (5061-3330), 75µl ultra pure water and 1µl supplementary amino acid mixture. Amino 
acid concentrations were determined by reverse phase HPLC. All samples were separated on an 
Agilent (1100 Series) chromatograph with ultraviolet (UV) detection using a Zorbax eclipse 
AAA column (4.6 x 75mm, 3.5μm) with pre-column derivatisation using Orthophthalaldehyde, 
(OPA; Agilent, UK, 5061-3335) and Fluorenylmethyloxycarbonyl chloride (FMOC; Agilent, 
UK, 5061-3337). Samples were eluted with 40mM Na2HPO4, pH 7.8 supplemented with a linear 
gradient of 0-57% v/v Acetonitrile:Methanol:water (45:45:10) applied between t = 1 and 9.8 
minutes in each run. At the end of each run, the column was purged with 100% 
aceonitrile:methanol:water for two minutes and re-equilibrated with 100% 40mM Na2HPO4, pH 
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7.8 for two minutes before injecting the next sample. Peaks were integrated using the Agilent 
Chemstation software and concentrations calculated in relation to the standard. 
 
2.4 Protein Assays 
Total protein concentration of acid precipitates from muscle and cell cultures was measured 
using the Folin Lowry protein assay. Protein in lysates intended for Western blotting was 
analysed using the BioRad Detergent Compatibile (DC) assay (BioRad, UK, 500-0116). 
 
2.4.1 Folin Lowry protein determination 
Acid-precipitated protein pellets were dissolved in 1ml 0.5M sodium hydroxide and heated at 
70˚C in a water bath for 30 minutes.  Just before use, Folin Reagent A was mixed with Reagent 
B (see Appendix A) at a ratio of 50:1 to give Reagent C and Folin Ciocalteu’s Phenol reagent 
(Sigma, Dorset, UK, 47641) was diluted 1:2 using water. Samples were diluted to bring them 
within the range of the standard calibration (0-500μg/ml). Generally, muscle sample precipitates 
were diluted 1:10 using 0.5M sodium hydroxide and L6 precipitates were diluted 1:1. Standards 
and diluted samples (50μl) were then mixed with Folin C reagent (600μl) with immediate 
vortexing. After 10 minute incubation, diluted Folin Ciocalteu reagent (60μl) was added with 
immediate vortexing and tubes were incubated for a further 40 minutes at room temperature and 
subsequently read at 660nm on a Titertek Multiscan spectrophotometer. 
 
2.4.2 Bio-Rad DC Assay 
Reagent A (1ml) and Reagent S (20μl) were mixed immediately prior to use, producing reagent 
As.  The muscle lysates to be assayed were diluted 1:10 with 1% v/v IGEPAL CA-360 detergent 
(Sigma, Dorset, UK, I3021) and the L6 lysates were diluted 1:1 in order to bring them into the 
range of the standard curve. Standards (0-20μg/ml) and diluted samples (5μl) were pipetted in 
triplicate into a clean 96 well plate. Reagent As (25μl) was added to each well, followed by 
Reagent B (200µl). The plate was gently agitated to mix the reagents and left to incubate for 15 
minutes and read at 750nm on a Titertek Mulitscan spectrophotometer.  
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2.5 Protein techniques 
2.5.1 Cell Membrane Preparation 
Following incubation with test media, cells were washed three times in 5ml ice cold 0.9% w/v 
NaCl. Cells were immediately scraped in 3ml per 9cm Petri UIC3 Protease Inhibitor Cocktail 
(see Appendix A) using a plastic cell scraper. Cells were centrifuged at 200g for 5 minutes at 
4°C to pellet the intact cells.  The supernatant was aspirated and cells were re-suspended in 12ml 
fresh UIC3 and incubated on ice for 30 minutes. Cells were then lysed by drawing them through 
a pre-chilled 33 gauge needle twice. Lysates were then microcentrifuged at 7500rpm for 10 
minutes at 4°C. The pellets were discarded and supernatants centrifuged at 170,000g for 60 
minutes at 2°C. The resulting membrane pellets were dissolved in UIC3 plus 1% IGEPAL CA-
630 detergent (Sigma, Dorset, UK, I3021) and stored at -80°C. Protein concentration was 
determined using the BioRad DC assay as described in Section 2.4.2 and 30µg protein was 
mixed with an equal volume of SDS-PAGE reducing sample buffer and run on an SDS-PAGE 
gel as described below. 
 
2.5.2 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE gels) 
All samples were run on 12.5% gels using Mini PROTEAN 2 and 3 systems (Bio-Rad, 
Hertforshire, UK) and blotted using a semi-dry transfer cell (Bio-Rad, Hertfordshire, UK). All 
protein extracts were resolved under reducing conditions. 
 
2.5.3 Casting the gels 
The resolving gel was poured between two glass plates and over-laid with butanol. Once set, the 
butanol was removed and the stacking gel was poured over the top of the resolving gel and the 
well comb inserted in between the top of the glass plates creating loading wells. The gels were 
made up as follows, 
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Table 2.1. SDS-PAGE resolving gel, all volumes are shown per gel 
Final Acrylamide % 12.5% 
Water 3.19ml 
Acrylamide (30% w/v) 4.17ml 
1.5M Tris-HCl pH 8.8 2.5  ml 
SDS (10% w/v) 0.1  ml 
APS1 (10% w/v) 0.05ml 
TEMED2 5  μl 
 
Table 2.2. SDS-PAGE stacking gel, all volumes are shown per gel 
Final Acrylamide %      4% 
Water 3.03  ml 
Acrylamide (30% w/v) 0.65  ml 
0.5M Tris-HCl pH 6.8 1.25  ml 
SDS (10% w/v) 0.05  ml 
APS1 (10% w/v) 0.025ml 
TEMED2           5μl 
1 Ammonium Persulphate 
2 Tetramethylethylenediamine 
2.5.4 Preparation of muscle samples for protein SDS-PAGE  
As well as skeletal muscle from CKD patients and healthy volunteers, skeletal muscle samples 
from rats were also taken as a positive control. Freeze-dried muscle samples to be analysed by 
Western blotting were homogenised in SDS-PAGE Muscle Lysis Buffer (see Appendix A) and 
run on a gel on the same day as the homogenisation in order to prevent any loss of signal by 
freeze-thawing. Samples were processed according to the method used by Karlsoon et al. (2004). 
Approximately 4mg dw muscle was homogenised (T8.01 Netzgerät, IKA, Germany) in 90µl/mg 
dw SDS-PAGE Muscle Lysis Buffer and rotated at 4°C for 90 minutes. The tubes were 
microcentrifuged at 13,000rpm for 15 minutes at 4°C and the resulting lysate supernatant was 
taken off and transferred to a new tube. The pellet was retained and stored at -80°C to be used 
later for determination of 14kDa actin fragment concentration. The lysate supernatant was 
assayed for protein concentration using a Bio-Rad DC assay (see Section 2.4.2) and a volume 
yielding 150μg protein was mixed with an equal volume of Laemelli Reducing Sample Buffer 
(see Appendix A), heated at 100˚C and briefly centrifuged in a microcentrifuge (13,000rpm for 
10 seconds at room temperature).  
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The protocol for the detection of the 14kDa fragment was based on the protocols developed by 
Du et al. (2004) and Workeneh et al. (2006) modified as follows. The pellets were resuspended 
in 150µl SDS-PAGE Muscle Lysis Buffer without Bromophenol Blue, vortexed and heated at 
100°C for 5 minutes. Samples were then sonicated and heated again at 100°C for 5 minutes and 
this step was repeated until the pellet had gone back into solution. A volume yielding 50µg of 
protein was loaded onto an SDS-PAGE gel with a small amount of Bromophenol Blue. The 
protein concentration in this solution was assayed by mixing 50µl with an equal volume of 20% 
w/v Trichloroacetic Acid (TCA). This was vortexed and placed in the refrigerator at +4°C for 30 
minutes. The samples were microcentrifuged at 13,000rpm for 10 minutes at 4°C, the 
supernatant was aspirated and the pellet was washed twice in 200µl 10% TCA. Following the 
final centrifugation, the supernatant was aspirated and the pellet dissolved in 50µl 0.5M NaOH. 
The tubes were placed in a water bath at 70°C to ensure that all the protein had dissolved and 
protein concentration was determined using the Folin assay (see Section 2.4.1).   
 
2.5.5 Preparation of L6 skeletal muscle cell samples for SDS-PAGE  
Following incubation with test media, medium was aspirated and the plates were scraped on ice 
in SDS-PAGE L6 Sample Buffer (see Appendix A) and the cell lysates were microcentrifuged at 
13,000rpm at 4˚C for 10 minutes. The supernatant was assayed for protein using the Bio-Rad DC 
assay.   
A volume yielding 30μg protein was mixed with an equal volume of Laemmli Reducing Sample 
Buffer. The tubes were heated at 100˚C on a heating block for 5 minutes and briefly centrifuged 
in a microcentrifuge as described above. 
 
2.5.6 Running the gels 
The gel rig was assembled and transferred to a tank containing Running Buffer (See Appendix 
A). The molecular weight markers (Full-Range Molecular Weight Markers, GE Health Care Life 
Sciences, Little Chalfont, UK, RPN800E) and prepared samples were loaded into the wells. The 
gel was run at 200V until the Bromophenol Blue dye front had almost reached the bottom of the 
glass plates (approximately 50 minutes). Gels run for 14kDa fragment and 4E-BP1 were stopped 
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slightly earlier (approximately 40 minutes) to ensure these small proteins did not run off the 
bottom of the gel.   
 
2.5.7 Western Blotting 
Once the gels had been run, they were soaked in Transfer Buffer (see Appendix A) along with 
blotting paper and the appropriate transfer membrane for 15 minutes. Western blots for P-S6 
were transferred onto Polyvinylidine Fluoride (PVDF) membranes (Bio-Rad, Hertfordshire, 
UK). Western blots for 14KDa fragment, P-PKB and P-4E-BP1 were transferred onto 
nitrocellulose membranes (GE Health Care Life Sciences, Little Chalfont, UK) and the semi-dry 
transfer was performed at 15V for 30 minutes. The membranes were blocked using 5% w/v non-
fat dry milk powder (NFDM) in TTBS (see Appendix A) for 1 hour at room temperature to 
prevent non-specific binding of the antibody to proteins. In some experiments the PVDF 
membranes were treated with an enhancer reagent (Qentix Western Blot Signal Enhancer, 
Thermo Scientific, Northumberland, UK) and rinsed in ultra pure water prior to blocking. After 
blocking, the membranes were washed 3 times in TTBS As the enhancer reagent had little 
obvious effect on signal intensity and prevented the membranes from being re-probed with other 
antibodies, its use was discontinued in later experiments.  
 
2.5.8 Immunostaining 
Membranes were then probed with primary antibodies made up in TTBS and milk powder or 
Bovine Serum Albumin (BSA) (Sigma, Dorset, UK) as indicated in Table 2.3. The membranes 
were incubated with the primary antibody overnight at 4˚C with continuous agitation.  They were 
then washed 3 times with TTBS and incubated with horseradish peroxidise conjugated secondary 
antibody: goat anti rabbit (Dako, Denmark, P0448) or rabbit anti-mouse (Dako, Denmark, 
P0260) at a dilution of 1:1500. After 1 hour incubation, the membranes were again washed 3 
times in TTBS. The bands were visualised using enhanced electrochemiluminescence (ECL) 
detection system according to the manufacturers’ instructions (Thermo Scientific, 
Northumberland, UK). 
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Table 2.3. Details of Antibodies 
Antibody 
  Source Ref No Dilution 
  Blocking 
    Agent  
Secondary 
 Antibody 
PSer235/236rpS6 
 
Cell  
Signalling 2211 1:1000 5% BSA             R 
Total rpS6 
Cell  
Signalling 9456 1:1000 
5% BSA 
R 
PSer473PKB 
Cell  
Signalling 9271 1:750 
 5% BSA 
R 
Total PKB 
Cell  
Signalling 9272 1:1000 
5% BSA 
R 
PThr389P70S6K 
Cell  
Signalling 9206 1:1000 
5% BSA 
   M 
Total P70S6K 
Cell  
Signalling 2708 1:1000 
5% BSA 
R 
PSer654E-BP1 
Cell  
Signalling 9456 1:1000 
5% Milk 
Powder R 
Total 4E-BP1 
Cell  
Signalling 9452 1:1000 
5% Milk 
Powder R 
Anti-Actin 
Clone 
AC40 (14kDa) 
Sigma A4700 1:500 
5% Milk 
Powder 
     M 
SNAT2 Ap JE* - 1:4000 
5% Milk 
Powder 
    R 
Na, K, ATPase Abcam Ab7671 1:4000 
5% Milk 
Powder 
   M 
Annexin II Santa Cruz Sc-1924 1:4000 
5% Milk 
Powder 
   G 
M denotes rabbit anti-mouse HRP secondary antibody was used (Dako P0260) 
R denotes polyclonal goat anti-rabbit HRP secondary antibody was used (Dako P0448) 
G denotes rabbit anti goat HRP secondary antibody was used (Sigma A5420) 
* A kind gift from Professor J Erickson, Louisiana State University Health Sciences Centre. 
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2.6 RNA techniques 
All RNA techniques were performed using RNAse free consumables and diethylpyrocarbonate-
treated (DEPC) water. Any glassware that was used was baked at 200°C for 4 hours and 
equipment including the homogeniser was treated with RNase Zap (Sigma, Dorset, UK).  
 
2.6.1 RNA extraction 
RNA was extracted from muscle tissue using the guanidinium thiocyanate-phenol-chloroform 
extraction described by Chomczynski and Sacchi (1987) commonly known as TRIzol. 
Approximately 2mg dw muscle was homogenised in TRIzol (1.5ml) (Invitrogen, UK, 15596) 
and incubated at room temperature for 15 minutes. The tubes were microcentrifuged at 
13,000rpm for 15 minutes at 4°C to remove any insoluble material and the TRIzol solution was 
transferred to a fresh tube and Chloroform (200µl/ml TRIzol) was added. The tubes were 
vortexed thoroughly and following a 10 minute incubation at room temperature, they were 
microcentrifuged at 13,000rpm for 15 minutes at 4˚C resulting in the formation of three phases. 
The aqueous phase, containing RNA was taken off and transferred to a new tube.  Isopropanol 
(500μl/ml TRIzol) was added to precipitate the RNA and the tubes were vortexed and incubated 
at room temperature for 10-15 minutes, then microcentrifuged at 13,000rpm for 15 minutes at 
4°C. The resulting pellet was washed in 75% ethanol and dissolved in DEPC treated water 
(20µl). The RNA concentration was quantified from the optical density using a Nanodrop (ND 
1000) Spectrophotometer (Thermo Scientific, Northumberland, UK). RNA extracts were stored 
at -80°C. 
RNA was extracted from L6-G8C5 cells also using the TRIzol technique. At the end of the 
incubation time, test media was aspirated and 1ml TRIzol was added. The cells were then frozen 
at -80˚ until a time when the RNA was extracted using the method described above. 
 
2.6.2 Reverse transcription 
RNA was reverse transcribed to cDNA using the Reverse Transcription System (Promega, 
Hampshire, UK A3500). RNA (1μg) was heated at 70˚C for 10 minutes to remove any secondary 
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structure, briefly centrifuged as previously described and incubated on ice.  The reaction buffer 
was made up as follows: 
Table 2.4. RT- Reaction 
For a single 20µl reaction Volume 
(µl) 
MgCl2 4 
10X Reverse Transcription Buffer 2 
10mM dNTP Mix 2 
Rnasin Ribonuclease Inhibitor 0.5 
AMV Reverse Transcriptase 15 Units 
Primers1 
RNA 
Water                                                   
1μl 
1µg 
to 20µl 
1A mix of random and oligo dT primers was used in a 1:1 ratio. Preliminary experiments showed this 
gave the greatest RNA yield over and above that gained by using each primer individually. 
The tubes were then placed in a controlled heat block at 42˚C for 1 hour, 95˚C for 5 minutes and 
4˚C for 5 minutes. The resulting cDNA was then stored at -20˚C. 
 
2.6.3 Validation of an appropriate reference gene 
To control for the variation in the loading of cDNA into the PCR reaction it is important to have 
a reference gene whose level of expression remains stable over all the experimental conditions. 
Commonly used exercise reference genes are β-actin, β-microglobulin and GAPDH (Jemiolo and 
Trappe, 2004; Mahoney et al. 2004). qPCR primers for these genes were available in our 
laboratory, but preliminarily experiments showed that the expression of all of these genes in 
skeletal muscle from the exercising patients varied outside the acceptable limits (1 comparative 
threshold, cT value) to be used as a reference gene. Therefore, in order to identify the most 
appropriate reference gene, an endogenous control plate (Applied Biosystems, Warrington, UK, 
4396840) was used to screen 32 different control genes using the cDNA derived from one patient 
before and after exercise training. The results showed ribosomal protein L30 (RPL30) and beta-
glucuronidase (GUSB) were the most stable with exercise training (see Table 2.5) and the most 
highly expressed. 
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Primers were designed for RPL30, GUSB and SNAT2 using Primer-3 software version 0.4.0 
(www.primer3.Sourceforge.net) using gene sequences obtained from the NCBI nucleotide 
database. They were all designed to span an intron-exon boundary to allow any product 
amplified contaminating genomic DNA to be distinguished. Primers were checked for sequence 
homology to other genomic sequences using the NCBI Basic Local Alignment Search Tool 
(BLAST) and were commercially synthesized (Invitrogen, UK). All primers were designed and 
optimised to amplify with an annealing temperature of 56°C allowing all genes to be run on the 
same plate. Primer’s PCR efficiency was calculated by performing a serial dilution reaction and 
drawing a standard curve (see Table 2.6 for efficiencies). 
 
Table 2.5. Results of endogenous control plate  
Gene Name Coefficient of 
Variation (%) 
Gene Name Coefficient of 
Variation (%) 
18S 4.7 MT-ATP6 0.7 
ABL1 0.6 PES1 0.01 
ACTB 5.8 PGK1 1.6 
B2M 2.3 POLR2A 3.2 
CASC3 0.4 POP4 1.7 
CDKN1A 2.1 PPIA 1.7 
CDKN1B 0.2 PSMC4 1.7 
EIF2B1 1.6 PUM1 1.3 
ELF1 1.7 RPL30 0.17 
GADD45A 1.3 RPL37A 0.4 
GAPDH 3.3 RPLPO 2.4 
GUSB 0.6 RPS17 3.3 
HUBS 1.3 TBP 1.7 
HPRT1 1.4 TFRC 0.2 
IPO8 1.3 UBC 2.5 
MRPL19 2.1 YWHAZ Undetermined 
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2.6.4 DNA sequencing 
The amplified products generated from the SNAT2, RPL30 and GUSB primers were sequenced 
to confirm that the correct amplicon was produced. 
 
2.6.5 Principle of the DNA sequencing technique 
Primer amplification products were sequenced at the Protein Nucleic Acid Chemistry Laboratory 
(PNACL) at the University of Leicester using Fluorescence-Based Sequencing and Dye 
Terminator Chemistry on an Applied Biosystems 3730 sequencer (Applied Biosystems, 
Warrington, UK). This technique requires the DNA template, a modified DNA polymerase, 
nucleotides (dNTPs), and dideoxynucleotides (DdNTPs) with each of the four bases labelled 
with a different colour fluorescent dye, and a buffer. This is then subjected to cycles of 
annealing, extension and denaturation in a thermo cycler. The modified DNA polymerase allows 
the incorporation of DdNTP into the product. As DdNTP lacks a 3-hydroxyl (3-OH) group on its 
deoxyribose sugar which is already lacking a 2-OH group, no further nucleotides can be added as 
a phosphodiester bond is unable to be formed and this terminates the fragment. The ratio of 
dNTP and DdNTP is balanced to ensure that a mixture of long and short extension products are 
produced. This has the result of producing many extension products of different sizes. At the end 
of the reaction, a high voltage charge is applied to the buffered reaction products forcing the 
negatively charged fragments into a capillary separating them by size based upon their total 
charge. Before reaching the positive electrode, the fragments pass through a laser beam causing 
the dyes to fluoresce emitting a wavelength specific to the base. This signal is then converted to a 
digital signal producing a series of peaks indicating the DNA sequence. 
 
2.6.6 Sequencing protocol for fluorescence-based sequencing using dye terminator 
chemistry 
The PCR product was run out on a 1% agarose gel in DNA sample buffer (see Appendix A) plus 
Ethidium Bromide with a DNA molecular weight ladder (ΦΧ174 Hae III Digest, Sigma, Dorset, 
UK). An electric current was applied at 120V until the DNA sample buffer dye front had moved 
approximately three quarters of the way down the gel. The bands were visualized under UV 
light, cut out of the gel and placed in pre-weighed tubes. The DNA was extracted from the gel 
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using a Qiaex II gel extraction kit according to the manufacturer’s instructions (GE Health Care 
Life Science, Little Chalfont, UK). The extracted DNA was quantified by running on a 0.8% 
agarose gel with the DNA markers (φχ174 DNA Hae III digest, Sigma, Dorset, UK). Two 
sequencing reactions were then performed, one using the forward primer and the second using 
the reverse primer. 20μg DNA template was required for each sequencing reaction plus the 
primer (4pmol) and 8μl BigDye terminator V1.1 (PNACL Laboratory, University of Leicester). 
The sequencing reaction was performed in a controlled heat block at 94˚C for 30 seconds then 30 
cycles of the following, 96˚C for 10 seconds, 50˚C for 5 seconds and 60˚C for 4 minutes. Any 
unincorporated dyes were removed using the ethanol/sodium acetate precipitation method; 3M 
sodium acetate (2μl) and 95% ethanol (50μl) was added and incubated on ice for exactly 10 
minutes. The tubes were then centrifuged at 13,000rpm for 30 minutes at room temperature. The 
supernatant was removed and pellets washed with 70% ethanol (150μl) by gently agitation and 
centrifuged at 13,000rpm for 1 minute at room temperature. The supernatant was taken off and 
pellets left to dry. They were then sent to the PNACL at the University of Leicester for the 
amplicon to be sequenced (3730 sequencer, Applied Biosystems, Warrington, UK). 
 
2.6.7 Real time qPCR 
All qPCR was carried out on an Applied Biosystems Light cycler real time PCR machine. 
Amplification reactions for SNAT2 were set up in 25µl volumes containing 12.5µl Power 
SYBR® Green PCR Master Mix (Applied Biosystems, Warrington, UK) with 10pmol per 25µl 
forward primer, 10pmol per 25µl reverse primer and 10.5µl sterile water. cDNA (or water if a 
negative control) (1µl) was added once 24µl of the mastermix detailed above had been added to 
the plate. All samples were run in triplicate with negative controls for each gene. All Primers 
were optimised to run at 56°C for the extension phase of the amplification. A dissociation step 
was added onto the end of the cycling to check that no non-specific product amplification had 
occurred. Primers and probes for MAFbx and MuRF-1 were supplied as Taqman gene 
expression assays from Applied Biosystems (Applied Biosystems, Warrington, UK, MAFbx 
Hs00369714_m1, MuRF-1 Hs00822397_m1, RPL30 Hs00265497_m1) 
The stability of expression of RPL30 and GUSB in response to exercise training was then tested 
in five more patients. RPL30 proved to be the most stable (RPL30 = 1.7% CV and GUSB 1.9% 
CV)  and so was selected as the house keeping gene to be used in all qRT- PCR experiments 
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using RNA extracted from human muscle samples. For qRT-PCR experiments performed using 
L6 rat skeletal muscle cells, cyclophilin was used as the reference gene as it had been used 
previously in L6 cell cultures and in rat skeletal muscle in catabolic states (Pickering et al. 2003). 
qRT-PCR primers were designed and sequenced for rat SNAT2 and Cyclophilin using the same 
method as that described above. 
Table 2.6. Primer sequences and efficiencies 
Gene 
 
Forward 
Sequence 
Reverse 
Sequence 
 
       PCR 
Efficiency (%) 
SNAT2 (Hu) AGTGGAATCCTTGGGCTTTC TCCTTCATTGGCAGTCTTCA 96.1% 
RPL30 (Hu) GGGTACAAGCAGACTCTGAA CCAGTTTTAGCCAACATAGC      97.5% 
GUSB (Hu) CTTTTTCAACTACGCTGGAC ACGACTTTGTTTTCTGCATC      96.3% 
SNAT2 (Rat) GCTCATTCTCCCATTGTCAC TTGCAAATCACCACAATCAG      98.5% 
Cyclophilin 
(Rat) 
CACCGTGTTCTTCGACATC TGCTGTCTTTGGAACTTTGTC      96.0% 
PCR data were quantified and presented as the Pfaffl ratio according to the following equation 
cited in Pfaffl (2001). 
 
ratio = 
ሺE Targetሻ ∆CT Target ሺControl כ –  Treatmentሻ
ሺE Referenceሻ∆CT Reference ሺControl כ െTreatmentሻ
 
Where E = PCR efficiency and CT = comparative threshold value. 
*In the exercise studies this control value was the baseline value at the start of the study 
 
2.7 Quantification of bands from Western and Northern Blotting 
Band intensities were quantified using a Bio-Rad GS7000 densitometer and Molecular Analyst 
v1.4 software. 
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2.8 Statistical Analysis 
Data were tested for normal distribution using the Kolmogorov–Smirno test. All normally 
distributed data are presented as mean ± SEM. All non-normally distributed data are presented as 
median and range values.  Western and Northern blotting data are expressed as a percentage of 
the positive control run on the same gel. For both the one month pilot study and the six month 
study, baseline vs post-treatment values were analysed using Paired t tests for normally 
distributed data where appropriate and non-parametric Wilcoxon Signed Ranks test for non- 
normally distributed data. Data from cell culture experiments were analysed for statistical 
significance by ANOVA and post hoc testing with Duncan multiple range test. Changes were 
regarded as significant when P<0.05. Correlation was expressed as the Spearman Rank 
Correlation Coefficient Rs. All statistical analysis was carried out using SPSS 16.0 software 
(SPSS, Chicago, IL). 
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Chapter 3 
 
 
 
In vivo study of the effect of exercise and metabolic 
acidosis correction on amino acid and protein metabolism 
in skeletal muscle in CKD 
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3.1 Introduction 
It is well documented that CKD patients have poor physical functioning (reduced ability to 
perform everyday activities) and low exercise capacity (Painter, 2005; Johansen et al. 2007). 
This is caused by a combination of inactivity (Tawney et al. 2003), muscle wasting and reduced 
muscle function and metabolism (Diesel et al. 1990), inflammation (Kaizu et al. 2003) and 
anaemia (Painter and Moore, 1994) It has been suggested that the abnormalities in muscle 
metabolism are the most important limiting factors to exercise capacity (Diesel et al. 1990).There 
is growing evidence that exercise can provide benefits to haemodialysis patients such as 
improved exercise capacity (Painter et al. 2002; Kouidi et al. 2004), a reduction in cardiac risk 
factors (Goldberg et al. 1986), improved insulin sensitivity and glucose disposal (Goldberg et al. 
1983, 1986), increased quality of life and reduced depression (Painter et al. 2000). However, 
there has been little research performed in this area on the pre-dialysis population. 
 
As previously described in Chapter 1.6, metabolic acidosis is a common problem in CKD 
patients (Kovacic et al. 2003) and is an accepted cause of muscle wasting (Mitch, 2006). 
Acidosis is known to disrupt insulin action resulting in insulin resistance, but it has been shown 
that this can be improved following exercise training in haemodialysis patients (Goldberg et al. 
1980, 1986) and there is some evidence that muscle catabolism (indicated from accumulation of 
the 14kDa fragment) can be slowed by combined strength and endurance exercise training in 
dialysis patients (Workeneh et al. 2006). Furthermore, Storer and colleagues (2005) found eight 
weeks of intradialytic exercise (three times a week) significantly increased quadriceps strength, 
power and fatigability. These authors attributed this effect of endurance exercise on muscle 
strength to the significant deconditioned state of the patients prior to the exercise training. 
However, Kopple et al. (2007) were unable to detect any increases in lean body mass following 
an 18 week exercise programme of either aerobic or resistance training, alone or in combination. 
The reason for this failure of exercise to induce any detectable increase in muscle mass is 
unknown, but exercise in non-dialysed patients could potentially result in a transient worsening 
of acidosis through exercise-induced lactic acid generation, and could therefore off-set any 
potential benefits gained from the exercise. It might be possible to neutralise this acid through 
the administration of extra alkali, but there are no studies to date that have investigated the effect 
of exercise training in combination with sodium bicarbonate therapy in these patients. 
Favourable gains in body mass have been achieved however, in peritoneal dialysis patients, 
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using a high alkali dialysis fluid (Stein et al. 1997) and additional alkali in the form of sodium 
bicarbonate (Szeto et al. 2003). 
As described above, acidosis correction alone (Kooman et al. 1997), and exercise alone 
(Workeneh et al. 2006) can both reduce accelerated muscle protein degradation, but the effect of 
the two therapies combined has not been investigated. Therefore, the aim of this study was to 
implement a six month aerobic training study in pre-dialysis patients with and without additional 
bicarbonate therapy, and to investigate the resulting effects upon muscle amino acid and protein 
metabolism.  Owing to the results of Storer et al. (2005), this study used walking exercise to 
investigate these changes. Exercise had not previously been implemented in our renal unit and 
although there are no reports in the literature of any adverse effects of exercise in this population, 
it was believed walking exercise would be safer and easier to implement in a non-supervised 
exercise programme.  
 
It was hypothesised that six months of walking exercise would increase LBM (as measured by 
DEXA) compared to the control group. This would be associated with increased myofibrillar 
protein synthesis rates and reduced protein degradation rates. Increased protein synthesis would 
be detected by increased basal insulin signalling (increased phosphorylation of PKB, P70S6K and 
4E-BP1). Increased myofibrillar protein degradation would be detected by a reduction in MuRF-
1 and MAFbx mRNA expression, reduced levels of 14kDa fragment, reduced 3-MH excretion 
rates and an increase in muscle protein:DNA ratio. It was also hypothesised that additional 
sodium bicarbonate therapy would further correct acidosis causing the effects of exercise and 
acidosis correction to be additive. 
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3.2 Methods 
3.2.1 Ethical approval 
The studies described in Chapters 3 and 4 which required patient involvement received ethical 
approval from the Medicines and Health Regulatory Authority (MHRA) and the Local Ethics 
Committee. The sampling of skeletal muscle from healthy volunteers in Chapter 3, received 
ethical approval from the Loughborough University Ethical Advisory Committee. Potential 
participants from the patient population were approached in person at a routine hospital 
appointment. They were contacted a few days later by telephone to confirm their interest to 
participate. Potential healthy volunteer participants were approached in person, or contacted by 
email or telephone.   
All participants were given information regarding the study protocol, assessments and any 
associated risks.  Following any questions, participants who wished to volunteer signed a written 
statement of consent and were made aware of their right to withdraw from the study at any point 
without the need to give a reason. 
 
3.2.2 Participant information 
Patient characteristics and basic clinical biochemical measurements for the participants are 
summarised in Table 3.1. Patient volunteers were recruited from the Leicester General Hospital. 
Participants were CKD patients classified as CKD stage 4-5. Exclusion criteria included a 
physical disability (sufficient to prevent involvement in an exercise programme), age under 18 
years, pregnancy, regular intake of aspirin, (or any other substance that would affect blood 
clotting) and particularly for the main study, those patients judged to be in imminent need of 
renal replacement therapy. Healthy volunteers were recruited from the University or hospital 
staff, as well as spouses of those participants in the patient arm of the study. All healthy 
volunteers were required to be in good general health with no signs of renal impairment or other 
diseases associated with muscle wasting.   
 
 
 
Table 3.1.  Patient characteristics at baseline. Values are displayed as median and range. 
Patient 
Involvement 
Completed 
(n) Males Females 
Age   
(years) 
Weight 
(kg) 
Height 
(m) BMI 
Serum 
Creatinine 
(µmol/l) 
eGFR 
(ml/min) 
Plasma 
Bicarbonate 
(mmol/l) 
 
STD 
Bicarb 
(n) 
 
XS 
Bicarb 
(n) 
One Month 24 18 6 60         (30-76) 
78         
(53-116) 
1.70        
(1.45-1.92) 
26.6        
(20.4-37.4) 
292        
(132-960) 
19        
(7-35) 22 (19-29) 13 11 
One Month 
+ Biopsy 16 12 4 
60         
(30-76) 
79         
(53-116) 
1.70        
(1.48-1.92) 
27.1        
(20.4-37.4) 
256         
(132-960) 
21        
(9-35) 22 (19-28) 9 7 
Six Months 18 11 7 62         (50-73) 
80         
(53-116) 
1.72        
(1.48-1.92) 
28          
(20.4-33.5) 
205         
(132-506) 
26        
(11-36) 25 (19-29) 10 8 
Six Months  
+ Biopsy 15 8 7 
62         
(50-73) 
80         
(53-116) 
1.70        
(1.48-1.92) 
29.9     
(20.4-33.5) 
190         
(132-506) 
26        
(11-36) 25 (19-27) 9 6 
Non-
Exercising 
controls 
14 8 6 56         (31-83) 
85.5       
(60-125) 
1.76        
(1.55-1.87) 
29.2        
(19-38) 
205         
(139-427) 
28        
(12-37) 27 (19-30) 8 6 
Non-
Exercising 
controls       
+ Biopsy 
11 5 6 50         (31-83) 
85.5       
(66-115) 
1.73        
(1.57-1.87) 
29.6        
(19-38) 
214         
(154-427) 
24       
(12-33) 26 (19-30) 8 3 
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3.2.3 Explanation of study design 
A flow diagram to illustrate patient’s involvement and study design is shown in Figure 3.1. A 
one month pilot study preceded this six month exercise training study. The pilot study was 
designed to test the logistics of running a training study in this patient population and to address 
any problems that were identified prior to embarking on the main study. At baseline the patients 
underwent an exercise tolerance test, assessments of skinfold thickness and mid-arm 
circumference, blood sampling, if consent was given, a muscle biopsy, and were asked to keep a 
3-day food diary.  Patients also travelled to the Royal Derby Hospital for a full body Dual 
Energy X-ray Absorptiometry (DEXA) scan. These assessments were repeated after one month 
and six months of exercise training. At the end of the pilot study all patients were given the 
choice of continuing into the main study or finishing their involvement upon completion of one 
month of exercise.  Those patients who consented to continue into the main study did so without 
a break to avoid contaminating the baseline results of the main study with the effects of a 
previous one month of exercise. Those who did not wish to participate any further in the study 
withdrew and were replaced with a new patient who entered the 6 month study with no 
assessments at the one month time point. The non-exercising control patients took part only in 
the 6 month study, with assessments made at baseline and after 6 months during which time 
physical activity was not encouraged. By volunteering, the patients self-selected themselves into 
the exercise group.  
 
Participants were randomized to receive additional acidosis correction by sodium bicarbonate 
supplementation (abbreviated to XS throughout this thesis), or to remain on their standard 
sodium bicarbonate prescription (abbreviated to STD throughout this thesis). The target serum 
bicarbonate level in the XS group was 28mmol/l and 25mmol/l in the STD group, the level that 
clinicians at the Leicester Renal Unit routinely aim to achieve. 
 
Muscle biopsies were also taken from a group of healthy volunteers. This was a single biopsy 
(with no intervention) and served only to provide reference material for comparison with the 
CKD patients for some of the analyses. 
 
 Figure 3.1. Flow diagram to illustrate patient involvement and study design. 
5 Months
14 non-exercising 
controls complete
18 exercisers 
complete
Repeat Baseline Tests
Repeat Baseline Tests
1Month
10 dropout
Randomised 
to STD or XS 
bicarbonate 
group 
Baseline Tests
1) Exercise tolerance tests with blood sampling before and after
2) Muscle Biopsy with arterial and venous blood sampling
3) Anthropometric assessments
4) 3-day food diary
5) 24h urine collection following 3 days of diet free from animal protein (To 
also be used in Chapter 4)
6) DEXA scan in collaboration with Derby City Hospital
33 CKD patients 
Stage 4-5 
recruited for one 
month study
20 CKD patients 
stage 4-5 
recruited as 
non-exercising 
controls 6month 
study
5 CKD patients 
stage 4-5 
recruited to 
replace exercisers 
who left after 1 
month
6 Months
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3.2.4 Description of the exercise tolerance test 
The exercise test was performed at the Leicester General Hospital on a treadmill (Life Fitness, 
UK) with a physician present. The test was a 30 minute submaximal exercise tolerance test, the 
intensity of which was measured throughout using Rating of Perceived Exertion (RPE) using the 
Borg scale (Borg, 1982) and heart rate (HR). Despite the reproducibility of RPE being 
questionable, it is frequently used in exercise tests and in exercise prescription in the CKD 
population (Sakkas et al. 2003; Koufaki et al. 2002; Segura-Orti et al. 2009; Fuhrmann and 
Krause, 2004) due to the inherent variability in HR in these patients and also because it provides 
a sensitive index of how the patients feel during the exercise bout (Koufaki et al. 2002). Patients 
were familiarized with the RPE scale and the treadmill and were fitted with a polar heart rate 
monitor (Polar Electro, Kempele, Finland). The treadmill was set at a 1% incline to mimic the 
energy cost of walking outside and the speed was increased to elicit a RPE of 12-14, somewhat 
hard. Every two minutes the patient’s heart rate was recorded, they were asked their RPE and the 
treadmill speed was then altered or remained the same depending upon their response. In the 
event of the patient being unable to complete the 30 minute test, the time completed was noted 
along with their heart rate and RPE. After the one and/or six month period, the baseline exercise 
test was replicated exactly as at baseline: treadmill speeds were the same at each corresponding 2 
minute time point over the 30 minute test, and heart rate and RPE were recorded as before. 
Blood samples were drawn from a superficial antecubital vein prior to, and immediately upon 
completion of the exercise test. Blood samples were handled as described in Chapter 2.2. 
 
3.2.5 Exercise prescription 
The results from the exercise test were used to prescribe individual exercise programmes that 
were reassessed on a monthly basis. Patients were asked to exercise for 30 minutes five times a 
week at a level of intensity that they deemed to be “somewhat hard”. The exercise usually 
involved brisk walking, although a few of the patients were fit enough to begin light jogging. 
They were informed of their heart rate range at the desired exercise intensity during the test and 
were given a heart rate monitor that was to be used as an individual guide of exercise intensity 
when exercising at home. Patients were also asked to record all their exercise in a diary stating 
what they did, the duration and how hard they rated it overall on the Borg scale. Once a month 
the patients attended an exercise class held at the physiotherapy gymnasium at the Leicester 
General Hospital to meet with a doctor to discuss any problems that may have arisen, update 
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exercise programmes, check bicarbonate levels and dosage for those patients on XS bicarbonate 
treatment, and to help increase motivation. 
  
3.2.6 Blood sampling, handling and analysis 
Prior to the muscle biopsy, a 7ml venous blood sample was taken from a superficial antecubital 
vein, drawn into a dry syringe and dispensed into a tube containing the anticoagulant K2 EDTA. 
This sample served as the baseline or pre-exercise sample and was also the sample that was used 
in the analysis of plasma amino acid concentrations. Immediately following the exercise test a 
second venous blood sample was taken from a superficial antecubital vein and treated as above. 
In additional to this, an arterial blood sample was also taken prior to the muscle biopsy. A 3ml 
sample was taken from the brachial artery following the administration of 1% lignocaine, drawn 
into a blood as syringe containing heparin and taken to the Pathology Department at the 
Leicester General Hospital for analysis of arterial pH and bicarbonate.  Unless otherwise stated, 
all assays described below were performed in duplicate. 
Duplicate 100µl aliquots of whole blood in K2 EDTA were immediately deproteinsed in 1ml ice 
cold 0.3M Perchloric Acid (PCA). These tubes were then centrifuged and the resulting 
supernatant was used in the spectrophotometric determination of blood glucose concentration 
measured on the day of the assessment using a commercially available kit (GodPAP; Randox, 
Co.Antrim, UK). The remaining acid supernatant was then frozen at -80°C for the fluorometric 
determination of blood lactate and β- hydroxybutyrate using the methods described by Maughan 
(1982). 
 The EDTA-treated whole blood was used in the spectrophotometric determination of 
haemoglobin (Hb) using the cyanmethaemoglobin method and Packed Cell Volumes (PCV) 
measured in triplicate on a microhaematocrit centrifuge. Both were measured on the day of 
assessment. The remaining EDTA-treated blood was centrifuged at 1500g for 15 minutes at 4°C. 
The plasma was taken off and 1ml aliquots were stored at -80°C for the analysis of plasma amino 
acid concentration.  The blood collected from healthy volunteers was dispensed into a plain tube 
and allowed to clot at room temperature for approximately 1 hour. The clot was removed and the 
sample centrifuged at 1500g for 10 minutes at 4˚C. The serum was removed and placed into a 
fresh tube and analysed for creatinine concentration using a commercially available colorimetric 
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assay kit (BioAssay Systems, CA, USA, DICT-500) according to the manufacturer’s 
instructions. 
 
3.2.7 Muscle sampling and handling  
Muscle biopsies were taken from patients using a Bergström needle by a trained physician at the 
Leicester General Hospital. Patients reported to the procedure room on the nephrology ward after 
an overnight fast. Fasting conditions were used to allow for the investigation of amino acid 
metabolism under the same conditions as those used by Bergström et al. (1990). 
 
All biopsies were taken using a Bergström needle from the vastus lateralis muscle of the right leg 
with the patient in the supine position, and any subsequent biopsies were taken 1cm above or 
below the initial site. The area was first cleaned using an antiseptic and 1% lignocaine was 
administered superficially under the skin and fascia. A 1cm incision was made and the needle 
was inserted to a depth of approximately 3cm. Suction was used to draw the muscle tissue into 
the needle. To minimise trauma, small samples (rather than one large sample) were drawn as 
rapidly as possible until approximately 100mg wet weight had been obtained. The sample was 
immediately extracted from the needle and following the removal of any visible fat or connective 
tissue it was placed into a pre-weighed Eppendorf tube and quickly frozen in liquid nitrogen. 
Pressure was applied to the biopsy site for a few minutes and steri-strips placed over the incision. 
In the laboratory, the Eppendorf tube was removed from liquid nitrogen and immediately re-
weighed to the nearest 0.1mg to obtain the wet weight of the sample. This allowed for the 
calculation of the water content of the biopsy to investigate if XS bicarbonate had caused any 
water loading in these patients. A correction of 0.0027g was subtracted from all values to allow 
for frost formation on the outside of the tube. This was based on the result of the difference in the 
weight of Eppendorf tubes at room temperature and immediately following freezing in liquid 
nitrogen repeated ten times. The results ranged from 0.0026g to 0.0032g with a mean of 0.0027g. 
The Eppendorf tube containing the muscle tissue was placed into a glass flask and freeze-dried 
(Edwards, Modulyo, UK with RV8 vacuum pump). The sample was re-weighed at regular 
intervals and was considered to be dried when there were no further changes in weight. 
Approximately 20mg dry weight in total was obtained using the Bergström needle. The muscle 
sample was stored at -80°C.  
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All healthy volunteer muscle biopsies were taken in the department of Sport, Exercise and 
Health Sciences at Loughborough University by the same physician who performed the patient 
sampling, using the same method. 
Samples from all time points and patient groups were processed and analysed at the same time 
and were subjected to three types of analysis; amino acid concentration determined by HPLC, 
gene expression using real time polymerase chain reaction (PCR) and protein detection using 
Western Blotting. 
 
3.2.7.1 Determination of the protein content of muscle biopsies 
The total soluble protein content of muscle biopsies was measured using the Folin Lowry assay 
(see Chapter 2.4.1).  Determination of protein concentration in muscle lysates to be run on SDS-
PAGE was done using the Bio-Rad DC assay (see Chapter 2.4.2). 
 
3.2.7.2 Determination of the concentrations of intramuscular and plasma amino acids 
Muscle and plasma were analysed for their full amino acid profiles by High performance liquid 
chromatography (HPLC) (see Chapter 2.3) Results are shown for the 18 amino acids that were 
readily detectable in the muscle biopsies. 
 
3.2.7.3 Determination of DNA content of muscle biopsies using Burton DNA Assay 
Total DNA concentration in muscle extracts was measured using the Burton DNA assay. The 
pellet obtained following acid precipitation and centrifugation in Section 2.3.1 above, was 
resuspended in 10% PCA (400μl). The tubes were placed in a water bath at 70°C for 20 minutes 
to hydrolyse the DNA and vortexed at regular intervals throughout. They were then incubated at 
4 °C for 30 minutes and microcentrifuged at 13,000rpm for 15 minutes at 4°C. The resulting 
supernatant was used in the determination of DNA concentration using the Burton assay.  
Standards (0 - 200µg/ml of calf thymus DNA) and samples (100μl) were added to Eppendorf 
tubes followed by the addition of 4% w/v diphenylamine (DPA) (100μl) and 0.2% v/v 
acetaldehyde (20μl), (both of which were made up in glacial acetic acid) and vortexed. The tubes 
were incubated overnight at room temperature in the dark. The following morning, 190µl from 
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each tube was pipetted into a 96 well plate and read at 595nm and immediately again at 710nm 
with subtraction of the 710nm value as a blank from all samples. 
 
3.2.7.4 Determination of the chloride concentration of muscle samples 
Chloride was determined by turbidimetry by a modification of the method of Mesquita et al. 
(2002). This assay was performed on the neutralised muscle and plasma samples obtained in 
Sections 2.3.1 and 2.3.2.  Prior to the assay, the plasma samples were diluted 1:100 using ultra 
pure water. A 50µl aliquot of Cl- standard (0 – 1mM) or sample was pipetted into a 1.5ml 
Eppendorf tube with 50µl Precipitating Reagent (5mM Silver Perchlorate, 4% dextran in 2M 
PCA) and vortexed. From this, 95µl was transferred into a 96 well plate and incubated for 2h 
before reading at 405nM on a Titertek Mulitscan spectrophotometer. 
 
3.2.7.5 Determination of phosphorylated signals and 14kDa accumulation by Western 
blotting 
The phosphorylation status of proteins in the PI3-K/PKB signalling pathway were analysed by 
Western Blotting before and after exercise training. Proteins analysed were PKB, rpS6, P70S6K 
and 4E-BP1. The accumulation levels of the 14kDa actin fragment were also analysed using this 
technique. Western Blotting method used is detailed in Section 2.5.2. 
 
3.2.7.6 Determination of protein mRNA expression by real-time PCR 
The mRNA expression levels of SNAT2, MuRF-1 and MAFbx in the muscle biopsies were 
analysed before and after exercise training. Primers for MuRF-1 and MAFbx were supplied as 
Taqman gene expression assays from Applied Biosystems (Applied Biosystems, Warrington, 
UK, MAFbx Hs00369714_m1, MuRF-1 Hs00822397_m1). SNAT2 gene expression was 
quantified using SYBR green real-time PCR. Methods for RNA extraction and PCR experiments 
are detailed in Section 2.6. 
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3.2.8 Urine sampling and handling 
Those patients who consented, underwent a diet free from animal protein for four days prior to 
the exercise training, with a 24h urine collection on the final day. This was repeated after one 
and/or six months of exercise training.  Urine samples were analysed for volume and aliquots 
stored at -20°C for later analysis of 3-MH by HPLC as described in Section 2.3.2. 
 
3.2.9 Analysis of food diaries 
Patients were asked to keep a 3-day food diary prior to the commencement of exercise training, 
following one month, and at the end of the six month training period. Food diaries were analysed 
for energy content and macronutrients using the CompEat Pro version 5.8.0 nutritional analysis 
software (Grantham, UK). 
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3.3 Results 
3.3.1 Bicarbonate therapy and completion rates 
No ill effects were reported as a result of taking extra bicarbonate; however, technical difficulties 
were experienced in obtaining muscle biopsies at the one month point from patients receiving XS 
bicarbonate: specifically the biopsies were found to contain considerable amounts of fibrotic 
tissue and will be discussed in more detail in Section 3.4.6. For this reason, data from this group 
will not be presented. 
Throughout these results, standard bicarbonate therapy is referred to as STD and additional 
bicarbonate as XS. 
 
Table 3.2. Effect of STD and XS bicarbonate therapy on blood bicarbonate levels and pH 
for those patients in the one month pilot study. Data are presented as median and range. * 
denotes significant difference from corresponding baseline value (P<0.05). a denotes significant 
difference from STD group at corresponding time point(P<0.05). 
    Baseline One Month 
Arterial pH 
1 Mth Ex STD Bicarbonate 7.38 (7.31 – 7.42) 7.4 (7.27 – 7.49) 
1 Mth Ex XS Bicarbonate 7.36 (7.33 -7.40) 7.4 (7.36 – 7.42)* 
PCO2 (kPa) 
 
1 Mth Ex STD Bicarbonate 3.5 (1.8 – 4.2) 3.4 (1.3 – 4.3) 
1 Mth Ex XS Bicarbonate 3.5 (1.8 – 4.6) 3.6 (1.4 – 5.6) 
Venous 
Bicarbonate 
(mmol/l) 
1 Mth Ex STD Bicarbonate 21 (19 -27) 22 (16 – 28) 
1 Mth Ex XS Bicarbonate 21 (19 – 29) 27 (21 -30)*a 
 
 
 
 87 
 
Table 3.3. Effect of STD and XS bicarbonate therapy on blood bicarbonate levels and pH 
for those patients in the six month study. Data are presented as median and range. * denotes 
significant difference from corresponding baseline value (P<0.05). a denotes significant 
difference from STD group at corresponding time point (P<0.05). 
   Condition Baseline Six Months 
 6 Mth Ex STD Bicarbonate 7.41 (7.31 – 7.43) 7.39 (7.34 – 7.48) 
Arterial pH 
6 Mth Ex XS Bicarbonate 7.36 (7.28 – 7.40) 7.41 (7.35 – 7.44) 
Non-exercising Control STD 
Bicarbonate 
7.39 (7.30 – 7.45) 7.42 (7.35 – 7.44) 
 
Non-exercising Control XS 
Bicarbonate 
7.39 (7.31 – 7.48) 7.36 (7.32 – 7.42) 
  6 Mth Ex STD Bicarbonate 3.7 (1.8 – 4.5) 3.7 (2.4 – 4.5)  
PCO2 (kPa) 
6 Mth Ex XS Bicarbonate 3.6 (1.1 – 4.6) 3.8 (3.3 – 4.6)  
 Non-exercising Control STD 
Bicarbonate 
4.1 (2.8 – 4.7) 3.6 (2.6 – 4.7) 
 
Non-exercising Control XS 
Bicarbonate 
2.9 (1.9 – 4.8) 3.7 (3.2 – 4.9)  
  6 Mth Ex STD Bicarbonate 25 (21 – 26) 25 (20 – 28)  
Venous 
Bicarbonate 
(mmol/l) 
6 Mth Ex XS Bicarbonate 22 (19 – 29) 27 (26 – 30)*
a  
 Non-exercising Control STD 
Bicarbonate 
25 (19 – 30) 26 (23 – 27)  
 Non-exercising Control XS 
Bicarbonate 
27 (24 – 32) 30 (26 – 31)
a
  
 
The effect of bicarbonate therapy on arterial pH and partial pressure of CO2 are displayed in 
Tables 3.2 and 3.3. The XS bicarbonate therapy successfully raised venous bicarbonate 
concentrations above those in the STD group after both one and six months, and in the one 
month study, XS therapy was also able to significantly increase the arterial pH. 
 
The patient completion rates are shown in Table 3.4. The lowest dropout rate of 10% was seen in 
the six month exercising patients, while the non-exercising control group and one month pilot 
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study saw a 30% dropout rate each. A higher dropout was seen in those taking XS compared to 
STD bicarbonate therapy but this did not reach statistical significance P>0.05 χ2 test.  Reasons 
for withdrawal from the study were progression onto haemodialysis, clinical deterioration and 
family or work commitments. There were no fatalities.  
 
Table 3.4. Patient completion rates. 
Group 
Patients Consented 
(n) 
Patients Completed (n) 
All patients One Month Ex 30 24 
All Patients Six Months Ex 20 18 
All  Non-exercising Controls 20 14 
One Month Ex STD 16 13 
One Month Ex XS 14 11 
Six Months Ex STD 10 10 
Six Months Ex XS 10 8 
Non-exercising Controls STD 10 8 
Non-exercising Controls XS 10 6 
 
3.3.2 Exercise tolerance tests 
Mean response in the exercise tolerance test is shown in Figures 3.2 – 3.4 and average walking 
speeds during the test are presented in Table 3.5. Exercise tolerance (individuals’ RPE averaged 
over the whole 30 minute test) significantly improved after one (P<0.001) and six months 
(P<0.001) of exercise which is demonstrated by a lower RPE to the same absolute exercise 
intensity as that recorded prior to the training period (Figures 3.2 and 3.3). The decline in RPE 
following one month of training was more apparent in the XS bicarbonate group (Figure 3.2B) 
than in the STD bicarbonate group (Figure 3.2A). However, this apparent effect of XS 
bicarbonate was not sustained at six months; indeed the decline in RPE seemed less marked at 
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this time in the XS group (Figure 3.3B) compared to the STD group (Figure 3.3A). The non-
exercising control group showed only small time-dependent changes in RPE over the six month 
period (Figure 3.4). 
Table 3.5. Patient walking speeds during the exercise tolerance test. 
 Walking Speed (km/h) 
Time 
(minutes) One Month Study 
Exercising Patients: Six 
Month Study 
Non-Exercising Control 
Patients: Six Month Study 
2 2.8 ± 0.2 2.7 ± 0.2 2.6 ± 0.2 
4 3.5 ± 0.3  3.5 ± 0.3 3.3 ± 0.3 
6 4.0 ± 0.3  3.8 ± 0.3 3..8 ± 0.4 
8 4.2 ± 0.3  4.0 ± 0.3 4. 0 ± 0.4 
10 4.4 ± 0.3  4.1 ± 0.3 4.2 ± 0.4 
12 4.5 ± 0.3  4.2 ± 0.3 4.2 ± 0.4 
14 4.6 ± 0.3  4.4 ± 0.4 4.3 ± 0.4 
16 4.6 ± 0.3  4.6 ± 0.4 4.3 ± 0.4 
18 4.7 ± 0.3  4.6 ± 0.3 4.3 ± 0.4 
20 4.7 ± 0.3  4.7 ± 0.3 4.4 ± 0.4 
22 4.8 ± 0.3  4.7 ± 0.3 4.2 ± 0.3 
24 4.8 ± 0.3  4.8 ± 0.3 4.2 ± 0.3 
26 4.8 ± 0.4  4.7 ± 0.4 4.2 ± 0.3 
28 4.7 ± 0.4  4.7 ± 0.4 4.2 ± 0.3 
30 4.8 ± 0.4  4.8 ± 0.3 4.2 ± 0.3 
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Figure 3.2. Rating of perceived exertion (RPE) during an exercise tolerance test before 
(baseline) and after one month of exercise with STD (A) or XS (B) bicarbonate therapy. * 
Denotes a significant difference from corresponding time point during the baseline trial (P<0.05). 
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Figure 3.3. Rating of perceived exertion (RPE) during an exercise tolerance test before 
(baseline) and after six months of exercise with STD (A) or XS (B) bicarbonate therapy. * 
Denotes a significant difference from corresponding time point during the baseline trial (P<0.05). 
A 
B 
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Figure 3.4. Rating of perceived exertion during an exercise tolerance test before (baseline) 
and after six months without exercise with STD (A) or XS (B) bicarbonate therapy. * 
Denotes a significant difference from corresponding time point during the baseline trial (P<0.05). 
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3.3.3 Blood lactate and glucose response to acute exercise 
At baseline, the acute 30 minute treadmill exercise test led to a significant increase in the blood 
lactate concentration (Tables 3.6 and 3.7). One or six months of exercise with STD bicarbonate 
therapy had no effect on this lactate response to acute exercise (P = 0.582 and P = 0.674 
respectively) (Figures 3.5A and 3.6A), and the magnitude of this rise with exercise was similar at 
both time points. However, after one month of exercise with XS bicarbonate therapy the lactate 
response to exercise was markedly suppressed, declining to less than a quarter of the baseline 
value (Table 3.6; Figure 3.5B) (P = 0.005). This trend was still present after six months, but was 
less marked and only reached marginal statistical significance (Figure 3.6B) (P = 0.057). There 
was no significant time-dependent change in the lactate response to exercise in the non-
exercising control group receiving STD bicarbonate therapy (P = 0.197), nor in the non-
exercisers receiving XS bicarbonate (Figure 3.6C and 3.6D) (P = 0.072). 
 No acute effect of exercise was observed on the blood glucose concentration in any of the 
groups (P>0.05, Tables 3.6 and 3.7). There were no abnormalities in the concentration of β-
hydroxybutyrate in any group, all basal values falling within the normal range of 20-270µmol/l 
(data not shown) suggesting that keto acidosis was not a contributor to the metabolic acidosis in 
these patients. 
Table 3.6. Effect of one month of exercise training on blood lactate (mmol/l) and glucose 
(mmol/l) concentration at rest and following the acute 30 minute treadmill exercise test. * 
Denotes a significant difference between one month and the corresponding value at baseline (P < 
0.05). a Denotes a significant difference from the corresponding pre-exercise value in each trial 
(P < 0.05). 
    Baseline One Month 
  Condition Pre-
Exercise
Post Ex Post-
Pre
Pre-
Exercise
Post Ex Post-
Pre 
Lactate 
(mmol/l) 
1 Mth Ex STD 
Bicarbonate 
1.1 ± 
0.1 
2.1 ± 
0.2
a
 
1.0 ± 
0.2 
1.0 ± 
0.1 
1.8 ± 
0.2
a
 
0.8 ± 
0.2 
1 Mth Ex XS 
Bicarbonate 
1.0 ± 
0.1 
2.5 ± 
0.4
a
 
1.4 ± 
0.4 
1.2 ± 
0.2 
1.5 ± 
0.2 
0.3 ± 
0.2* 
Glucose 
(mmol/l) 
1 Mth Ex STD 
Bicarbonate 
5.4 ± 
0.5 
5.6 ± 
0.6 
0.2 ± 
0.3 
5.6 ± 
3.6 
5.6 ± 
2.7 
0.1 ± 
0.3 
1 Mth Ex XS 
Bicarbonate 
6.1 ± 
0.9 
5.9 ± 
0.8 
0.9 ± 
0.6 
6.1 ± 
1.7 
6.0 ± 
1.5 
0.2 ± 
0.4 
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Table 3.7. Effect of six months of training or without training on blood lactate (mmol/l) and 
glucose (mmol/l) concentration at rest and following the acute 30 minute treadmill exercise 
test. * Denotes a significant difference between six months and the corresponding value at 
baseline (P < 0.05). a Denotes a significant difference from the corresponding pre-exercise value 
in each trial (P < 0.05). Δ Denotes a near significant difference from the corresponding value at 
baseline (P = 0.057) 
    Baseline Six Months 
  Condition Pre-
Exercise 
Post Ex Post-Pre  Pre-
Exercise 
Post Ex Post-Pre 
 
6 Mth Ex STD 
Bicarbonate 
1.3 ±  
0.1 
2.4 ± 
0.4
a
 
1.2 ±  
0.2 
1.4 ±   
0.3 
2.4 ± 
0.5
a
 
1.0 ±  
0.3 
Lactate 
(mmol/l) 
6 Mth Ex XS 
Bicarbonate 
0.9 ±  
0.1 
2.8 ± 
0.4
a
 
1.8 ±  
0.5 
1.2 ±  
0.1 
2.0 ± 
0.3
a
 
0.8 ± 
0.3Δ 
Non-exercising 
Control STD 
Bicarbonate 
1.2 ±  
0.2 
2.1 ± 
0.4
a
 
0.9 ±  
0.3 
0.8 ± 
0.1* 
1.2 ± 
0.1
a
 
0.4 ±  
0.1 
 
Non-exercising 
Control XS 
Bicarbonate 
1.0 ±  
0.2 
1.7 ± 
0.2
a
 
0.8 ±  
0.2 
0.9 ±  
0.1 
2.2 ± 
0.4
a
 
1.3 ±  
0.4 
  
6 Mth Ex STD 
Bicarbonate 
5.4 ±  
0.6 
5.8 ± 
0.6 
0.4 ±  
0.3 
5.2 ±  
0.9 
5.0 ± 
0.7 
0.2 ±  
0.2 
Glucose 
(mmol/l) 
6 Mth Ex XS 
Bicarbonate 
5.2 ±  
0.8 
6.0 ± 
0.7 
0.7 ±  
0.2 
3.0 ±  
0.1 
3.8 ± 
0.4 
0.8 ±  
0.1 
 Non-exercising 
Control STD 
Bicarbonate 
3.6 ±  
0.3 
4.5 ± 
0.4 
0.9 ±  
0.3 
6.2 ±  
0.2 
5.9 ± 
0.4 
0.3 ±  
0.4 
  
Non-exercising 
Control XS 
Bicarbonate 
4.4 ±  
1.0 
4.6 ± 
1.0 
0.2 ±  
0.1 
8.3 ±  
2.1 
8.7 ± 
2.1 
0.5 ±  
0.2 
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Figure 3.5. Effect of one month of exercise training on the lactate response to exercise with 
STD (A) or XS (B) bicarbonate. Due to sampling difficulties, n = 9 in both graphs A and B. 
 
 
Figure 3.6. Effect of six months with (A,B) or without (C,D) exercise training on blood 
lactate response to exercise with STD (A,C) or XS (B,D) bicarbonate. Due to sampling 
difficulties, n = 8, n = 7, n = 7 and n = 6 in graphs A, B, C and D respectively.  
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3.3.4 Haemoglobin and Haematocrit Response to Acute Exercise 
Basal haemoglobin (Hb) concentration and haematocrit (Hct) were not affected by one or six 
months of exercise training with STD or XS bicarbonate therapy (Tables 3.8 and 3.9). There was 
also no acute effect of the 30 minute treadmill exercise test on Hb concentration or Hct in any of 
the groups (data not shown). It is possible, however, that the erythropoietin treatment received by 
a number of the patients during the study obscured the effects of exercise. 
 
Table 3.8. Basal blood haemoglobin concentration (Hb; g/dl) and haematocrit (Hct; %) at 
baseline and after one month of exercise with STD or XS bicarbonate therapy. 
    
Baseline One 
Month 
Hb 
(g/dl) 
1 Mth Ex STD Bicarbonate 13.9 ± 0.6 13.2 ± 0.4 
1 Mth Ex XS Bicarbonate 13.0 ± 0.5 13.4 ± 0.6 
Hct (%) 
1 Mth Ex STD Bicarbonate 38.0 ± 2.5 36.0 ± 1.0 
1 Mth Ex XS Bicarbonate 36.0 ± 1.5 36.5 ± 1.5 
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Table 3.9. Basal blood haemoglobin concentration (Hb; g/dl) and haematocrit (Hct;%) at 
baseline and after six months of exercise or no exercise with STD or XS bicarbonate 
therapy. 
    Baseline Six Months 
 6 Mth Ex STD Bicarbonate 13.9 ± 0.6 13.2 ± 0.3 
Hb 
(g/dl) 
6 Mth Ex XS Bicarbonate 13.2 ± 0.6 13.6 ± 0.7 
Non-exercising Control STD Bicarbonate 13.2 ± 0.4 13.0 ± 0.6 
  Non-exercising Control XS Bicarbonate 13.6 ± 0.6 12.2 ± 1.2 
 6 Mth Ex STD Bicarbonate 38.0 ± 1.5 38.0 ± 1.0 
Hct (%) 
6 Mth Ex XS Bicarbonate 36.0 ± 1.5 36.5 ± 1.5 
Non-exercising Control STD Bicarbonate 36.0 ± 1.0 36.0 ± 1.5 
  Non-exercising Control XS Bicarbonate 35.5 ± 2.0 33.0 ± 2.5 
 
 
3.3.5 Effect of exercise training on body composition data 
Body composition data is tabulated in Table 3.10. There was no change in body weight 
following one or six months of exercise (P>0.05). There was a tendency for a decrease in body 
weight to occur in those patients who had exercised for six months with XS bicarbonate, but this 
failed to reach statistical significance (P = 0.063). A significant decline in the body weight of the 
non-exercising controls on STD bicarbonate was observed after six months (P = 0.025), but not 
in the XS group. There were, however, significant decreases in the body mass index (BMI) of 
those patients who exercised for one month regardless of bicarbonate treatment (P = 0.018) and 
for six months (P = 0.006), but the apparent decrease seen in the control group was not 
significant (P = 0.103). Furthermore, this decrease in BMI at one and six months was seen only 
in those patients who received XS bicarbonate therapy (Table 3.7) (P = 0.051 and P = 0.009 
respectively) and not in those on STD bicarbonate therapy (P = 0.209 and P = 0.223 
respectively). There was no change in BMI in either of the non-exercising control groups 
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suggesting there was no effect of bicarbonate supplementation in these patients or an effect of 
seasonal variation. 
 
When bicarbonate groups were combined, full body DEXA scans revealed that there was a 
significant increase in LBM after one month of exercise (P = 0.013), that was not seen after six 
months of exercise (P = 0.188). No effect of bicarbonate was observed on LBM following one 
and six months of exercise or after a six month control period without exercise (P>0.05). 
However, expressing LBM data as % of total body mass reveals a significant increase following 
one month of exercise in both STD and XS bicarbonate groups (from 59.1 ± 2.6% to 59.8 ± 
2.5%; P = 0.038 and from 65.4 ± 3.6% to 66.3 ± 3.8; P = 0.027 respectively) (Figure 3.7). 
Following six months of exercise this increase persisted only in the XS bicarbonate group, with 6 
of the 7 patients showing an apparent increase (P = 0.028) (Figure 3.8B). 
 
There were also demonstrable effects of upon fat mass measured by DEXA. One month of 
exercise with STD bicarbonate reduced fat mass by 0.6 ± 0.2kg (P = 0.018). A similar reduction 
of 0.6 ± 0.3kg was also seen in the XS bicarbonate group, but this fell short of significance (P = 
0.063). After six months, the decline in fat mass on STD bicarbonate therapy had disappeared (P 
= 0.593). However, following six months of exercise with XS bicarbonate there was a reduction 
in fat mass of 1.5 ± 0.6kg achieving marginal significance (P = 0.054). These changes were 
reflected in an increase in the lean / fat mass ratio in the six month exercising patients receiving 
XS bicarbonate from 2.3 ± 0.5 to 2.9 ± 0.7 (P = 0.043). No detectable effect of exercise or 
bicarbonate on bone density was seen in any group (data not shown). 
 
Two anthropometric measurements were also made, mid-arm circumference (an indicator of 
muscle mass) and skin fold thickness (a measure of fat mass). The only significant effect 
observed was a decrease in mid-arm circumference from 33.6 ± 1.1cm to 32.2 ± 1.2cm in the 
non-exercising control group on STD bicarbonate therapy (P = 0.028). No other changes were 
observed in any of the groups with either measure. 
 
 
Table 3.10. The effect of one and six months of exercise training or a no-exercise control period on indices of body composition.                
* Denotes a significant difference from the corresponding baseline value (P<0.05). Δ Denotes  a near significant difference from baseline (P = 
0.054). 
 Body Mass (kg) BMI Lean Body Mass (kg) Fat Mass (kg) 
 Baseline Post Training Baseline Post Training Baseline Post-Training Baseline Post-Training 
All patients 
One Month Ex 78.7 ± 3.4  79.0 ± 3.5 27.3 ± 0.9 26.9 ± 0.9* 49.4 ± 2.2 50.1 ± 2.3* 28.1 ± 2.4 27.5 ± 2.4* 
All patients 
Six Months Ex 78.1 ± 3.4 78.0 ± 3.7 27.5 ± 1.0 26.9 ± 1.1* 46.4 ± 2.3 46.8 ± 2.4 29.0 ± 2.4 28.5 ± 2.5 
All non-
exercising 
controls 
84.2 ± 5.1 83.8 ± 4.8 29.2 ± 1.5 28.6 ± 1.3 49.1 ± 2.9 48.8 ± 2.7 32.3 ± 3.3 32.3 ± 2.7 
One Month Ex 
STD 81.8 ± 5.0 81.9 ± 5.1 28.7 ± 1.4   28.5 ± 1.4 47.4 ± 3.4 48.1 ± 3.6 31.2 ± 3.2 30.7 ± 3.0* 
One Month Ex 
XS 78.1 ± 4.3 78.2 ± 4.5 25.8 ± 1.0 25.4 ± 0.9* 53.0 ± 1.7 54.0 ± 1.7 24.1 ± 3.3 23.5 ± 3.4 
Six Months Ex 
STD 81.2 ± 5.0 81.9 ± 5.3 29.1 ± 1.3 28.8 ± 1.3 46.0 ± 3.4 46.4 ± 3.6 32.4 ± 2.9 32.7 ± 2.7 
Six Months Ex 
XS 73.8 ± 4.0 72.6 ± 4.4 25.5 ± 1.4 24.6 ± 1.5* 47.0 ± 3.0 47.3 ± 3.2 24.1 ± 3.5 22.5 ± 4.1Δ 
Non-exercising 
controls STD 84.4 ± 6.3 83.0 ± 6.3* 30.3 ± 1.8 29.4 ± 1.7 45.6 ± 3.3 44.7 ± 3.1 36.2 ± 3.7 35.7 ± 3.8 
Non-exercising 
controls XS 83.9 ± 9.1 84.9 ± 8.1 27.8 ± 2.5 27.6 ± 2.4 54.0 ± 4.6 54.2 ± 4.1 27.2 ± 5.6 27.9 ± 4.9 
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Figure 3.7. The effect of one month of exercise on LBM expressed as % of total body mass 
with STD (A) or XS (B) bicarbonate therapy. Due to logistical problems, n = 9 and n = 7 in 
graphs A and B respectively.  
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Figure 3.8. The effect of six months of exercise training (A,B) or a 6 month control period 
(C,D) on LBM expressed as % of total body mass with STD (A,C) or XS (B,D) bicarbonate 
therapy. Due to logistical problems, n = 10, n = 7, n = 8 and n = 6 in graphs A, B, C and D 
respectively. 
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3.3.6 Muscle biopsy composition 
The gross composition of the muscle biopsies obtained from the patients is shown in Table 3.11.  
Muscle DNA content did not change under any condition. The RNA content of the muscle 
biopsies taken from those patients who had exercised for six months with STD bicarbonate 
therapy increased from 1.2 ± 0.2 µg/mg dw to 1.5 ± 0.2 µg/mg dw (P = 0.017), an effect that was 
not seen under any other condition.  The water content was determined in the biopsies from the 
subtraction of dry weight from wet weight. Muscle biopsies were dried to constant weight, but 
the contribution to the weight from tightly locked water in the biopsy was unknown. No change 
was seen in the water content of the muscle biopsies from any group (P>0.05) indicating that the 
additional sodium load given to the XS bicarbonate group had not caused any detectable water 
loading in these patients.  
 
There was an apparent decline in the muscle protein content in the biopsies taken from those 
patients who exercised for six months with XS bicarbonate therapy (P = 0.052) which did not 
occur in any of the other groups. A similar effect was observed on muscle Protein:DNA ratio (P 
= 0.008) and as no corresponding effect on lean body mass was detected by DEXA in this group 
of patients, it is unlikely that this decline in biopsy protein content reflects muscle protein 
wasting. Significant amounts of fibrotic tissue were observed in the biopsies obtained from the 
CKD patients. While macroscopic connective tissue was dissected away during processing of the 
sample (see Methods Section 3.2.7), this does not exclude microscopic infiltration of the muscle 
by scar tissue that may have been particularly likely to occur near the biopsy site (see Discussion 
Section 3.4.6). The soluble protein content of the biopsies was determined using the Folin Lowry 
assay (see Section 2.4.1). This assay works by oxidising the tyrosine and tryptophan residues in 
the protein producing a blue colour, and as collagen contains little or none of either of these 
amino acids, it would not be detected by the assay and therefore would not have contributed to 
the total protein content.  No other effects on muscle protein:DNA ratio were seen in any other 
group. 
 
In view of this uncertainty, all of the biochemical data in the remainder of this thesis are 
expressed in ways aimed at minimising artefacts arising from variation in the myocyte content of 
the biopsies. Data have therefore been presented as metabolite concentrations expressed in 
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relation to intracellular water (e.g. amino acid concentrations), relative abundance of proteins 
determined by Western blotting after loading of fixed quantities of total soluble protein onto the 
gels, and abundance of molecules (e.g. mRNA’s and 14kDa actin fragment) expressed in relation 
to a reference molecule in the same sample. Intracellular water content was determined from 
intramuscular chloride concentrations assuming a normal membrane potential as described by 
Bergström et al. (1974). It was shown that changes in membrane potential result in only very 
small errors in intracellular water content and subsequently this method has frequently been to 
normalise amino acid concentration data. 
 
Table 3.11. The effect of six months of exercise or no exercise with STD or XS bicarbonate 
therapy on muscle biopsy composition. * Denotes a significant difference between six months 
and the corresponding value at baseline (P < 0.05). 
 Condition Baseline Six Months 
Muscle Protein 
Concentration 
(mg/mg dw) 
6 Mth Ex STD Bicarbonate 0.6 ± 0.1 0.6 ± 0.1 
6 Mth Ex XS Bicarbonate 0.5 ± 0.1 0.3 ± 0.1 
Non-exercising Controls STD 0.5 ± 0.1 0.5 ± 0.1 
Non-exercising Controls XS 0.5 ± 0.1 0.6 ± 0.2 
Muscle DNA 
Concentration 
(µg/mg dw) 
6 Mth Ex STD Bicarbonate 2.6 ± 0.3  2.6 ± 0.2 
6 Mth Ex XS Bicarbonate 2.7 ± 0.2 2.7 ± 0.4 
Non-exercising Controls STD 2.7 ± 0.2 2.8 ± 0.5 
Non-exercising Controls XS 2.8 ± 0.3 2.9 ± 0.4 
Muscle RNA 
Concentration 
(µg/mg dw) 
6 Mth Ex STD Bicarbonate 1.2 ± 0.2 1.5 ± 0.2* 
6 Mth Ex XS Bicarbonate 1.6  ± 0.2 1.5 ± 0.3 
Non-exercising Controls STD 1.6 ± 0.2 1.5 ± 0.2 
Non-exercising Controls XS 1.2 ± 0.3 1.4 ± 0.3 
Muscle 
Protein:DNA 
ratio (mg/mg dw) 
6 Mth Ex STD Bicarbonate 232.4 ± 124.1 263.6 ± 193.9 
6 Mth Ex XS Bicarbonate 202.5 ± 6.6 131.2 ± 35.1*
Non-exercising Controls STD 200.3 ± 62.1 193.0 ± 86.1 
Non-exercising Controls XS 202.9 ± 65.7 235.7 ± 66.5 
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3.3.7 Muscle and plasma amino acid concentrations 
Tables 3.12 – 3.14 show the changes that occurred in fasted plasma amino acid concentrations 
over the course of the study. No dramatic changes were observed, but statistically significant 
increases in L-Asn, L-Gln, L-His, and L-Ala were observed after one or six months of exercise 
in the STD bicarbonate groups. These changes observed at six months were not paralleled by 
changes in the exercising patients on XS bicarbonate (Table 3.13) who showed statistically 
significant increases only in Gly and L-Met and the non-exercising patients on STD bicarbonate 
also failed to show these changes. All the changes that were observed were increases above 
baseline concentrations (P<0.05), except for the concentration of L-Arg that was seen to decline 
significantly in the six months exercise group with STD bicarbonate (P = 0.008). In contrast, this 
amino acid increased in the non-exercising patients on STD bicarbonate (Table 3.14) (P = 
0.008). 
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Table 3.12. Changes in fasted plasma amino acid concentrations (µmol/l) following one 
month exercise on STD bicarbonate. * Denotes significant change from baseline (P<0.05). 
Amino Acid STD Baseline  STD One       
Month  
Δ 
Glu 61.9 ± 18.1 56.4 ± 14.5 -5.5 ± 5.6 
Asn 49.8 ± 5.7 63.1 ± 2.8 13.4 ± 5.3 
Ser 68.5 ± 10.1 86.6 ± 16.2 18.1 ± 12.2 
Gln 600.7 ± 59.4 732.3 ± 37.9* 131.7 ± 51.1 
His 51.3 ± 6.4 66.8 ± 6.6* 15.6 ± 7.1 
Gly 273.9 ± 81.6 366.5 ± 62.9 92.6 ± 66.7 
Thr 83.1 ± 9.7 119.0 ± 13.5 35.9 ± 18.8 
Arg 60.8 ± 13.0 80.8 ± 11.9 20.0 ± 11.3 
Ala 329.2 ± 42.4 414.0 ± 33.1 84.4 ± 52.8 
Tyr 50.7 ± 7.1 62.0 ± 5.6 11.3 ± 5. 0 
Cys 68.3 ± 6.7 75.8 ± 6.9 7.4 ± 7.1 
Val 145.9 ± 18.6 159.6 ± 18.3 13.7 ± 17.1 
Met 14.8 ± 2.9 15.2 ± 1.5 0.5 ± 3.5 
Tryp 38.7 ± 2.8 41.3 ± 2.8 2.6 ± 5.1 
Phe 51.9 ± 7.1 60.7 ± 5.2 8.8 ± 4.6 
Ile 45.8 ± 4.8 49.5 ± 4.3 3.7 ± 5.7 
Leu 88.4 ± 8.3 93.3 ± 4.1 4.9 ± 7.1 
Lys 154.0 ± 22.9 170.0 ± 8.5 15.9 ± 17.5 
 
 
 
 
 
 
 
 
 
3.13. Changes in fasted plasma amino acid concentration (µmol/l) following six months of exercise on STD or XS bicarbonate 
therapy. * Denotes significant change from baseline in each group (P<0.05). 
Amino Acid STD Baseline STD Six       Months STD Δ XS Baseline XS Six Months XS Δ 
Glu  80.5 ± 19.0 94.3 ± 13.5 20.3 ± 17.0 74.2 ± 21.3 89.9 ± 14.8 3.1 ± 11. 0 
Asn  49.1 ± 5.0 64.8 ± 5.4* 15.7 ± 5.0 71.5 ± 5.2 68.4 ± 6.5 -3.2 ± 7.2 
Ser  81.1 ± 10.5 100.0 ± 5.8 18.9 ± 9.5 88.5 ± 5.8 99.0 ± 8.0 10.4 ± 7.2 
Gln  599.4 ± 51.4 676.1 ± 27.8 76.6 ± 46.2 640.7 ± 41.4 712.1 ± 34.9 71.4 ± 5.3 
His  49.8 ± 5.3 67.7 ± 7.0* 19.9 ± 6.8 73.3 ± 7.8 74.2 ± 8.3 0.9 ± 8.5 
Gly  293.5 ± 72.4 342.7 ± 51.3 49.2 ± 33.5 233.7 ± 23.0 290.0±29.5* 56.3 ± 18.6 
Thr  93.8 ± 10.4 127.6 ± 9.8 33.9 ± 14.4 134.9 ± 12.7 145.1 ± 12.7 10.2 ± 11.7 
Arg  47.8 ± 11.7 29.3 ± 6.8* -18.5 ± 8.2 57.2 ± 11.0 43.4 ± 8.4 -13.8 ± 14.7 
Ala  337.4 ± 38.9 448.5 ± 38.3* 111.1 ± 43.6 497.8 ± 60.2 495.1 ± 60.0 -2.6 ± 65.5 
Tyr  56.0 ± 8.1 63.2 ± 5.1 7.2 ± 5.2 53.4 ± 5.1 50.7 ± 4.3 -2.8 ± 4.5 
Cys  66.5 ± 5.6 58.5 ± 3.1 -8.0 ± 5.6 58.9 ± 8.2 58.1 ± 3.5 -0.8 ± 5.1 
Val  157.6 ± 18.5 170.0 ± 26.4 12.4 ± 25.1 205.4 ± 28.8 196.6 ± 19.7 -8.8 ± 24.4 
Met  15.7 ± 2.6 17.4 ± 1.8 1.7 ± 3.3 18.0 ± 2.9 23.5 ± 3.7* 5.5 ± 1.6 
Tryp  41.2 ± 5.8 40.1 ± 3.9 -1.1 ± 5.8 41.8 ± 4.8 41.3 ± 4.2 -0.5 ± 4.3 
Phe  50.5 ± 5.5 59.9 ± 11.9 9.4 ± 7.1 54.6 ± 9.2 56.1 ± 7.3 1.5 ± 3.7 
Ile  46.1 ± 4.2 48.3 ± 4.8 2.3 ± 5.9 62.8 ± 9.6 62.0 ± 11.3 -0.8 ± 8.9 
Leu  93.5 ± 8.2 108.7 ± 11.8 15.2 ± 13.2 113.9 ± 11.4 120.5 ± 15.6 6.6 ± 10.0 
Lys  164.3 ± 21.1 179.1 ± 11.6 14.7 ± 21.6 189.1 ± 17.7 225.4 ± 37.5 36.3 ± 28.8 
Table 3.14. Changes in fasted plasma amino acid concentrations (µmol/l) following six months without exercise. * Denotes 
significant change from baseline in each group (P<0.05). 
 
Amino Acid STD Baseline STD Six Months STD Δ XS Baseline 
XS Six 
Months XS Δ 
Glu 51.7 ± 4.2 56.2 ± 5.8 4.4 ± 5.9 60.2 ± 8.2 49.2 ± 4.8 -11. 0 ± 4. 0 
Asn 51.1 ± 1.9  55.0 ± 3.4 3.9 ± 3.8 60.2 ± 5.3 56.6 ± 5.7 -3.6 ± 7.1 
Ser 89.3 ± 9.8 105.5 ± 16.3 16.2 ± 9.5 96.7 ± 21.0 87.6 ± 15.7 -9.1 ± 16.0 
Gln 598.3 ± 14.3 660.6 ± 32.0 62.3 ± 34.0 675.0 ± 55.2 684.0 ± 26.0 9.0 ± 55. 0 
His 56.4 ± 3.2 64.9 ± 5.8 8.5 ± 5.5 82.2 ± 12.8 77.3 ± 15.3 -4.8 ± 21.3 
Gly 263.7 ± 31.8 306.0 ± 53.8 42.2 ± 27.1 345.0 ± 28.7 405.2 ± 14.4 60.2 ± 14.3 
Thr 106.0 ± 11.2 117.7 ± 14.0 11.7 ± 9.5 141.8 ± 12.7 150.2 ± 11.3 8.4 ± 13.8 
Arg 34.7 ± 6.4 58.0 ± 7.1* 23.3 ± 6. 0 75.6 ± 15.1 83.2 ± 13.9 7.6 ± 3.8 
Ala 322.6 ± 33.5 392.1 ± 32.4 59.5 ± 54.7 479.1 ± 45.8 455.4 ± 84.7 -23.7 ± 87.2 
Tyr 45.6 ± 2.2 51.8 ± 5.8 6.1 ± 5.2 80.5 ± 19.6 74.0 ± 13.4 -6.5 ± 6.2 
Cys 53.6 ± 5.6 69.5 ± 11.1 15.8 ± 8.1  63.6 ± 10.5 59.9 ± 15.4 -3.7 ± 8.1 
Val 156.7 ± 13.8 168.3 ± 13.6 11.5 ± 8.2 234.8 ± 20.4 203.4 ± 13.9 -31.3 ± 14.2 
Met 16.5 ± 0.8 21.0 ± 2.2 4.5 ± 8.2 29.5 ± 2.4 28.5 ± 3.7 -1.0 ± 3.5 
Tryp 32.0 ± 2.2 38.3 ± 4.2 6.3 ± 3.2 40.3 ± 3.9 38.2 ± 5.8 -2.1 ± 2.4 
Phe 52.8 ± 3.1 62.6 ± 7.3 9.8 ± 7.6 70.2 ± 0.4 65.9 ± 2.0 -4.3 ± 1.7 
Ile 44.0 ± 3.1 51.8 ± 4.8* 7.8 ± 3.2 68.1 ± 2.9 61.7 ± 3.4 -6.4 ± 2.6 
Leu 87.5 ± 5.3 95.9 ± 7.8 8.4 ± 5.9 139.7 ± 12.3 116.2 ± 7.7 -23.5 ± 5.4 
Lys 127.9 ± 7.1 159.6 ± 22.7 31.7 ± 18.1 239.7 ± 67.5 188.9 ± 24.8 -50.7 ± 50.2 
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Tables 3.15-3.17 show the changes in muscle amino acid concentrations in the fasted state. The 
median baseline concentrations were comparable with those previously reported by Bergström et 
al. (1990) (Figure 3.9). However, some of the patients had high baseline concentrations of some 
of the amino acids causing the data to be skewed, especially in the STD bicarbonate group. No 
artifactual explanation could be found for this and so all the data were included in the analysis 
(however see Chapter 4, Section 4.4.5(2)). Methionine concentrations were virtually 
undetectable in these muscle biopsies and so have been omitted from the tables. After six months 
of exercise with STD bicarbonate therapy, nine amino acids showed a striking statistically 
significant depletion relative to the baseline value. Of these Threonine, Valine, Phenylalanine, 
Leucine and Lysine are essential amino acids. Interestingly no significant effects were seen in 
the intramuscular concentration of histidine, which is kown to be highly involved in the muscle 
buffering process. This amino acid depletion is illustrated in Figure 3.10B.  Such depletion was 
detectable after only one month on STD bicarbonate treatment, but was not yet statistically 
significant (Table 3.15; Figure 3.10A) This effect was not observed following six months of 
exercise with XS bicarbonate, nor was it seen in either the STD or XS non-exercising control 
groups (Figures 3.11 and 3.12). This depletion was also accompanied by a collapse in many of 
the muscle / plasma amino acid concentration gradients (Table 3.19). Again, this effect was 
apparently present at one month, but failed to reach statistical significance, except for L-Ser 
(Table 3.18). This collapse was not seen in any of the other groups (Tables 3.19. and 3.20).  
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Table 3.15. Changes in muscle amino acid concentration (mmol/l cell H2O) in the fasted 
state following one month of exercise with STD bicarbonate therapy. Values are presented as 
median and range. 
Amino Acid STD Baseline STD One Month Δ 
Glu 3.6  (0.3 – 16.7) 1.6  (0.9 – 64.2) -1.9 (-12.5 – 61.0) 
Asn 0.3  (0.3 – 1.9 ) 0.4 (0.1 – 3.3) -0.01 (-1.33 – 3.12) 
Ser 0.4 (0.08 – 7.78) 0.3 (0 – 8.5) -0.06 (-7.60 – 8.12) 
Gln 12.3 (3.0 – 92.1) 8.4 (3.3 – 196.1) -3.9 (-65.7 – 7.4) 
His 0.3 (0 – 2.9) 0.2  (0.04 – 2.27) -0.1 (-2.4 – 2.0) 
Gly 1.6 (0.6 – 9.9) 1.5 (0.4 – 17.4) -0.3 (-9.4 – 15.9) 
Thr 0.9 (0.3 – 5.7) 0.8  (0.7 – 13.7) 0.3 (-4.1 – 13.3) 
Arg 0.6 (0.09 – 4.2) 0.4 (0.1 – 8.0) -0.2 (-3.4 – 7.5) 
Ala 2.7 (0.7 – 29.6) 2.5 (1.1 – 51.1) -0.1 (-20.3 – 49.2) 
Tyr 0.78 (0.08 – 3.56) 0.21 (0.05 – 1.19) -0.03 (-3.5 – 1.1) 
Cys 0.09 (0.02 – 1.37) 0.05 (0.01 – 0.55) -0.01 (-1.50 – 0.18) 
Val 0.5 (0.1 – 6.9) 0.2 (0 – 2.9) 0.1 (-6.9 – 2.7) 
Met -- -- -- 
Tryp 0.27 (0 – 1.7) 0.10 (0 – 2.1) -0.03 (-0.45 – 0.16) 
Phe 0.5 (0.06 – 0.59) 0.2 (0.06 – 1.68) -0.05 (-1.01 – 1 .08) 
Ile 0.21 (0.06 – 2.38) 0.15(0.05 – 0.87) -0.02 (-2.33 – 0.18) 
Leu 0.35 (0.09 – 4.63) 0.2 (0.09 – 1.57) -0.08 (-4.53 – 1.36) 
Lys 0.5 (0.01 – 6.49) 0.2 (0.1 – 10.5) -0.2 (-6.3 – 10.0) 
 
 
 
 
 
Table 3.16. Changes in muscle amino acid concentration (mmol/l cell H2O) in the fasted state following six months of exercise 
with STD or XS bicarbonate therapy. * Denotes significant change from baseline in each group (P<0.05). Values are presented as 
median and range. 
Amino 
Acid STD Baseline STD Six Months STD Δ XS Baseline XS Six Months XS Δ 
Glu 3.6   (0.3 – 16.7) 1.7 (0.3 – 3.1)* -1.8 (-15.4 – 1.1) 2.1 (0.5 – 2.6) 3.3 (1.1 – 8.9) 1.4 (-1.0 – 6.6) 
Asn 0.39  (0.11 – 1.87) 0.18 (0.08 – 0.48)* -0.25 (-1.66 – 0.06) 0.14 (0.08 – 0.43) 0.43 (0.11 – 0.61) 0.3 (-0.3 – 0.4) 
Ser 0.4 (0.08 – 7.78) 0.2 (0 – 0.50) -0.09 (-7.40 – 0.08) 0.3 (0.04 – 0.86) 0.3 (0.05 – 2.15) 0.2 (-0.2 – 1.3) 
Gln 11.9 (3.0 – 92.2) 7.1 (2.2 – 10.6) -5.7 (-83.1 – 7.6) 7.6  (4.7 – 14.1) 8.9 (1.5 – 19.8) 4.3 (-6.4 – 9.2) 
His 0.3 (0 – 2.9) 0.20 (0.06 – 0.76) -0.10 (-2.8 – 0.6) 0.2 (0.05 – 0.48) 0.2 (0 – 2.4) 0.05 (-0.5 – 2.3) 
Gly 1.7 (0.6 – 9.9) 1.1 (0.7 – 10.6) -0.4 (-8.3 – 8.9) 1.0 (0.6 – 1.1) 2.6 (0.4 – 16.7) 1.6 (-0.7 – 11.7) 
Thr 0.7 (0.3 – 5.7) 0.3 (0.1 – 0.6)* -0.5 (-5.3 – 0.3) 0.3 (0.1- 0.5) 0.6 (0.3 – 1.9) 0.4 (-0.2 – 1.6) 
Arg 0.7 (0.09 – 4.19 ) 0.3 (0.1 – 0.5)* -0.39 (-3.86 – 0.01) 0.3 (0.09 – 0.48) 0.3 (0.2 – 1.1) 0.1 (-0.2 – 0.5) 
Ala 3.1 (0.7 – 29.6) 1.4 (0.03 – 1.87)* -2.0 (-26.8 – 0.1) 1.8 (1.6 – 12.3) 5.0 (0.8 – 7.3) 0.02 (-4.94 – 3.37) 
Tyr 0.42 (0.08 – 3.56) 0.09 (0.03 – 0.64) -0.08 (-3.37 – 0.54) 0.08 (0.03 – 0.37) 0.13 (0.03 – 1.32) 0.09 (-0.30 – 1.25) 
Cys 0.09 (0.02 – 1.37) 0.08 (0.01 – 0.21) -0.01 (-1.36 – 0.36) 0.04 (0.02 – 0.39) 0.02 (0 – 0.1) -0.02 (-0.04 – 0.10) 
Val 0.62 (0.1 – 6.9) 0.17 (0 – 0.3)* -0.28 (-6.66 – 0.01)  0.26 (0.08 – 0.3) 0.52 (0.07 – 1.96) 0.2 (-0.2 – 1.7) 
Met -- -- -- -- -- -- 
Tryp 0.09  (0 – 1.7) 0.06 (0 – 0.3) -0.03 (-0.25 – 0.16) 0.08 (0 – 0.6) 0.2 (0.04 – 0.26) 0.07 (-0.41 – 0.21) 
Phe 0.32 (0.09 – 2.58) 0.11 (0.04 – 0.17)* 0.26 (-2.24 – 0.05) 0.11 (0.07 – 0.13) 0.09 (0.04 – 0.49) 0.09 (-0.2 – 0.4) 
Ile 0.22 (0.06 – 2.38) 0.08 (0 – 0.6) -0.07 (-2.15 – 0.48) 0.08 (0.03 – 0.1) 0.09 (0 – 0.1) 0.05 (-0.06 – 0.21) 
Leu 0.5 (0.09 – 4.63) 0.2 (0.09 – 0.48)* -0.19 (-4.14 – 0.01) 0.15 (0.12 – 0.17) 0.3 (0.07 – 0.75) 0.12 (-0.07 – 0.59) 
Lys 0.9 (0.01 – 6.49) 0.2 (0.08 – 0.73)* -0.4 (-4.7 – 0.2) 0.3 (0.2 – 0.5) 0.4 (0.2 – 1.0) 0.06 (-0.09 – 0.55) 
Table 3.17. Changes in muscle amino acid concentration (mmol/l cell H2O) in the fasted state following six months without 
exercise with STD or XS bicarbonate therapy. Data are shown as median and range. 
Amino 
Acid STD Baseline STD Six Months STD Δ XS Baseline XS Six Months XS Δ 
Glu 1.4 (0.7-3.2) 2.1 (0.9 – 4.0) 0.4 (-1.6 – 2.1) 1.6 (1.1 – 2.30) 2.5 (0.3 – 2.8) 0.5 (-0.8 – 1.0) 
Asn 0.2 (0.1 – 0.4) 0.20 (0.05 – 0.56) -0.03 (-0.09 – 0.35) 0.14 (0.04 – 0.31) 0.22 (0.23 – 0.24) 0.08 (-0.06 – 0.16) 
Ser 0.3 (0.1 – 0.4) 0.3 (0.1 – 1.0) -0.09 (-0.1 – 0.7) 0.3 (0.2 – 0.5) 0.23 (0.08 – 0.45) -0.06 (-0.1 - -0.05) 
Gln 8.3 (1.6 – 13.7) 8.3 (0.6 – 20.9) 0.2 (-8.1 – 19.7) 8.7 (3.5 – 11.9) 12.2 (0.3 – 15.1) 0.3 (-3.2 – 6.4) 
His 0.14  (0.06 – 1.67) 0.17  (0.09 – 2.71) 0.05 (-0.36 – 1.36) 0.2 (0.1 – 0.4) 0.3 (0.1 – 0.4) -0.01 (-0.09 – 0.27) 
Gly 0.9 (0.4 – 3.4) 0.9 (0.5 – 2.7) -0.2 (-0.8 – 1.2) 0.9 (0.4 – 1.4) 1.1 (0.5 – 1.5) 1.1 (0.2 – 1.5) 
Thr 0.4 (0.1 – 0.9) 0.20 (0.09 – 0.60) -0.2 (-0.5 – 0.4) 0.1 (0.1 – 0.3) 0.29 (0.05 – 0.35) 0.03 (-0.06 – 0.16) 
Arg 0.3 (0.1 – 0.6) 0.4 (0.1 – 0.4) -0.01 (-0.23 – 1.11) 0.3 (0.2 – 0.5) 0.43 (0.05 – 0.54) -0.04 (-0.12 – 0.17) 
Ala 2.6 (0.7 – 3.7) 2.1(0.2 – 0.4) -0.3 (-0.8 – 6.9) 2.6 (0.7 – 3.0) 2.6 (0.7 – 3.0) -0.06 (-0.52 – 2.28) 
Tyr 0.08 (0.03 – 1.10) 0.20 (0.08 – 1.10) 0.09 (-0.8 – 0.7) 0.05 (0.05 – 0.40) 0.06 (0.02 – 0.12) -0.03 (-0.33 – 0.07) 
Cys 0.06 (0.02 – 0.53) 0.10 (0 – 0.7) 0.01 (-0.39 – 0.60) 0.05 (0.03 – 0.07) 0.2 (0.1 – 0.3) 0.27 (0.03 – 0.30) 
Val 0.3 (0.2 – 1.6) 0.6 (0.2 – 1.2) 0.12 (-0.9 – 0.5) 0.3 (0.1 – 0.3) 0.3 (0.1 – 0.4) -0.03 (-0.10 – 0.10) 
Met -- -- -- -- -- -- 
Tryp 0.3 (0.1 – 0.6) 0.5  (0 – 1.2) 0.05 (-0.64 – 1.0) 0.2 (0.1 – 0.2) 0.16 (0.08 – 0.24) -0.02 (-0.02 – 0.04) 
Phe 0.09 (0.03 – 0.3) 0.17 (0.08 – 1.63) 0.09 (-0.18 – 1.51) 0.10 (0.06 – 0.16) 0.11 (0.08 – 0.12) 0.01(-0.03 – 0.01) 
Ile 0.18 (0.07 – 0.34) 0.26 (0.07 – 1.25) 0.05 (-0.01 – 0.96) 0.12 (0.05 – 0.14) 0.10 (0.06 – 0.13) -0.01 (-0.02 – 0.01) 
Leu 0.19 (0.09 – 0.55) 0.21 (0.08 – 0.57) -0.01 (-0.26 – 0.23) 0.15 (0.07 – 0.43) 0.12 (0.11 – 0.21) 0.05 (-0.31 – 0.06) 
Lys 0.3 (0.1 -1.0) 0.7 (0.1 – 1.2) 0.3 (-0.5 – 1.0) 0.3 (0.1 – 0.3) 0.28 (0.03 – 0.86) -0.01 (-0.08 – 0.48) 
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Figure 3.9. Comparison of muscle amino acid concentrations recorded in the present study 
with those previously reported by Bergström et al. (1990). Data are expressed as log10.mmol/l 
Solid black line denotes r2 = 0.957, dashed black line symbolises r2 = 1.000. Median values from 
the six month exercise group on STD bicarbonate at baseline were used in the comparison. 
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Table 3.18. Changes in muscle / plasma amino acid gradients (mmol/l) following one month 
of exercise with STD bicarbonate therapy. * denotes significant change from baseline 
(P<0.05). Values are presented as median and range. 
Amino Acid STD Baseline STD One Month Δ 
Glu 13.9 (0.4 – 30.9) 4.6 (0.8 – 301.2) -1.9 (-30.0 – 278.2) 
Asn 7.2 (1.8 – 28.9) 5.9 (2.0 – 61.7) -1.2 (-38.0 – 52.2) 
Ser 5.9 (1.3 – 125.5) 0.27(0.07 – 8.39)* -2.7 (-125.4 – 0.1) 
Gln 25.9 (3.7 – 126.4) 10.9 (3.7 – 337.7) -14.2 (-91.9 – 309.2) 
His 4.7 (0 – 42.3) 3.3 (0.7 – 33.4) -2.11 (-37.4 – 29.0) 
Gly 9.6 (1.8 – 54.6) 3.2 (1.8 – 56.6) -2.9 (-52.7 – 43.9) 
Thr 11.4 (4.0 – 49.7) 7.9 (2.2 – 114.0) -1.6 (-47.5 – 106.1) 
Arg 15.6 (1.2 – 14.1) 5.9 (1.8 – 157.1) -8.0 (-51.7 – 143.0) 
Ala 10.6 (1.8 – 75.3) 6.9 (3.9 – 114.1) -2.1 (-54.0 – 102.1) 
Tyr 14.0 (2.5 – 41.0) 4.1 (0.6 – 22.1) -3.3 (-40.3 – 26.9) 
Cys 1.7 (0.9 – 23.6) 0.8 (0.3 – 8.4) -0.4 (-23.2 – 2.0) 
Val 4.1 (0.9 – 107.5) 1.3 (0 – 18.6) -1.4 (-106.2 – 1.2) 
Met -- -- -- 
Tryp 7.6 (0 – 33.0) 2.8 (0 – 61.4) -4.9 (-31.7 – 61.4) 
Phe 8.0 (1.5 – 74.7) 3.4 (0.9 – 30.6) -0.6 (-73.6 – 4.0) 
Ile 6.0 (1.3 – 50.1) 3.5 (0.9 – 19.4) -0.6 (-49.2 – 12.3) 
Leu 5.6 (0.9 – 45.2) 2.3 (0.9 – 18.4) -0.9 (-44.3 – 12.9) 
Lys 5.0 (0.06 – 31.1) 1.3 (0.6 – 62.7) -2.2 (-30.1 – 56.8) 
 
 
 
 
 
Table 3.19. Changes in muscle / plasma amino acid gradients (mmol/l) following six months of exercise with STD or XS 
bicarbonate therapy. * denotes significant change from baseline in each group (P<0.05). Values are presented as median and range. 
Amino 
Acid STD Baseline STD Six Months STD Δ XS Baseline XS Six Months XS Δ 
Glu 11.1 (0.4 – 30.9) 2.2 (0.6 – 8.3)* -9.3 (-69.6 – 5.1) 4.8 (2.1 – 12.5) 4.9 (4.0 – 9.1) 0.3 (-8.4 – 4.3) 
Asn 8.4 (1.8 – 28.9) 2.5 (1.8 – 8.2)* -6.0 (-32.9 – 0.1) 2.4 (1.0 – 5.5) 6.9 (1.15 – 11.5) 4.5 (-4.0 – 8.7) 
Ser 3.23 (1.4 – 125.5) 0.11  (0 – 0.39)* -3.1 (-125.2 – 1.3) 3.23 (0.4 – 12.3) 0.24 (0 – 2.05) -2.3 (-10.3 - -0.46)
Gln 25.6 (3.7 – 126.4) 10.7 (3.5 – 14.5)* -13.8 (-113.5 – 9.2) 12.5 (6.0 – 12.5) 12.5 (2.4 – 31.0) 2.2 (-10.5 – 12.5) 
His 4.6 (0 – 42.3) 5.0 (0.6 – 10.4) -1.8 (-39.8 – 6.7) 2.0 (0.7 – 6.0) 2.4 (0 – 45.6) 0.4 (-5.5 – 43.8) 
Gly 12.6 (1.8 -54.6) 3.4 (1.2 – 50.6) 1.5 (-47.3 – 35.3) 4.9  (1.9 – 28.0) 8.7 (1.6 – 70.4) 3.8 (-3.2 – 42.3) 
Thr 7.9 (1.0 – 49.7) 2.4 (0.8 – 4.5)* -4.3 (-41.0 – 3. 0) 2.1 (1.5 – 5.1) 4.5 (2.0 – 13.7) 2.9 (-3.0 – 11.6) 
Arg 23.8 (1.2 – 34.0) 14.3 (1.4 – 30.9)* -8.8 (-43.8 – 0.5) 5.9 (1.5 – 5.9) 7.7 (4.2 – 42.5) 6.2 (-17.1 – 36.0) 
Ala 11.5 (1.8 – 75.3) 2.9 (0.07 – 7.08)* -7.7 (-70.3 – 0.5) 4.2 (2.9 – 41.8) 12.1 (2.1 – 18.9) -0.5 (-22.9 – 8.5) 
Tyr 8.2 (2.5 – 41.0) 1.6 (0.4 – 11.5) -2.4 (-38.9 – 7.6) 2.3 (0.5 – 7.6) 1.9 (0.6 – 30.2) 1.4 (-6.0 – 29.1) 
Cys 1.5 (0.9 – 23.6) 1.1 (0 -3.6) -0.5 (-20.6 – 0.3) 0.7 (0.3 – 7.4) 0.5 (0 – 6.4) 0.2 (-7.4 – 5.7) 
Val 5.0 (0.9 – 107.5) 1.2 (0 – 5.0)* -2.3 (-102.5 - -0.2) 1.2 (0 – 5.0) 2.2 (0.4 – 12.0) 1. 0 (-1.6 – 10.3) 
Met -- -- -- -- -- -- 
Tryp 2.6 (0 – 33.0) 1.3 (0 – 5.7) -1.4 (-27.6 – 5.0) 2.6 (0 – 9.6) 5.4 (1.2 – 9.6) 0.3 (-6.9 – 7.4) 
Phe 5.2 (1.5 – 74.7) 1.8 (0.8 – 5.5)* -2.7 (-69.1 – 0.3) 2.1 (1.3 – 6.8) 3.2 (1.1 – 9.7) 1.1 (-5.7 – 7.9) 
Ile 4.9 (1.3 – 50.1) 1.8 (0 – 8. 0) -3.9 (-45.5 – 9.6) 1.6 (0.4 – 2.1) 1.1 (0 – 7.4) 0.5 (-1.6 – 5.8) 
Leu 5.8 (0.9 – 45.2) 1.5 (0.5 – 4.2)* -3.7 (-41.0 – 0.1) 1.4 (0.8 – 1.7) 1.7 (0.7 – 8.3) 0.8 (-0.9 – 6.8) 
Lys 5.9 (0.06 – 31.3) 1.4  (0.5 – 3.6)* -3.6 (-27.9 – 1.3) 2.1 (0.5 – 3.3) 1.5 (1.2 – 2.4) 0.2 (-1.0 – 2. 0) 
Table 3.20 Changes in muscle / plasma amino acid gradients (mmol/l) following six months without exercise with STD or XS 
bicarbonate therapy. * Denotes significant change from baseline in each group (P<0.05). Values are presented as median and range. 
Amino 
Acid STD Baseline STD Six Months STD Δ XS Baseline XS Six Months XS Δ 
Glu 24.9 (16.5 – 61.6) 36.6  (13.6 – 91.6) 4.6 (-23.3 – 66.2) 26.8  (24.3 – 31.0) 48.6 (7.4 – 56.8) 17.7 (-16.8 – 29.9) 
Asn 3.7 (2.6 – 8.7) 4.6  (0.8 – 8.0) -0.3 (-2.6 – 4.4) 2.4 (1.4 – 4.5) 3.9 (3.8 – 4.9) 2.4 (-0.5 – 2.5) 
Ser 4.0 (1.9 – 6.2) 3.9 (1.8 – 7.6) -0.01 (-3.3 – 4.9) 2.7 (1.6 – 4.0) 3.4 (0.6 – 3.8) -0.2 (-1.0 – 0.7) 
Gln 13.1 (2.8 – 16.3) 12.0 (0.9 – 32.8) 1.1 (-16.3 – 30.7) 11.1 (5.7 – 19.0) 16.9 (0.4 – 21.8) -2. 0 (-5.3 – 10.7) 
His 2.3 (1.1 – 33.3) 3.8  (1.2 – 38.0) 0.8 (-5.7 – 23.8) 1.7 (1.2 – 6.4) 5.8 (1.1 – 5.9) -0.5 (-0.6 – 4.6) 
Gly 3.8  (3.1 – 9.3) 4.4   (0.9 – 10.6) -0.8 (-3.0 – 6.9) 2.5 (1.3 – 4.7) 2.9 (0.6 – 3.7) -0.7 (-1.7 – 1.1) 
Thr 3.2  (1.1 – 7.8) 2.2 (0.9 – 7.3) -1.1 (-5.2 – 4.8) 1.2 (0.7 – 2.3) 2.0 (0.4 – 2.1) -0.1(-0.3 – 0.8) 
Arg 12.3 (1.8 – 22.6) 6.8 (1.8 – 33.8) -2.4 (-16.1 – 25.4) 3.4 (3.0 – 7.6) 4.9 (0.9 – 5.5) -2. 0 (-2.1 – 1.4) 
Ala 0.14 (0.05 – 0.56) 0.18 (0.05 – 2.43) -0.01 (-0.4 – 2.3) 0.3 (0.1 – 0.8) 0.18 (0.05 – 0.29) 0.01 (-0.05 – 2.2) 
Tyr 1.6 (0.7 – 23.0) 3.9 (1.1 – 12.8) 2. 0 (-19.5 – 7.4) 0.5 (0.5 – 9.3) 1.3 (0.3 – 1.5) -0.3 (-7.9 – 0.9) 
Cys 1.3 (0 – 11.4) 1.7 (0 – 21.0) -0.06 (-8.62 – 19.54) 0.7 (0.7 – 1.4) 3.2 (2.7 – 5.3) 2. 0 (1.8 – 4.6) 
Val 2.1 (1.6 – 6.8) 2.8 (1.9 – 8.1) 0.06 (-3.70 – 3.85) 1.2 (0.7 – 1.8) 1.3 (0.7 – 1.8) 0.01 (-0.05 – 0.06) 
Met -- -- -- -- -- -- 
Tryp 10.3 (4.3 – 38.8) 12.6 (0 – 36.5) 0.9 (-8.5 – 31.9) 4.1 (2.6 – 5.4) 4.7 (2.4 – 5.4) -0.1 (-0.6 – 0.8) 
Phe 1.6 (1.0 – 7.8) 3.5 (1.4 – 28.8) 1.9 (-4.5 – 26.7) 1.6 (0.9 – 2.3) 1.7 (1.1 – 1.9) -0.2 (-0.3 – 0.3) 
Ile 4.1 (1.4 – 10.7) 6.5 (1.6 – 13.3) 0.3 (-2.6 – 11.5) 1.7 (0.9 – 2.0) 1.7 (1.1 – 1.9) -0.01 (-0.07 – 0.2) 
Leu 2.2 (1.4 – 5.6) 2.1 (1.1 – 6.5) -0.4 (-2.7 – 3.4) 0.9 (0.5 – 3.2) 1.2 (1.0 – 1.7) 0.6 (-2.2 – 0.7) 
Lys 2.6  (1.0 – 6.1) 3.4 (0.8 – 13.5) 1.4 (-3.7 – 5.7) 1.2 (0.4 – 2.9) 1.9  (0.1 – 4.8) -0.2 (-0.9 – 3.5) 
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Figure 3.10. Summary of changes in muscle amino acid concentration from baseline 
following one month (A) or six months (B) of exercise with STD bicarbonate therapy. 
Values are calculated from median concentrations.   
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Figure 3.11. Summary of changes in muscle amino acid concentrations from baseline 
following six months of exercise with STD or XS bicarbonate therapy. Values are calculated 
from median concentrations 
 
Figure 3.12. Summary of changes in muscle amino acid concentrations from baseline 
following six months without exercise with STD or XS bicarbonate therapy. Values are 
calculated from median concentrations. 
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3.3.8 Dietary intake 
In principle, changes in diet may have contributed to the changes in amino acid concentrations 
described above. The effect of exercise and bicarbonate on dietary intake was assessed by diet 
diaries over three days at each time point. Only two patients from the six month exercise group 
receiving XS bicarbonate and from the non exercise group receiving XS bicarbonate completed 
and returned these diaries so data on bicarbonate will not be presented. 
 
Table 3.21. The effect of one month of exercise on dietary intake. 
 Baseline One Month 
 
Energy 
(kcal/kg 
bw) 
CHO 
(g/kg 
bw) 
Protein 
(g/kg 
bw) 
Fat   
(g/kg 
bw) 
Energy 
(kcal/k
g bw) 
CHO 
(g/kg 
bw) 
Protein 
(g/kg 
bw) 
Fat   
(g/kg 
bw) 
Exercise 23.2 ± 
4.2 
3.0 ±     
0.2 
0.90 ± 
0.07 
0.9 ±      
0.1 
24.5 ± 
4.2 
3.0 ±     
0.3 
0.92 ±     
0.07 
1.0 ±    
0.1 
 
Table 3.22. The effect of six months of exercise or without exercise on dietary intake.                        
* denotes significant change from corresponding value at baseline. 
 Baseline Six Months 
 
Energy 
(kcal/kg 
bw) 
CHO 
(g/kg 
bw) 
Protein 
(g/kg 
bw) 
Fat 
(g/kg 
bw) 
Energy 
(kcal/kg 
bw) 
CHO 
(g/kg 
bw) 
Protein 
(g/kg 
bw) 
Fat   
(g/kg 
bw) 
Exercise 24.5 ± 
3.2 
3.1 ±     
0.3 
0.97 ± 
0.10 
1.0 ±      
0.2 
19.2 ± 
1.2 
2.5 ±     
1.2 
0.76 ±   
0.03* 
0.7 ±      
0.1 
Controls 26.6 ± 
5.5 
3.2 ±     
0.8 
1.06 ± 
0.15 
1.0 ±      
0.2 
22.0 ± 
1.0 
2.7 ±    
0.6 
0.84 ±  
0.15* 
0.8 ±      
0.1 
 
Energy intake did not change following one month of exercise (Table 3.21), but was seen to 
decrease after six months of exercise and a no exercise control period, but this failed to reach 
significance in both groups (P = 0.078 and P = 0.094 respectively) (Table 3.22). There was also 
no change in the carbohydrate (CHO) intake following one month of exercise (P = 0.800) or in 
the non-exercising control group (P = 0.264). CHO intake fell after six months of exercise, but 
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this was not significant (P = 0.084). Protein intake did not change following one month of 
exercise (P = 0.973), but was seen to fall significantly after six months of both exercise and no 
exercise (P = 0.028 and P = 0.030 respectively).  
 
3.3.9 SNAT2 Expression 
Even though the effects on free amino acid concentrations and muscle/plasma concentration 
gradients described above imply changes in active amino acid transport in muscle, there was no 
effect of six months of exercise or bicarbonate treatment on the expression of the SNAT2 
transporter at the mRNA level (Figure 3.13).  The apparent small decrease following one month 
of exercise with STD bicarbonate was not statistically significant (P = 0.532) (Figure 3.13 inset), 
nor was the apparent effect of XS bicarbonate in non-exercising subjects (P = 0.742) (Figure 
3.13).  
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Figure 3.13. Changes in the expression of the SNAT2 amino acid transporter following six 
months with or without exercise with STD or XS bicarbonate therapy. Inset graph displays 
changes in SNAT2 expression following one month of exercise with STD bicarbonate therapy. 
Data are presented here as the Pfaffl Expression Ratio (See Chapter 2.6.7) in which, by 
definition, the baseline value is 1.0. 
 
 
3.3.10 Protein phosphorylation signals 
In agreement with earlier studies of the extent of rpS6 phosphorylation in the muscle of healthy 
fasted subjects (Dreyer et al. 2008), considerable difficulties were experienced in the detection of 
phosphorylated rpS6 in these wasted patients in the fasted and rested state. The negligible P-rpS6 
signal observed was not significantly affected by exercise or alkali treatment even in those 
subjects whose biopsies gave a quantifiable signal at baseline (Figures 3.14 and 3.15). 
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Figure 3.14. The effect of six months of exercise with STD or XS bicarbonate therapy on 
rpS6 phosphorylation. (A) Representative immunoblot showing rpS6 phosphorylation at Ser 
235/236. (B) Quantification by densitometry of pooled data from those patients who exercised 
for six months with STD or XS bicarbonate therapy. Inset shows the quantification by 
densitometry of the pooled data from those patients who exercised for one month with STD 
bicarbonate therapy. As a reference against which the patients’ samples were expressed a sample 
of a lysate from insulin-stimulated L6-G8C5 cells was run in parallel with the patients’ lysates 
on every blot. 
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Figure 3.15. The effect of six months without exercise with STD or XS bicarbonate therapy 
on rpS6 phosphorylation on the Ser 235/236 residue. (A) Representative immunoblot showing 
rpS6 phosphorylation at Ser 235/236. (B) Quantification by densitometry of pooled data from 
non-exercising controls with STD or XS bicarbonate therapy. As a reference against which the 
patients’ samples were expressed a sample of a lysate from insulin-stimulated L6-G8C5 cells 
was run in parallel with the patients’ lysates on every blot. 
 
Owing to the problems encountered in detecting a P-rpS6 signal, a random sample of biopsies 
from all patient groups was selected and probed for two further downstream targets of mTOR, 
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i.e. phosphorylated eukaryotic initiation factor 4E binding protein 1 (P-4E-BP1) and 
phosphorylated P70S6 Kinase (P-P70S6K). As with P-rpS6, the P-4E-BP1 and P-P70S6K signals 
were essentially undetectable in these biopsies and were not affected by exercise training or 
alkali therapy (Figure 3.16).  
 
           
           
 
           
                    
             Reference      0               6 
 
Figure 3.16. Representative immunblots of 4E-BP1 and P70S6K from a non-exercising 
control patient on STD bicarbonate therapy. Due to the negligible signal, immunostaining has 
not been quantified. The reference sample is the sample of lysate from insulin stimulated L6-
G8C5 cells presented in Figures 3.13 and 3.14. “0” denotes baseline and “6” six months.                     
 
In contrast to the mTOR signals, a readily detectable PKB phosphorylation signal was seen in the 
biopsies, but no statistically significant changes were detected after one or six months of exercise 
with STD or XS bicarbonate therapy (Figure 3.17).  
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Figure 3.17.  The effect of six months of exercise with STD or XS bicarbonate therapy on 
PKB phosphorylation on the Ser 473 residue. (A) Representative immunoblot showing PKB 
activation at Ser 473. (B) Quantification by densitometry of pooled data from those patients who 
exercised for six months with STD or XS bicarbonate therapy. Inset shows the quantification by 
densitometry of the pooled data from those patients who exercised for one month with STD 
bicarbonate therapy. As a reference against which the patients’ samples were expressed a sample 
of a lysate from insulin-stimulated L6-G8C5 cells was run in parallel with the patients’ lysates 
on every blot. 
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Figure 3.18. The effect of six months without exercise with STD or XS bicarbonate therapy 
on PKB phosphorylation on the Ser 473 residue. (A) Representative immunoblot showing 
PKB activation at Ser 473. (B) Quantification by densitometry of pooled data from non-
exercising controls with STD or XS bicarbonate therapy. As a reference against which the 
patients’ samples were expressed a sample of a lysate from insulin-stimulated L6-G8C5 cells 
was run in parallel with the patients’ lysates on every blot. 
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B 
D 
3.3.11 The 14kDa Actin Fragment 
Downstream from PKB, cleavage of actomyosin by caspase-3 to generate the 14kDa proteolytoic 
fragment was measured as an index of the early steps in myofibrillar protein catabolism (Du et 
al. 2004; Workeneh et al. 2006) (Figures 3.19 – 3.22). One month or six months of exercise 
resulted in no statistically significant change in the levels of the 14kDa fragment. Following six 
months of exercise the apparent decline from baseline in those patients taking STD bicarbonate 
was not statistically significant (P = 0.096) (Figure 3.21). There was also no detectable change in 
the non-exercising groups (Figure 3.22). 
                    
                       
 
                    
                              
Figure 3.19. Representative immunoblots to demonstrate the effect of one and six months 
of exercise with STD (A) or XS (B) bicarbonate therapy and six months without exercise 
with STD (C) or XS (D) bicarbonate therapy on the level of the 14kDa actin fragment. 
Muscle specimens obtained from healthy rat and from a healthy volunteer “H” were run on every 
blot for comparison with the CKD Patients.  “0” denotes baseline, “1” one month and “6” six 
months.  
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Figure 3.20. Bar graph denoting pooled quantification by densitometry of the effect of one 
month of exercise with STD bicarbonate therapy on the level of the 14kDa actin fragment. 
Two exposure times were used when developing these results, approximately 10 seconds for 
42kDa intact actin and a longer exposure of up to 10 minutes for 14kDa actin fragment (Figure 
3.18). These pairs of films were used to quantify 14kDa/42kDa ratio in Figures 3.19 – 3.21). 
 
Figure 3.21. Bar graph denoting pooled quantification by densitometry of the effect of six 
months of exericse with STD or XS bicarbonate therapy on the level of the 14kDa actin 
fragment.  
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Figure 3.22. Bar graph denoting pooled quantification of the effect of six months without 
exercise with STD or XS bicarbonate therapy on the level of the 14kDa actin fragment.  
 
3. 3.12 Ubiquitin E3 ligase mRNA expression 
In contrast to the 14kDa actin data, significant changes were observed in the mRNA expression 
of MuRF-1 and MAFbx. In the one month pilot study, patients receiving exercise therapy with 
STD bicarbonate treatment showed a detectable decrease in the expression of both of these 
enzymes (Figures 3.23 and 3.24). In the main six month study, this decrease was only sustained 
in the exercising patients who also received XS bicarbonate therapy.   
 
One month of exericse with STD bicarbonate therapy resulted in a statistically signifcant 
reduction in the mRNA expression of both MuRF-1 (P = 0.045) and MAFbx (P = 0.025). Six 
months of exercise with XS bicarbonate therapy resulted in a decrease in the mRNA expression 
of MuRF-1 to 41 ± 18% (P = 0.005) and MAFbx to 46 ± 18% (P = 0.04) of baseline, whilst no 
change was seen in the mRNA expression of either enzyme in the STD bicarbonate group (P = 
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significantly lower in those patients on XS bicarbonate compared to those on STD bicarbonate 
treatment (P = 0.049). No such change was observed in the mRNA expression of MuRF-1 or 
MAFbx in either of the non-exercising control groups, indeed there was a tendency for MAFbx 
mRNA expression to increase in those non-exercising control patients receiving STD 
bicarbonate therapy (Figures 3.23 and 3.24). 
 
 
Figure 3.23. Change in MAFbx mRNA expression with or without exercise and bicarbonate 
therapy. Graph inset shows change in MAFbx mRNA expression following one month of 
exercise with STD bicarbonate therapy. # denotes significant difference from baseline (P<0.05). 
Data are presented as the Pfaffl Ratio (See Chapter 2.6.7) in which, by definition, the baseline 
value is 1.0. 
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Figure 3.24. Change in MuRF-1 mRNA expression with or without exercise and 
bicarbonate therapy. Graph inset shows change in mRNA MuRF-1 mRNA expression 
following one month of exercise with STD bicarbonate therapy here # denotes significant 
difference from baseline (P<0.05). In main graph # denotes significant difference from 
corresponding baseline (P<0.05). * denotes significant difference between bicarbonate groups 
following six months of exercise (P<0.05). Data are presented as the Pfaffl Ratio (See Chapter 
2.6.7) in which, by definition, the baseline value is 1.0. 
 
3.3.13 3-Methyl Histidine (3-MH) excretion 
Excretion of 3-MH was measured as a marker of the overall rate of myofibrillar protein 
degradation, to assess the net effect of the apparent changes that had been examined by 
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change in the rate of myofibrillar protein degradation with or without exercise or additional 
bicarbonate treatment (Tables 3.23 – 3.24). This was true when the data were corrected for 
variation in lean body mass by calculating the 3-MH/creatinine excretion as is conventional (Elia 
et al. 1981), or by expressing 3-MH in relation to lean body mass measured directly using 
DEXA. Excretion of 3-MH apparently showed a paradoxical increase above baseline after one 
month of exercise on STD bicarbonate therapy when corrected for creatinine (Table 3.23), 
indicating an increase in myofibriliar degradation and a worsening of their muscle wasting, but 
this change was not statistically significant (P = 0.138).  
Table 3.23. 3-MH excretion rates corrected for creatinine or for lean body mass (LBM) 
(DEXA), following one month of exercise with STD bicarbonate therapy. 
 
Baseline STD 
One month 
Exercise STD 
3-MH/Creatinine 
(µmol/mmol crnn/24h) 
33.9 ± 4.6 46.9 ± 8.8 
3-MH/LBM          
(µmol/kg LBM/24h) 
10.4 ± 2.2 9.9 ± 1.9 
 
Table 3.24. 3-MH excretion rates corrected for creatinine or for lean body mass (LBM)  
(DEXA) following six months of exercise with STD or XS bicarbonate therapy. 
 Baseline STD 
Six 
Months 
Exercise 
STD 
Baseline 
XS 
Six Months 
Exercise        
XS 
3-MH/Creatinine 
(µmol/mmol crnn/24h)
33.9 ± 5.9 38.8 ± 8.1 32.0 ± 8.9 35.8 ± 8.0 
3-MH/LBM          
(µmol/kg LBM/24h) 
10.6 ± 2.6 9.4 ± 2.0 9.2 ± 1.2 12.3 ± 2.7 
 
 
 
 132 
 
Table 3.25. 3-MH excretion rates corrected for creatinine or for lean body mass (LBM) 
(DEXA) following six months without exercise with STD or XS bicarbonate therapy. 
  
Baseline  
STD 
Six 
Months 
STD 
Baseline 
XS 
Six 
Months 
XS 
3-MH/Creatinine  
(µmol/mmol crnn/24h) 
 
37.5 ± 6.9 29.0 ± 3.9 47.2 ± 13.9 60.8 ± 10.1 
3-MH/LBM           
(µmol/kg LBM/24h) 
 
8.6 ± 1.7 9.0 ± 1.4  12.4 ± 4.1  16.3 ± 3.9 
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3.3.14 Summary 
Table 3.26. Summary of the principal effects observed in this study.  ND denotes not 
determined 
Parameter One Month 
Ex STD 
One Month 
Ex XS 
Six Months 
Ex STD 
Six Months 
Ex XS 
Figure / Table 
Exercise 
Tolerance 
↑  ↑  ↑  ↑  Figures 3.2 and 
3.3 
Lactate 
Response to 
Exercise 
↔  ↓  ↔  ↓ 
Tables 3.6 and 
3.7 
Hb and Hct 
Response to 
Exercise 
↔  ↔  ↔  ↔ 
Tables 3.8 and 
3.9 
Body Weight  ↔  ↔  ↔  ↔  Table 3.10 
BMI  ↔  ↓  ↔  ↓  Table 3.10 
LBM % Total 
Body Weight 
↑  ↑  ↔  ↑  Figure 3.7 
Fat Mass  ↓  ↔  ↔  ↓  Table 3.10 
Biopsy DNA 
Content 
ND  ND  ↔  ↔  Table 3.11 
 Biopsy RNA 
Content 
ND  ND  ↑  ↔  Table 3.11 
Biopsy Total 
Protein 
ND  ND  ↔  ↓  Table 3.11 
Overall Trend 
for Plasma 
Amino Acids 
↔  ND  ↑  ↔ 
Tables 3.12 – 
3.14 
Overall Trend 
for Muscle 
Amino Acids 
↔  ND  ↓  ↔ 
Tables 3.15 – 
3.17 
 
Muscle SNAT2 
Expression 
↔  ND  ↔  ↔  Figure 3.13 
P‐PKB  ↔  ND  ↔  ↔  Figure 3.17 
14kDa  ↔  ND  ↔  ↔  Figures 3.20 and 
3.21
MAFbx 
Expression 
↓  ND  ↔  ↓  Figure 3.23 
MuRF‐1 
Expression 
↓  ND  ↔  ↓  Figure 3.24 
3‐MH Excretion  ↔  ↔  ↔  ↔  Tables 3.23, 3.24 
and 3.25 
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3.4 Discussion 
The main results produced from this study were that exercise tolerance did improve following six 
months of walking exercise, an effect that was not seen in the non-exercising patients, and that 
XS sodium bicarbonate did appear to provide the exercisers with some additional benefits. These 
patients were seen to have larger increases in LBM, greater reductions in the mRNA expression 
of MuRF-1 compared to those who remained on their standard bicarbonate dose, and were able 
to maintain amino acid concentration gradients between the plasma and muscle, and therefore 
were also able to maintain intramuscular amino acid concentrations, which might have 
significant implications for muscle protein synthesis rates. 
 
3.4.1 Exercise tolerance 
These results confirm previous reports that exercise tolerance and capacity can be improved in 
CKD patients (Painter et al. 1986; Koudi et al. 1997; Molsted et al. 2004). One and six months of 
aerobic exercise training significantly improved the patients’ ability to exercise. A small 
improvement was seen in the exercise tolerance of the non-exercising patients who received STD 
bicarbonate therapy: this may have arisen through a psychological effect of participating in an 
exercise training study, or through improper familiarisation with the RPE scale. However, no 
improvement was observed in the non-exercising group receiving XS bicarbonate in which 
similar psychological factors could also have led to an improvement, but none was observed. It is 
possible therefore, that in sedentary CKD patients, XS bicarbonate worsens their exercise 
tolerance, but there was no clear evidence for such a detrimental effect of bicarbonate alone in 
the other measurements described in this study. It was decided not to present the HR data from 
the exercise test in this thesis. In a separate arm of this study that has not been reported here, the 
effect of exercise on many clinical parameters was investigated, including blood pressure and the 
dose of anti-hypertensive’s the patients were taking. Patients in the exercise group were on 
greatly reduced doses of their ant-hypertensive medication following six months of walking 
exercise, which would undoubtedly affect heart rate response in subsequent exercise tests and 
this in combination with an inherent HR variability in these patients due to cardiac dysfunction 
lead to the conclusion the HR data was an unreliable measure of exercise tolerance in these 
patients.  
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The reduced lactate response to acute exercise that was observed after one and to some extent six 
months of exercise with XS bicarbonate (Figures 3.4B and 3.5B) has been reported previously in 
CKD (Kouidi et al. 1998; Akiba et al. 1995) in which 6 and 3 months respectively of a mixed 
exercise training programme resulted in lower blood lactate concentrations.  Kouidi et al. (1998) 
attributed this to a block in glycolysis resulting in an increase in muscle glycogen levels, similar 
to that seen in McArdle’s disease, but this has not been confirmed and also seems unlikely. It is 
more likely that this reduced lactate response at one or six months to the same absolute exercise 
intensity as at baseline, might be attributed to a training effect (MacRae et al. 1992). If so, this 
implies that the training effect of aerobic exercise was enhanced here by administering extra 
bicarbonate. A possible factor limiting the ability to exercise in CKD is acidosis: the normal 
intracellular acidification of skeletal muscle that occurs during exercise, as a result of lactic acid 
generation, is enhanced in patients with CKD. Nishida et al. (1991) observed using 31-P NMR 
that there was a greater decline in sarcosolic pH during aerobic exercise compared to healthy 
controls and a slower rate of its recovery, an observation that has been confirmed by other 
groups (Durozard et al. 1993; Kemp et al. 2004). In healthy individuals it has also been 
demonstrated that an induced metabolic acidosis by NH4Cl administration or through diet 
manipulation reduces exercise capacity in high intensity exercise (Jones et al. 1977; Greenhaff et 
al. 1987). Intramuscular acidification during exercise historically was considered to be a major 
factor in the development of fatigue (Karlsson et al. 1975), which has latterly become a 
somewhat controversial point (Westerblad et al. 2002). It is possible however, that the 
administration of extra bicarbonate helped to blunt the onset of acidification and fatigue during 
exercise, allowing more prolonged and effective exercise in these patients and hence, an 
enhanced training effect. Indeed this has recently been demonstrated in healthy rats with a 
chronic alkalosis. Compared to rats on placebo, rats that received sodium bicarbonate before 
each training session exhibited a longer time to exhaustion following five weeks of interval 
training, and greater improvements in mitochondrial mass and mitochondrial respiration 
measured in the soleus (Bishop et al. 2010). This suggests that chronic ingestion of sodium 
bicarbonate may sufficiently reduce the muscle hydrogen ion accumulation during training 
allowing for greater adaptations to occur. 
Although the plasma lactate levels here that were generated by the exercise test were only 1-
2mmol/l above the resting values, it is important to note that this was imposed on an existing 
metabolic acidosis and these values only represent the appearance of lactate in the blood and the 
impact of the exercise on intramuscular acidification was unknown. Any attempt to minimise an 
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additional acid load in these patients may well result in significant beneficial effects, such as 
those observed here. 
 
3.4.2 Body composition 
Exercise training resulted in a small but statistically significant increase in LBM of 0.5kg after 
one month and in LBM as % of total body weight after six months in the XS bicarbonate group 
only. Going et al. (1993) quoted the precision error in DEXA scanning of lean body mass to be 
0.8kg, and so caution is required when interpreting these small apparent effects. The precision 
error in detecting changes in fat mass by DEXA is generally stated at 1% (Salamone et al. 2000) 
changes that the results presented here exceed. The decline in fat mass and the rise in LBM/fat 
mass ratio that were observed in the present study are of functional interest because CKD 
patients are chronically inflamed (Pereria et al. 1994). Many of the pro-inflammatory cytokines 
such as TNF-α and IL-6 that are reported to be elevated in these patients (Pereria et al. 1994) are 
produced by adipose tissue (Coppack, 2001) and can stimulate protein degradation (Goodman, 
1991, 1994). By decreasing fat mass, the production of these cytokines may also be reduced and 
this may help alleviate the patient’s pro-inflammatory condition that can result in cardiac disease 
(Kalantar-Zadeh and Balakrishnan, 2006) which is the biggest cause of mortality in this 
population (Pecoits-Filho et al. 2002). (The effect of exercise on the inflammatory processes in 
these patients is described in a PhD thesis by J. Viana, Loughborough University). 
 The changes that were observed in body composition are small changes, but they were achieved 
with aerobic exercise alone. This may be a reflection of how cachectic these patients are; effects 
being more readily observed because of the initial wasted state of the patients. In future studies, 
larger gains might be expected with resistance exercise training or a combination of the two. 
 
It was also noted that no body composition changes whatever were detected in the STD 
bicarbonate group at six months (Table 3.10), the small apparent changes being confined to the 
XS bicarbonate group as with the lactate response data in Section 3.3.3 above. This may mean 
that muscle acidification during exercise was a limiting factor in these patients and XS 
bicarbonate therapy rendered exercise more effective. 
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3.4.3 Free amino acids 
A striking decline was observed in the fasting intramuscular amino acid concentrations of those 
patients who received STD bicarbonate therapy. This was apparent after one month of walking 
exercise, but a more consistent and significant decline was seen after six months. As there were 
generally no changes or small increases in the extracellular (plasma) amino acid concentrations, 
this decline in the fasted steady-state intracellular amino acid concentration seems to have arisen 
from a collapse of the concentration gradient between the intramuscular and extracellular 
compartments. This gradient is normally maintained by active transporters, for example SNAT2, 
which is the major amino acid pump in skeletal muscle cells (Evans et al. 2007, 2008). This 
decline was not observed in the XS bicarbonate group, suggesting that it was an acidosis-
mediated effect. Furthermore, it was not seen in the non-exercising control group receiving STD 
bicarbonate therapy, indicating that it was not the result of a resting metabolic acidosis, but of an 
exercise-induced exacerbation of acidosis and therefore may have been a limiting factor for 
exercise in the exercising patients. The decline in dietary protein intake after six months of 
exercise on STD bicarbonate therapy may have contributed to the accompanying changes in 
intramuscular amino acid concentrations, but this seems an inadequate explanation because a 
similar decline in dietary protein intake was observed in the non-exercising patients with no 
accompanying effects on muscle free amino acids. 
  
There was no change seen in the gene expression of the SNAT2 transporter, but previous studies 
in vitro have shown that acidified medium significantly decreases the activity of this transporter 
(Bevington et al. 2002) probably through a direct effect of low pH on the SNAT2 protein (Baird 
et al. 2006) resulting in a reduction of the intracellular concentration of glutamine and many 
other amino acids without any detectable decline in SNAT2 expression at mRNA or protein level 
(Evans et al. 2007, 2008). The reduction in muscle amino acid concentrations and subsequent 
collapse of gradients in the present study may be the result of a reduced activity of the SNAT2 
transporter caused by a local decrease in pH by the production of lactic acid during exercise, an 
effect that was apparently prevented by the administration of XS bicarbonate. 
It has previously been reported that CKD patients show abnormalities in amino acid metabolism 
(Kopple, 1978) and exhibit lower concentrations of many muscle and plasma amino acids 
(Bergström et al. 1990; Gulyassy et al. 1968; Young and Parsons, 1970). This is a problem that 
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appears to be worse in non-dialysed patients and improves upon initiation of dialysis therapy 
(Bergström et al. 1990). The muscle and plasma amino acid concentrations that are presented 
here varied widely between individuals, but were similar to those reported by Bergström and 
colleagues (1990). Further depletion of these concentrations following exercise in these patients 
has not previously been reported.  
 
3.4.4 Protein phosphorylation signals 
3.4.4.1 Signals through mTOR 
Significant changes in free amino acid pools that were observed in response to exercise (Tables 
3.12 – 3.17) could in principle affect protein metabolism, acting through amino acid sensors such 
as mTOR (see Section 1.11.4). However, in the fasted and rested state, under which conditions 
the muscle biopsies were drawn in the present study, negligible phosphorylation of rpS6, P70S6 
kinase and 4E-BP1 was observed (Figures 3.14 and 3.16) implying that only a low level of 
signalling was occurring through mTOR under these conditions. It has been reported that the 
concentration of most signalling proteins is lower in human skeletal muscle than in rodent 
muscle (Wackerhage, 2006) and the observation of a negligible P-rpS6 and P-P70S6K signal in 
human muscle in the fasted and rested state is not a new finding (Karlsson et al. 2004; Dreyer et 
al. 2006, 2008; Fujita et al. 2007). The low intensity of these phosphorylation signals 
downstream from mTOR suggest that sensing of the changes in free amino acid pool size 
through mTOR is unlikely to have been a major factor under these conditions. Nevertheless, the 
weakness of the signals is of practical importance because it confirms the fasted nature of these 
patients and suggests that the observed amino acid profiles are a true reflection of their 
endogenous amino acid metabolism and not simply a reflection of the amino acid content of their 
last meal. The muscle biopsies were taken in the fasted state to allow the amino acid data to be 
compared to that of Bergström and colleagues (1990) who also studied uraemic patients in the 
fasted state. 
 
3.4.4.2 Signals through PKB 
An important stimulus for the muscle wasting that is seen in CKD patients is a reduction in 
insulin/IGF-1 signalling (Bailey et al. 2006). These authors observed that under basal conditions 
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IRS-1 associated PI-3K activity was suppressed in rats with induced CKD resulting in a reduced 
phosphorylation of PKB. In IRS-1 knockout models, mice exhibit abnormal glucose handling, 
peripheral insulin resistance and growth defects (Araki et al. 1994), problems that are frequently 
reported in CKD patients, suggesting that this is an important defect, but is yet to be confirmed 
by data from human studies. As evidence from rodent studies show the PI-3K/PKB signalling 
pathway is a critical regulator of muscle mass and hypertrophy in vivo (Bodine et al. 2001a), 
activation of this pathway through exercise training could lead to reduced protein degradation 
through a suppressed expression of E3 ubiquitin ligases, as it is thought that ubiquitin-
conjugation by E3 ligases is the rate limiting step in protein degradation (Lecker et al. 1999), and 
increased protein synthesis through phosphorylation of the downstream effectors of PKB (Lecker 
et al. 2006).   
 
A recent study by Wang and colleagues (2009) examined the effect of muscle overload or 
treadmill running in CKD rats on indices of muscle protein synthesis and degradation. They 
observed an inhibitory effect of both forms of exercise on protein degradation, but less of an 
effect on protein synthesis with treadmill running compared to overload. This inhibition of 
protein degradation was accompanied by a small increase in PKB phosphorylation following 
treadmill running, an effect that was again larger in the rats with muscle overload.  
 
In the present study no overall change was seen in the phosphorylation of PKB in response to 
exercise (Figure 3.16) apparently contradicting the results by Chen and Colleagues (2008) and 
Wang and colleagues (2009) who observed in rats, workoverload and treadmill exercise was 
capable of increasing PKB phosphorylation levels and ultinatley protein synthesis rates. The 
differences between these studies may stem from a species variation, from the compliance of the 
patients to perform the required amount of unsupervised exercise or from the fact that PKB 
phosphorylation in humans was studied here at rest; Differences may have become apparent if 
the muscle samples had been taken in the period following the exercise bout. Recent evidence 
from human volunteers has suggested there is a dissociation between anabolic signalling and 
muscle protein synthesis rates suggesting this pathway is more complex in humans than evidence 
from rodent studies would suggest, and therefore PKB phosphorylation in humans may simply 
be reflecting insulin availability (Greenhaff et al. 2008). This would agree with the very low 
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signals detected in these patients who were studied in the fasted state. However, in spite of this 
there was a significant reduction in mRNA expression of the E3 ligases, MuRF-1 and MAFbx 
after one month of exercise with STD bicarbonate and after six months of exercise on XS 
bicarbonate therapy (Figures 3.23 and 3.24). Previous studies have reported that an increase in 
PKB phosphorylation causes an increase in the phosphorylation of the FOXO transcription 
factors resulting in a reduced expression of E3 ubiquitin ligases. The large decline in E3 ligase 
expression seen here therefore, appears to have occurred via a mechanism that is independent of 
PKB. It is possible that exercise-induced stimulation of PKB phosphorylation was missed in the 
present study through some technical artefact. For example, it has previously been suggested that 
a high phospho-protein phosphatase activity may explain some unexpected results in PKB 
phosphorylation (Foster et al. 2005) so that exercise and chronic PKB phosphorylation may lead 
to a compensatory stimulation of protein phosphatases, resulting in artifactual dephosphorylation 
of PKB in the time taken to draw the biopsy. Such artefacts seem an inadequate explanation, 
however, because activation of PKB suppresses myofibrillar proteolysis by suppressing caspase-
3 activation (Workeneh et al. 2006) (and production of the 14kDa actin fragment) as well as by 
suppressing E3 ligase expression. In the present study, no statistically significant effects were 
seen on the 14kDa actin fragment, especially in the patients on XS bicarbonate therapy (Figure 
3.20) so suppression of the E3 ligase expression independent of PKB activation would seem a 
more likely explanation. 
 
The observation here that after six months of exercise, suppression of mRNA E3 ligase 
expression was confined to the XS bicarbonate group and there was no change in expression in 
the STD bicarbonate group correlates with marked differences in the accompanying changes in 
free amino acid pool size between these two patient groups (Figure 3.10). It has been suggested 
that depletion of amino acids can increase proteolysis (Sadiq et al. 2007) through the ubiquitin 
proteasome pathway independent of PKB, although these authors attributed this effect largely to 
amino acid sensing through mTOR. This also seems an inadequate explanation in the present 
study (Figures 3.13 and 3.15) as no corresponding changes in mTOR signalling were detected. 
However, regulation of the ubiquitin-proteasome pathway by amino acids independent of mTOR 
has also been recently described (Eley et al. 2007). 
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A recent study by Moriscot and colleagues (2010) has shown that following denervation, MuRF-
1 is preferentially expressed in type II fibres. It is possible that the reduced expression of this E3 
ligase seen in the present study might be explained by a training induced fibre type shift from a 
type II fast fibre to a type I slow fibre that was not created in the STD group due to the limiting 
effect of acidosis on exercise training and adaptation (see Section 3.4.1).However, the 
contribution of a possible fibre type change to this reduced expression in the individual muscle 
biopsies is unknown as no quantification of fibre type distribution was made. 
 
3.4.5 Myofibrillar proteolysis 
Complete proteolysis of myofibrillar proteins requires both an initial caspase-3 dependent 
cleavage step (leading to accumulation of the 14kDa actin fragment) (Workeneh et al. 2006) and 
a subsequent degradation of the cleavage fragments through the ubiquitin proteasome pathway. 
Suppression of both of these processes would therefore be expected to bring about overall 
suppression of myofibrillar proteolysis. In practice in the present study, even through conditions 
were found which strongly suppressed E3 ligase expression (Figures 3.22 and 3.23), and even 
though some decline in 14kDa actin fragment may have occurred at six months in the STD 
bicarbonate group (Figure 3.20), under none of the conditions did they occur simultaneously. 
Overall suppression of myofibrillar proteolysis (indicated by 3-MH excretion) was not therefore 
detected in response to the treatments applied in this study (Tables 3.23 and 3.24). In addition to 
this, muscle protein:DNA ratio has been used to get a sensitive index of muscle protein mass 
(Crossland et al. 2008). A significant decline in the muscle protein:DNA ratio was observed in 
those patients that exercised for six months whilst receiving XS bicarbonate therapy. It is 
unlikely that this reflects muscle wasting, and can probably be attributed to the decline in total 
protein content in the biopsy (discussed in more detail in Section 3.4.6). There were no other 
changes observed in the muscle protein:DNA ratio in any of the other groups indicating walking 
exercise was unable to increase muscle mass in these patients, but similarly, did not cause 
muscle mass to be reduced. 
 
In spite of this failure to observe net reduction in 3-MH excretion or an increase in muscle 
protein:DNA ratio, small apparent increases in LBM were detected by DEXA, especially after 
one month of exercise (Table 3.10). Bearing in mind the technical limitations of DEXA in 
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detecting small changes (as discussed in Section 3.4.2 above), this may be a reflection of the 
accompanying suppression of E3 ligase expression which, even though it would be expected to 
have little effect on overall myofibrillar proteolysis, might still lead to some net accumulation of 
non-myofibrillar protein whose protein degradation is not thought to require prior processing via 
caspase-3. Exercise-induced stimulation of muscle synthesis may also have contributed, 
especially in the fed state. 
 
3.4.6 Adverse effects of sodium bicarbonate 
Even though exercise therapy in combination with XS bicarbonate may have had beneficial 
effects on the lactic acid response to acute exercise (Figure 3.5B), body composition (Figures 
3.7B and 3.8B), free amino acid pools (Figure 3.11) and E3 ligase expression (Figures 3.23 and 
3.24), in principle adverse effects may also occur as a result of this increased bicarbonate load. 
There are two potential dangers when administering high doses of sodium bicarbonate. Firstly, 
sodium loading (with secondary fluid loading) may occur, which is of a particular concern in the 
more hypertensive patients. Secondly, pH overshoot could also occur possibly resulting in a 
localised alkalosis.  These patients did not appear to have been sodium loaded as there were no 
detectable increases in the water content of the muscle biopsies in the XS bicarbonate group, 
suggesting that secondary fluid retention in the tissues had not been a major problem. The 
possibility of alkalosis is more difficult to refute. While blood pH or bicarbonate concentration 
did not exceed the top end of the normal range, it is difficult to exclude the possibility of 
transient alkalosis localised to tissue interstitial fluid. Such effects may have contributed to 
difficulties encountered in obtaining muscle biopsies from those patients randomised to receive 
XS bicarbonate. While biopsies were routinely obtained without problems from patients 
receiving STD bicarbonate therapy at all time points, and from XS bicarbonate patients at 
baseline, significant difficulties were experienced in obtaining subsequent biopsies from this 
group. It was noted that considerable amounts of fibrous tissue or fascia, were present in these 
subsequent biopsies, which was particularly a problem after one month of exercise and, for this 
reason, XS bicarbonate data are not presented at this time point. At six months, fibrous tissue in 
the muscle biopsies was still observed and is reflected in the significant decline in the soluble 
protein content of these biopsies relative to baseline (Table 3.11).  
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This consistent decline in soluble protein of the muscle biopsies and in muscle protein:DNA ratio 
that was seen in those patients who had exercised for six months with XS bicarbonate is a 
surprising finding and has not previously been reported. As DEXA measurements indicated that 
this decline in biopsy soluble protein content was accompanied by gains in LBM, (that were 
more apparent when expressed as a percentage of total body weight and in relation to fat mass), 
this protein loss seems to be confined to the biopsy site. The reason for these sampling 
difficulties is unknown, but there are two possible explanations. Firstly, the distance between 
biopsies was only 1cm. This may have meant the second and third biopsies were infiltrated by 
scar tissue altering the biopsy composition and so the close proximity of the multiple biopsy sites 
might be responsible for the decline in soluble protein. Secondly, as it was only seen in the XS 
group, it may reflect an adverse pro-fibrotic effect of XS bicarbonate on the tissue regeneration 
response of the vastus lateralis muscle following the initial biopsy. Recent evidence from mouse 
models suggests that skeletal muscle regeneration following injury in CKD is significantly 
impaired and is accompanied by fibrosis (Zhang et al. 2010) and this may have been a problem 
in the present study. The accompanying amount of protein in the insoluble fraction of the 
biopsies did not increase, showing that this problem did not occur simply through inadequate 
homogenisation of the tissue.  
 
In conclusion, six months of aerobic exercise combined with XS bicarbonate therapy resulted in 
an improved exercise tolerance and associated lactate response, favourable changes in body 
composition and a reduced mRNA expression of the E3 ubiquitin ligases. This suggests that XS 
bicarbonate allowed the patients to exercise more effectively by buffering acid that was produced 
during the exercise bout and demonstrates that the beneficial effects of alkali supplements that 
have previously been seen in peritoneal dialysis patients (Stein et al. 1997) may also be observed 
in pre-dialysis patients, but only in combination with exercise. Exercise without XS bicarbonate 
therapy appeared to disrupt amino acid gradients, resulting in a decline in intramuscular amino 
acid concentration and perhaps ultimately limited protein synthesis. Overall there was no 
decrease in myofibrillar protein catabolism (3-MH), possibly resulting from a failure of the 
treatments to increase PKB phosphorylation sufficiently and decrease casapase-3 mediated 
cleavage of myofibrils and, in the case of STD bicarbonate therapy, to effectively buffer the 
additional acid produced during exercise. Whether hypertrophy in CKD can be attained by alkali 
therapy combined with resistance exercise warrants further investigation. These results suggest 
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that acidosis is a functionally significant problem in CKD patients attempting an exercise 
programme, and factors determining the magnitude of this problem are the subject of the next 
chapter. 
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Chapter 4 
 
In vivo study of the regulation of sulphuric acid 
production in CKD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 146 
 
4.1 Introduction 
The catabolism of sulphur-containing amino acids (as described in detail in Chapter 1.6.1) results 
in the production of taurine and sulphate (Stipanuk et al. 2004; Coloso and Stipanuk, 1989) and 
accounts for the majority of the daily titratable acid load in humans. The metabolism of sulphate 
may be abnormal in CKD, because despite normal plasma methionine concentrations (Gulyassy 
et al. 1970; Condon and Asatoor, 1971), the concentrations of cysteine and homocysteine, a 
homologue of cysteine, both in the free and bound forms, are frequently seen to be raised in 
uraemic patients (Flűgel-Link et al. 1983; Robins et al. 1972). Plasma taurine levels, however, in 
non-dialysed and haemodialysis patients tend to be lower than those seen in healthy individuals 
(Alvestrand et al. 1982; Qureshi et al. 1989; Suliman et al. 1996) and Bergström and colleagues 
(1989) reported that in CKD patients the muscle and plasma taurine concentrations were both 
reduced by the same margin, suggesting that this represents a true depletion of taurine from the 
cells rather than a decline in the cell/plasma concentration gradient. 
The concentrations of cysteinesulphinate (CSA) in uraemic plasma have also been reported to be 
high (Suliman et al. 1996) and it was speculated that low plasma taurine accompanied by these 
high levels of CSA arises from a defect in the activity of cysteinesulphinate decarboxylase 
(CSAD), the rate limiting step in the conversion of CSA to taurine (Suliman et al. 1996).  This 
enzyme requires vitamin B6 as a cofactor, a vitamin in which CKD patients are commonly 
deficient (Kopple et al. 1981). However, patients in a number of studies by Suliman and 
colleagues (1999, 2001, 2002) were administered vitamin B6 supplements and so the authors 
concluded that uraemia itself inhibits CSAD. Anorexia and malnutrition are frequently seen in 
these patients (Suliman et al. 2002) and it is likely this results in a reduced taurine intake that, 
when coupled with a reduced taurine synthesis from CSA as proposed by Suliman et al. (1996), 
results in these reduced plasma taurine levels. Taurine has many important cellular functions 
including stabilization of the membrane potential, antioxidant properties and a positive inotropic 
effect on the heart (Suliman et al. 2002; Schaffer et al. 2009) and taurine depletion could 
possibly result in muscle fatigue and cardiovascular disease (Suliman et al. 2002), common co-
morbidities in CKD patients (Nussbaum and Garcia, 2009; Pecoits-Filho et al. 2002). 
It was therefore hypothesised that in CKD the flux through this pathway is diverted away from 
taurine and towards the generation of pyruvate and sulphuric acid (H2SO4) (Chapter 1, Figure 
1.5) thus exacerbating the metabolic acidosis that is already present because of impaired 
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excretion of acid. Such enhanced catabolism of cysteine to H2SO4 has been observed previously 
in cancer and HIV infection - conditions which both show prominent cachexia (Breitkreutz et al. 
2000; Hack et al. 1996), but has yet to be demonstrated in CKD patients.  
It has been shown previously in peritoneal dialysis patients that alkali therapy results in weight 
gain and improvements in morbidity (Stein et al. 1997; Szeto et al. 2003), but this was achieved 
with only small changes in plasma bicarbonate or pH, suggesting that plasma bicarbonate and pH 
are not sensitive indicators of muscle wasting or clinically significant levels of acidosis in the 
tissues. It is possible that measures of sulphur amino acid catabolism might be more sensitive 
clinical biochemical markers of tissue acidification leading to cachexia. Therefore, the aims of 
this study were 
1) To compare sulphate, CSA and taurine excretion in CKD patients (Stage 4-5) who 
were still producing urine, with a group of healthy control subjects to determine 
whether these patients do excrete more sulphate and less taurine than the healthy 
individuals, consistent with a decreased flux through the CSAD enzyme. 
2) To examine if sulphate excretion rate correlates with 3-MH excretion (as a measure 
of myofibrillar protein catabolism) in either group, possibly allowing identification of 
those patients who produce more sulphate and may therefore be at a greater long-term 
risk of muscle wasting. 
3) To examine the effect of exercise and bicarbonate therapy on sulphur metabolism.  
 
It was hypothesised that compared to healthy controls, CKD patients would exhibit higher 
excretion rates of sulphate and lower excretion rates of taurine indicating an impairment in the 
CSAD enzyme, and that the acid generated from the diet would be functionally important in 
CKD patients resulting in a positive correlation between sulphate excretion and 3-MH excretion 
rates. 
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4.2 Methods 
4.2.1 Participant information 
This study received ethical approval from the local ethics committee. Prior to the start of the 
study, all potential participants received written information regarding the nature of the protocol. 
Following any questions, participants signed a written statement of consent and were made 
aware of their right to withdraw from the study at any point without the need to give a reason. 
The healthy volunteers in this study were free of any renal impairment, assessed by serum 
creatinine and of any known disorder in the metabolism of sulphate. Twenty CKD patients Stage 
4-5 who had not yet started dialysis therapy and twenty healthy controls were recruited. 
Table 4.1. Participant characteristics. Values are presented as median and range. 
 Males Females Age (years) Weight (kg) Height (m) 
Plasma 
bicarbonate 
(mmol/l) 
CKD 
Patients 
14 6 
60        
(38 – 77) 
80.3            
(53.0 – 116.0) 
1.73        
(1.48 – 1.92) 
23           
(20 – 29) 
Healthy 
Controls 
8 12 
39        
(31 – 57) 
63.0            
(48.0 – 94.0) 
1.68          
(1.54 – 1.82) 
26           
(22 – 30) 
 
 
4.2.2 Protocol for urine collection and handling 
As described in Chapter 3, the excretion of 3-MH was analyzed as a measure of myofibrillar 
protein degradation. To do this, patients were required to undergo three days on a vegan diet (i.e. 
devoid of 3-MH and low in taurine), followed by a complete 24h urine collection on the fourth 
day, whilst on the same diet and before the initiation of exercise or bicarbonate therapy. These 
urine samples were also used to perform analyses of sulphate, taurine, CSA and 3-MH excretion 
(see Chapter 2.3). As part of the exercise study protocol (see Chapter 3.2.3), patients were 
required to repeat this vegan diet and 24h urine collection after one month and/or after six 
months to investigate changes in 3-MH excretion, and so the analyses of sulphur metabolites 
were repeated in these samples to give an indication of the effect of exercise and bicarbonate 
therapy on excretion rates. The healthy control group gave a 24h urine sample following the 
vegan diet as for the patients, but the procedure was also repeated six months later whilst on their 
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normal ad libitum diet. Taurine, CSA and 3-MH excretion were analysed by HPLC, (see Chapter 
2.3). Sulphate excretion was analysed by turbidimetry (see Section 4.2.2.1). 
 
4.2.2.1 Urinary sulphate quantification by turbidimetry 
Sulphate precipitated in the form of Barium Sulphate was determined by turbidimetry as 
described by Ma and Chan (1973).  Protein was precipitated from the urine sample by the 
addition of 5% w/v TCA (200μl) to 50µl of the urine sample or sodium sulphate standard (0-
100mM) (50μl), vortexed and incubated on ice for 5 minutes. The tubes were then 
microcentrifuged at 13,000rpm for 10 minutes at 4˚C. 200μl of the resulting supernatant was 
transferred to a new tube and 1% BaCl2 plus 10% dextran (50μl) was added and immediately 
vortexed. 200μl from each tube was pipetted into a 96 well plate and incubated at room 
temperature for 10 minutes to allow barium sulphate turbidity to develop. The plate was then 
read at an optical density of 660nm on a Titertek Mulitscan spectrophotometer. 
 
4.2.3 Blood sampling and handling 
On the day of collection, patients arrived at the hospital fasted and a venous and arterial blood 
sample was taken for the determination of blood bicarbonate concentrations. 7ml venous samples 
were drawn into tubes containing lithium heparin. Arterial blood samples were drawn from the 
brachial artery into a blood gas syringe containing heparin. Venous and arterial blood samples 
were taken to the Pathology Department at the Leicester General Hospital for the determination 
of blood bicarbonate concentrations. In the case of healthy volunteer samples, a 10ml venous 
blood sample was taken and dispensed into a plain tube and a tube containing K2 EDTA. No 
arterial blood sample was taken. 
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4.3 Results 
4.3.1 Excretion rates 
Sulphate excretion rates over 24h on a vegan diet are shown below in Figure 4.1. Although body 
weight will have an effect upon sulphate excretion, these results are initially presented as 
absolute excretion rates before a correction for body weight is made. 
 
Figure 4.1. Variation in daily sulphate output in healthy individuals and in CKD patients 
on a vegan diet. Healthy controls n = 20; CKD patients n = 20. 
Daily sulphate output varied widely, up to five fold, in both the CKD patients (35.5 ± 
4.7mmol/24h) and in healthy individuals (35.8 ± 3.9mmol/24h), but there was no significant 
difference in the sulphate output between the two groups (P = 0.771). There was also no 
significant difference when these values were corrected for body weight (healthy subjects = 
0.56mmol/24h/kg bw; CKD patients = 0.45mmol/24h/kg bw; P = 0.158). These values presented 
in Figure 4.1 are comparable with those previously reported in CKD (Nakanishi et al. 2002) and 
to those reported in healthy individuals of approximately 40mmol/day in Documenta Geigy 
(Diem and Lentner, 1970). The wide variation in the age of the subjects studied showed no 
detectable correlation with the rate of sulphate excretion (both in the CKD and healthy groups) (r 
= -1.81; P = 0.431) (data not shown).  
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Figure 4.2. Variation in daily sulphate output in healthy individuals on a vegan compared 
to an ad libitum diet.  Lines represent changes in each individual, n = 16. 
In healthy subjects, sulphate excretion was significantly higher on the ad libitum diet (49.3 ± 
5.3mmol/24h) compared to the vegan diet (33.4 ± 4.6mmol/24h) (P = 0.036), but there was no 
correlation between sulphate excretion rates measured on the two diets (r = 0.196; P = 0.483). 
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Figure 4.3. Variation in daily taurine (A) and CSA excretion (B) between healthy subjects 
and CKD patients on a vegan diet. (C) ratio between sulphate and taurine excretion in 
healthy subjects and CKD patients. 
Similar to the results for sulphate excretion, there was also a wide variation in the excretion of 
taurine and CSA in both groups.  There was a tendency for taurine excretion to be lower and 
CSA excretion to be higher in the CKD patients compared to the healthy subjects (Figure 4.3A 
and 4.3B respectively), but these apparent differences did not achieve statistical significance. 
There was no statistically significant difference in the sulphate/taurine ratios between the healthy 
subjects and CKD patients (P = 0.792) (Figure 4.3C), nor was there a difference in the 
taurine/CSA ratios (P = 0.555). Consequently, even in the healthy subjects, more than 95 % of 
the total sulphur excreted was in the form of sulphate.  
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A strong positive correlation was observed between 3-MH excretion rate and sulphate excretion 
rate in CKD patients (Figure 4.4A) (r = 0.755; P<0.001). This correlation persisted when 3-MH 
and sulphate were corrected for body weight (r = 0.761; P<0.001), creatinine (r = 0.529; P = 
0.016) and DEXA-derived lean body mass (r = 0.714; P<0.001) (Figures 4.4A, C, E and 4.5), 
demonstrating that the expected increases in 3-MH and sulphate production with increasing 
tissue mass were not the cause of the correlation. In contrast, no significant correlation was seen 
between the excretion rates of 3-MH and sulphate in the healthy control group (r = 0.347; P = 
0.133), or when these values were corrected for creatinine (P = 0.061). There was however a 
significant correlation when corrected for body weight (P = 0.024) (Figures 4.4B, D, F). 
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Figure 4.4. Correlation between daily 3-MH and sulphate excretion in CKD patients (A) 
corrected for creatinine (C) and body mass (E) and in healthy individuals (B) corrected for 
creatinine (D) and body mass (F). 
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Figure 4.5. Correlation between daily 3-MH and sulphate excretion corrected for LBM in 
CKD patients.  
 
4.3.2 Correlations with net tissue wasting (cachexia) 
At this stage in the disease progression (CKD 4-5) it was not possible to demonstrate a 
correlation between elevated rates of 3-MH excretion and net wasting of lean tissue. For 
example, when the DEXA-derived LBM was expressed as a percentage of total body weight (a 
measure of cachexia), no correlation was observed with the 3-MH excretion rate (Figure 4.6A). 
Consequently, no correlation was observed between sulphate excretion rate and severity of 
wasting (Figure 4.6B). 
 
Figure 4.6. Correlation between LBM expressed as a % of total body weight and (A) daily 
3-MH excretion corrected for creatinine and (B) sulphate excretion corrected for 
creatinine. 
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4.3.3 Comparison with conventional measures of acid-base status 
The proposed catabolic effect of acidosis in CKD (Stein et al. 1997; Szeto et al. 2003) would be 
expected to lead to a correlation between elevated rates of 3-MH excretion and low blood 
bicarbonate concentration or pH. In spite of this, no correlation was observed between venous 
bicarbonate levels and 3-MH excretion rate in either the CKD patients (r = 0.231; P = 0.342) 
(Figure 4.7A) or in healthy individuals (r = 0.196; P = 0.407) (data not shown). There was 
however, a significant inverse relationship as expected between arterial bicarbonate and 3-MH 
excretion in CKD patients (r = -0.680; P = 0.011) (Figure 4.7B). 
 
 
 Figure 4.7. Correlation between 3-MH excretion rate and venous bicarbonate (A) and 
arterial bicarbonate (B) in CKD patients. Note, 6 of the 20 patients refused consent for an 
arterial blood sample. 
The accumulation of acid in those CKD patients with higher rates of sulphuric acid production 
would also be expected to lead to an association between high sulphate excretion and low blood 
bicarbonate. At least for arterial bicarbonate, the expected trend was observed (Figure 4.8B), but 
fell short of statistical significance (P = 0.113).  
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Figure 4.8. Correlation between blood bicarbonate and daily sulphate excretion in CKD 
(A) venous blood (B) arterial blood. 
An unexpected observation was that there was a strong positive correlation between venous 
bicarbonate and sulphate excretion in the healthy controls (r = 0.800; P = 0.001) (Figure 4.9), in 
marked contrast with that in the CKD patients (Figure 4.8A), presumably indicating that in 
healthy individuals producing large amounts of sulphuric acid, potent compensatory mechanisms 
exist to prevent acidosis (Figure 4.9) and prevent increased protein catabolism (Figure 4.4B) 
 
Figure 4.9. Correlation between venous bicarbonate concentration and daily sulphate 
excretion in healthy subjects. 
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4.3.4 Relationship with free amino acid concentrations 
No relationship was identified between sulphate excretion and muscle or plasma concentrations 
of methionine, cysteine, or any other free amino acid (P>0.05) (data not shown). 
 
4.3.5 Effects of exercise or bicarbonate therapy on sulphur metabolism 
Values in Tables 4.2 and 4.3 show that exercise had no significant effect upon sulphate 
excretion. After one month, sulphate excretion did appear to have increased, but this change was 
not statistically significant (P = 0.109) and had disappeared after six months of exercise. XS 
sodium bicarbonate therapy had no effect on sulphate excretion after one month of exercise 
(>0.05), however, the excretion rates after six months of exercise from those patients receiving 
STD and XS bicarbonate were significantly different (P = 0.020). This difference remained when 
sulphate excretion rates were corrected for body weight (P = 0.012) and LBM (P = 0.028), but 
not creatinine (P = 0.240). It is important to note however, that most of this apparent difference 
in sulphate excretion between the STD and XS groups was already present at baseline, but was 
not statistically significant at that time point (P = 0.125) (Tables 4.2 and 4.3), indicating that the 
therapy had exerted negligible effect on sulphate output. 
Table 4.2. Effects of one month of exercise and bicarbonate therapy on sulphate excretion 
(mmol/24h). 
 Baseline One Month 
All Patients 33.0 ± 4.8 41.4 ± 7.4 
STD Bicarbonate 28.3 ± 4.6 31.9 ± 4.7 
XS Bicarbonate 40.7 ± 10.0 57.3 ± 17.0 
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Table 4.3. Effects of six months of exercise and bicarbonate therapy on sulphate excretion 
(mmol/24h). * denotes a significant difference from corresponding value in STD bicarbonate 
group (P<0.05). 
 Baseline Six Months 
All Patients 33.0 ± 5.0 34.7 ± 5.5 
STD Bicarbonate 26.5 ± 4.8 25.2 ± 4.2 
XS Bicarbonate 45.7 ± 11.0 51.7 ± 10.1* 
 
Even though this study was not designed to test the stability of sulphate excretion rate in 
individual patients, it is interesting to note that differences in the sulphate excretion rate between 
individuals generally persisted over time. A strong correlation was observed between baseline 
and six month sulphate excretion rates (R = 0.814; P<0.001) (Figure 4.10C) i.e. those individuals 
who produced large amounts of sulphate at baseline still produced large amounts six months 
later, possibly indicating that these individuals are at a higher long-term risk of acidosis-related 
complications when their ability to excrete this acid is lost. 
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Figure 4.10. Change in sulphate excretion over time in those CKD patients who received 
STD bicarbonate (A) and XS bicarbonate (B) therapy. (C) Stability of sulphate excretion 
over time assessed by correlating baseline and six month data in those patients on STD 
bicarbonate therapy. 
 There was no significant effect of exercise or bicarbonate therapy on the excretion rates of 
taurine or CSA (Tables 4.4 – 4.7). 
Table 4.4. Effects of one month of exercise and bicarbonate therapy on taurine excretion 
(µmol/24h).  
 Baseline One Month 
All patients 816.8 ± 168.3 879.0 ± 286.8 
STD Bicarbonate 862.5 ± 228.6 882.0 ± 320.3 
XS Bicarbonate 734.6 ± 258.7 873.6 ± 615.7 
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Table 4.5. Effects of six months of exercise and bicarbonate therapy on taurine excretion 
(µmol/24h). 
 Baseline Six Months 
All patients 710.4 ± 178.9 868.8 ± 262.5 
STD Bicarbonate 748.9 ± 250.3 986.9 ± 378.9 
XS Bicarbonate 623.7 ± 191.3 603.0 ± 26.7 
 
Table 4.6. Effects of one month of exercise and bicarbonate therapy on CSA excretion 
(µmol/24h). 
 Baseline One Month 
All patients 109.4 ± 25.8 95.7 ± 26.0 
STD Bicarbonate 122.8 ± 36.6 116.4 ± 32.7 
XS Bicarbonate 85.3 ± 31.8 58.5 ± 41.8 
 
Table 4.7. Effects of six months of exercise and bicarbonate therapy on CSA excretion 
(µmol/24h). 
 Baseline Six Months 
All patients 97.6 ± 26.0 109.3 ± 27.3 
STD Bicarbonate 114.9 ± 36.1 125.4 ± 34.6 
XS Bicarbonate 66.3 ± 33.2 80.3 ± 46.5 
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4.4 Discussion 
4.4.1 Uraemic defects in sulphur metabolism 
It has previously been reported that CKD patients have abnormal plasma concentrations of the 
sulphur containing amino acid cysteine and their catabolites (Flűgel-Link et al. 1983; Alvestrand 
et al. 1982; Suliman et al. 1996) indicating a defect in their metabolism. In particular Suliman 
and colleagues (1996) proposed that a defect may be present in the activity of the CSAD enzyme 
which may result in cysteine metabolism being diverted away from non-acidic products such as 
taurine and towards sulphuric acid. By making the assumption that dietary sulphur intake and 
urinary sulphur excretion are at steady state, the present study attempted to investigate fluxes 
through these sulphur amino acid catabolic pathways by measuring excretion rates on a vegan 
diet. This failed to detect statistically significant changes in these fluxes (Figure 4.1) when 
compared with healthy individuals, although the tendency towards decreased taurine excretion, 
increased CSA excretion (Figures 4.3A and B) may be consistent with the proposed impairment 
of flux through CSAD in CKD. Nevertheless, it should be emphasised that, even in healthy 
people, 95% of the total sulphur excreted is in the form of sulphuric acid rather than taurine 
(Section 4.3.1). Therefore, even if CSAD is strongly inhibited in CKD, this would probably have 
little additional impact on acid production in these patients.  
It is frequently reported that CKD patients have low muscle and plasma taurine levels (Qureshi 
et al. 1989; Bergström et al. 1989) which, in the presence of high cysteine and CSA 
concentrations, led to the suggestion of a defect in the activity of the enzyme CSAD in uraemia. 
The median taurine excretion rate in the patients in the present study was less than half of that 
seen in the healthy control group (Figure 4.3), but this apparent difference fell short of statistical 
significance. The patients studied by Suliman and colleagues (1996), leading them to the 
conclusion of a defective CSAD flux, were established haemodialysis and peritoneal dialysis 
patients, unlike the pre-dialysis patients in the current study. It may be that there is a disorder in 
sulphur metabolism in end-stage renal disease that is not yet fully developed in pre-dialysis 
patients of the type studied here. It has also been observed that the dialysis procedure itself 
results in a loss of taurine (Loftberg et al. 2000), which may also explain why clearer depletion 
of taurine levels was observed in the earlier studies. 
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4.4.2 Correlation with protein catabolism 
No significant increase was observed in the sulphate excretion rate in the present CKD patients, 
when compared with healthy control subjects. This contrasts with the results from other catabolic 
diseases, such as cancer and HIV infection (Breitkreutz et al. 2000; Hack et al. 1996), in which 
large sulphur losses have been reported. However, an important finding in the present study was 
that there was very wide variation in the sulphate excretion rate between individuals (both in the 
healthy control group and in the CKD patients (Figure 4.1)) and this wide variation showed a 
strong positive correlation with 3-MH excretion, but only in the CKD patients. Two possible 
interpretations of this observation are that: 
a) Increased sulphuric acid production causes increased protein catabolism if excretion of 
the acid is impaired, OR 
b) Increased protein catabolism liberates L-Met and L-Cys from the degraded proteins 
which are then further degraded, leading to increased sulphuric acid production. 
In vivo both effects may occur: (a) may contribute to the lethal effects of the acidosis generated 
in chicks receiving supraphysiological doses of L-Cysteine (Dilger & Baker, 2008) whereas (b) 
may contribute to the strongly increased L-Cysteine catabolism and sulphate excretion reported 
in severe cachexia (Breitkreutz et al. 2000; Hack et al. 1996). In the present study (a) seems to be 
the dominant factor because this interpretation predicts that sulphuric acid production should not 
lead to acid accumulation and hence protein catabolism if acid excretion is normal. This was 
indeed the case in healthy individuals (Figure 4.5B) and the 3-MH/sulphate correlation was not 
seen in this group, presumably because in non-uraemic individuals there is a significant ability to 
buffer and excrete the sulphuric acid. 
This suggests that in the patient population, sulphate excretion may be a good indicator of 
myofibrillar protein degradation, and those patients who consistently produce large amounts of 
sulphate in their urine may be at a greater long-term risk of muscle wasting. The rate of sulphate 
production in each individual did appear to remain relatively stable over time (Figure 4.10C): 
those individuals who were seen to produce large amounts of sulphate (sulphuric acid) at 
baseline generally still produced large amounts six months later, which has not been shown 
previously. This needs to be confirmed in a larger long-term study but, if verified, is potentially 
important because it might allow a single 24h urine sample, early in the progression of the 
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disease, to be used to screen for those patients at greatest risk from metabolic acidosis and 
muscle wasting.  
As expected, the rate of sulphate excretion was higher in healthy individuals on the ad libitum 
diet compared to the vegan diet, presumably because of a greater intake of foods high in sulphur 
amino acids, for example meat (Nakamura et al. 2002) and therefore a greater flux through the 
sulphuric acid pathway. If this also applies to CKD patients on their usual diet, this implies that 
the severity of the apparent effect on protein catabolism observed on the vegan diet in Figure 4.5 
is probably an under-estimate.  
 
4.4.3 Correlation with cachexia 
There was no detectable relationship in this study between LBM and 3-MH excretion (Figure 
4.6A), contrary to what might have been expected. If indices of myofibrillar degradation increase 
as in Figure 4.5, this might be expected to be reflected in whole body measures of LBM. Several 
factors probably contributed to the failure to observe this. The inability of DEXA to detect small 
changes in muscle mass was discussed in the previous chapter (Section 3.4.2). At this stage in 
the disease progression (CKD 4-5), it may also be too early for significant wasting to be 
demonstrated, and the patients may have achieved a steady-state in which increased protein 
catabolism is compensated by increased protein synthesis (Reaich et al. 1995). Further long-term 
studies may therefore be required to demonstrate the clinical significance of elevated sulphuric 
acid production rate in cachexia. 
 
4.4.4 Conventional measures of acid-base status 
More conventional means of assessing a patient’s acid base status are venous and arterial 
bicarbonate measurements and pH measurements (Robertson, 1989). Venous bicarbonate 
measurements are routinely used by clinicians in the treatment of CKD, but as this is prone to 
influence by many factors for example diet and environment, it is a less desirable measure than 
arterial bicarbonate, which is usually lower than the venous bicarbonate levels.  Unlike the 
relationship observed between sulphate and 3-MH excretion in the present CKD patients, no 
relationship was found between venous bicarbonate and either sulphate or 3-MH excretion 
(Figures 4.7A and 4.8A). There was however, a significant inverse relationship between arterial 
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bicarbonate and 3-MH excretion (Figure 4.7B), suggesting that arterial bicarbonate rather than 
venous measurements may be a more reliable indicator of acidosis leading to protein catabolism. 
The reason for this observed correlation with arterial but not venous bicarbonate is unknown, but 
may reflect the variable nature of venous bicarbonate levels as described above. As arterial blood 
sampling involves considerable discomfort to the patients, further investigation of urinary 
sulphate excretion as a surrogate, non-invasive measure of acid-base status in CKD may be 
worth pursuing. 
 
4.4.5 Alkali therapy and 3-MH excretion 
Even though the positive correlation between sulphate excretion and 3-MH excretion 
demonstrated in Figure 4.5 and the inverse correlation between arterial bicarbonate and 3-MH 
excretion demonstrated in Figure 4.7B suggest that acid accumulation in CKD is driving 
myofibrillar protein degradation, six months of XS bicarbonate therapy with or without exercise 
therapy in Chapter 3 (see Section 3.3.12) failed to show the expected suppression of 3-MH 
excretion in these patients. This failure might be attributable to three factors: 
1) The XS bicarbonate therapy may have had insufficient impact on pH/bicarbonate 
concentration in the tissue interstitial fluid and indeed there was no significant change in 
arterial pH following XS bicarbonate therapy (P = 0.110; see Chapter 3, Table 3.3). 
However, clear effects were observed in Chapter 3.3.11 on muscle E3 ligase expression 
suggesting that this is an inadequate explanation. 
 
2) This discrepancy might also have arisen from a stimulatory effect of bicarbonate therapy 
on appetite and feeding. Metabolic acidosis is a known appetite suppressant (Koch & 
Kaske, 2008) and increased dietary protein intake (and hence sulphur intake) leads to the 
generation of sulphuric acid (Trilock and Draper, 1989; Leman and Relman, 1959). 
However, no significant increase in sulphate excretion was found to accompany the XS 
bicarbonate therapy: sulphate excretion was indeed higher in the XS bicarbonate group 
than in the STD group after 6 months (Table 4.3) but this seemed to arise mainly from a 
pre-existing elevation in sulphate output in the XS bicarbonate patients which was 
present at baseline (Table 4.3). This observation of a higher rate of sulphuric acid 
production at baseline and after six months in the XS bicarbonate patients may partly 
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explain however the low muscle amino acid concentrations and amino acid gradients that 
were observed in Chapter 3 in these patients (Tables 3.13 and 3.16). This may mean that 
in future studies of this type it will be necessary to match the different patient groups for 
sulphur intake/sulphate excretion at the start of the study. 
 
3) Failure of XS bicarbonate to suppress 3-MH excretion in spite of an apparent link 
between sulphuric acid production and 3-MH (Figure 4.5A) may mean that some toxic 
product of the sulphuric acid pathway other than acid is contributing to myofibrillar 
protein catabolism. In addition to acid, this pathway also generates the toxic intermediate 
sulphite (SO32-) from sulphurous acid (H2SO3) (See Chapter 1, Figure 1.5). Sulphite 
accumulates in patients with advanced CKD, attaining concentrations of approximately 5 
µmol/L (Kajiyama et al. 2000) - concentrations which are known to induce oxidative 
stress (Vincent et al. 2004) and hence inflammation – a known contributor to cachexia. 
This accumulation is made possible by the fact that the detoxifying enzyme sulphite 
oxidase (Chapter 1, Figure 1.5) which converts sulphite to sulphate (SO42-) has much 
lower activity in humans than in other mammals such as rat (Kucukatay et al. 2006). 
 
4.4.6 Conclusions 
In conclusion, no significant difference was observed between healthy subjects and CKD 
patients in their excretion rates for sulphate, taurine or CSA. The observation of a lack of a 
relationship between venous bicarbonate and 3-MH excretion, and the identification of a strong 
correlation between sulphate and 3-MH excretion, suggests that sulphate excretion might be a 
better clinical indicator of acidotic patients at risk of cachexia than conventional measures such 
as venous bicarbonate. This relationship between sulphate and 3-MH excretion also implies that 
sulphuric acid production is functionally important in these patients, and therapy aimed at 
slowing sulphur catabolism or diverting it away from sulphuric acid, for example towards the 
non-acidic end product taurine, might be worth investigating in high-risk acid-generating 
patients. A possible way in which this might be achieved is examined in the next chapter. 
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Chapter 5 
 
 
In Vitro modelling of the factors that generate acidosis, 
and the effects of stress signals on sensing of acidosis 
through the SNAT2 transporter 
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5.1 Introduction 
In the previous two chapters it was concluded that metabolic acidosis may be an important 
influence on muscle metabolism in CKD, particularly when exercise, resulting in generation of 
lactic acid, is imposed on a background of uraemic metabolic acidosis. Two important 
observations were: 
• Acid generation A strong positive correlation between the rates of sulphuric acid 
production and myofibrillar protein catabolism (3-MH excretion) in these patients. At the 
end of Chapter 4, it was suggested from this correlation that patients with a high rate of 
sulphate generation may be at a higher risk of acidosis-induced muscle wasting. 
• Acid sensing Collapse of the intramuscular/extracellular amino acid concentration 
gradients after six months of exercise – a defect which was concluded to be a 
consequence of acidosis because it was prevented by administering additional oral 
bicarbonate (Chapter 3).  
 
These observations lead to two important questions: 
1) Acid generation Is the higher rate of sulphuric acid generation seen in some patients a cause 
of increased protein catabolism (through worsening acidosis) or a consequence of protein 
catabolism (through liberation of sulphur amino acids from protein)? 
2) Acid sensing Inhibition of pH sensitive System A amino acid transporters (especially 
SNAT2/slc38a2) by acidosis could account for the observed collapse of amino acid gradients, 
but this inhibition is thought to be a direct, rapidly reversible, effect of low pH on the SNAT2 
protein (Bevington et al. 2002; Baird et al. 2006) implying that collapse of the amino acid 
gradients would only occur while acidosis was at its most severe during lactic acid generation 
accompanying exercise, but in practice, the effects on amino acids were detected in the resting 
state. This leads to the question of whether the metabolic stress of acidosis can also exert long-
term inhibitory effects on SNAT2 over a time scale of hours. 
 
For technical reasons these problems were difficult to investigate directly in the patients in vivo. 
In order to measure SNAT2 activity directly in vivo, 11C-MeAIB must be used and the analysis 
of which requires a cyclotron adjacent to the clinical research facility, therefore the effect of 
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exercise on SNAT2 activity could therefore not be measured directly in vivo. In order to address 
the question on acid generation above, rates of protein metabolism would need to be manipulated 
using cycloheximide and MG132. This would be unsafe and unethical to do in vivo and therefore 
in this chapter in vitro experiments using cultured cell models are described which attempt to 
answer the questions raised above. The chapter is divided into three parts:  
 
Part A investigates in vitro the factors controlling the production of sulphuric acid in cultured 
L6-G8C5 skeletal muscle cells and HepG2 hepatocytes. The L6-G8C5 myotube model has been 
used extensively in this laboratory to study metabolic effects of acidosis (Evans et al. 2008; 
Evans et al. 2007; Pickering et al. 2003; Bevington et al. 2002; Bevington et al. 2001; Bevington 
et al. 1998). The HepG2 cell line has been used previously as an in vitro model to study 
regulation of sulphur amino acid catabolism in liver (Dominy et al. 2007) which is the dominant 
organ responsible for sulphuric acid production in mammals (Stipanuk, 2004). Muscle makes a 
smaller contribution to whole-body sulphuric acid production (Ensunsa et al. 1993) but it was 
also felt to be important to study a muscle model here because locally generated sulphuric acid 
may be the pool with the most direct access to the myocytes in vivo and hence a greater possible 
influence on muscle catabolism. 
Initial experiments in this laboratory using the turbidimetric sulphate assay that was applied  to 
the patients’ urine in Chapter 3 showed that sulphate production by HepG2 and L6-G8C5 cells 
was detectable in vitro and that a confluent 35mm culture well of HepG2 cells produced 
approximately 20nmoles over three days (A. Eltagouri and J.R. Brown, unpublished 
observations). However, this technique was too insensitive for routine use in investigating effects 
on sulphate metabolism. A more sensitive technique was therefore developed, measuring 35S-
sulphate generation from catabolism of 35S-L-Methionine, followed by selective harvesting of 
the 35S-sulphate by precipitation with Barium as described in Chapter 2.10.2. 
This 35S assay system was also used to test the feasibility of manoeuvres aimed at diverting 
sulphur metabolism away from sulphate (sulphuric acid) towards non-acidic end products such 
as taurine. Boelens et al. (2003) observed that trauma patients frequently had low plasma 
glutamine and taurine concentrations and, following previous reports on the beneficial effect of 
glutamine supplementation in decreasing infections (Houdijk et al. 1998) and restoring body-
fluid distribution (Scheltinga et al. 1991), they hypothesised that glutamine supplementation may 
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help to increase plasma taurine concentrations, an amino acid that is involved in these two 
processes. They found that enteral glutamine supplementation resulted in increased plasma 
taurine levels, a finding that they also confirmed in surgically stressed rats (Boelens et al. 2003). 
In the current study, it was hypothesised that glutamine supplementation (possibly by trapping 
sulphur in the form of taurine) might decrease sulphuric acid generation in both L6 and HepG2 
cells.  
 
Parts B and C investigate in vitro (using L6-G8C5 myotubes) whether stress signals generated 
by acidosis or exercise might induce longer term inhibition of the SNAT2 transporter than would 
be obtained by the direct inhibitory effect of low pH on the SNAT2 protein (Baird et al. 2006). 
Two potential stress signals were investigated: 
 
Part B: The effect of glucocorticoid 
It is widely accepted that acidosis is an important contributor to muscle wasting and impaired 
growth (Mitch, 2006; Reaich et al. 1993; Kalhoff et al. 1993; McSherry and Morris, 1978). 
However, in vivo low pH is not the only catabolic signal generated by acidosis (Chapter 1.7.2): 
metabolic acidosis results in an increase in glucocorticoid secretion (May et al. 1986; Pickering 
2003) and a positive correlation has been identified between muscle proteolysis and plasma 
cortisol levels (Garibotto et al. 1994).  
As glucocorticoid and acid appear to work in a coordinated manner in vivo (Chapter 1.7.2), it 
was hypothesised that like acid, glucocorticoid might also be acting through an inhibitory effect 
upon SNAT2.  
At present this is difficult to test directly in vivo. System A/SNAT2 activity has been measured 
in human skeletal muscle in vivo and has been shown to be inhibited in CKD (Asola et al. 2001), 
but this involves measuring uptake of 11C-MeAIB which requires a cyclotron adjacent to the 
clinical research facility. Plasma glucocorticoid concentration (cortisol) is reported to be elevated 
in CKD patients (McDonald et al. 1979; Rosman et al. 1982), but the assays for cortisol are 
prone to possible interference by glucuronide conjugates which circulate at high concentrations 
in patients with CKD (Nolan et al. 1981). For these reasons, the effects exerted by glucocorticoid 
on SNAT2 were investigated in vitro. Initial experiments in this laboratory (H. Butler, 
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unpublished observations) had indicated that SNAT2 activity in L6-G8C5 myotubes is inhibited 
after 4 – 24h of exposure to Dexamethasone. The experiments described below extend and 
characterise this observation. It was therefore hypothesised that glucocorticoids like acidosis, 
would cause a decrease in SNAT2 transport activity and would also result in similar reductions 
in intracellular glutamine concentrations. If the action of glucocorticoids and acidosis is through 
distinct mechanisms, the effects of the two combined would be expected to be additive. 
 
Part C: The effect of mechanical stretch upon this transporter. 
It is well known that mechanical stimuli play a key role in the maintenance of skeletal muscle 
mass in vivo and in vitro (reviewed in Chapter 1.17). Such signals arising from mechanical stress 
during exercise could potentially modulate System A/SNAT2 activity. Henriksen et al. (1992) 
found that an acute exercise bout in rats increased the System A transporter activity in skeletal 
muscle in the presence of a submaximal concentration of IGF-1 and two other studies have also 
reported an acute stimulatory effect of exercise on System A activity in rat (Henriksen et al. 
1993; King, 1994). This is of interest because of recent evidence that SNAT2 can activate PI3-K 
and PKB and increase phosphorylation of proteins downstream of mTOR (Evans et al. 2007; 
Evans et al. 2008) leading to the hypothesis that this transporter may be a sensor of mechanical 
stretch and may mediate the anabolic signals reviewed above. 
 
Clearly such acute stimulatory effects on System A transporters cannot explain the collapse of 
muscle/ECF amino acid gradients observed in the exercising patients in Chapter 3. However, 
long-term effects of mechanical stress on System A activity in skeletal muscle cells (as in the 
patients) have not been investigated. The final part of this chapter therefore investigated the 
effect of passive continuous stretch and cyclic stretch (up to 48h duration) on the activity and 
expression of the SNAT2 transporter in L6-G8C5 myotubes and it was hypothesised that both 
passive and cyclic stretch would cause an up-regulation of SNAT2 transport activity through an 
increase in transcriptional regulation. 
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5.2 Methods 
 
5.2.1 Cell culture 
Cells used in this thesis were L6-G8C5 rat skeletal muscle from the European Collection of 
Animal Cultures (ref. 92121114) and human Hep G2 hepatoma (ref.85011430). 
 
5.2.1.1 Maintenance of cell lines 
L6-G8C5 cells were routinely passaged and were grown to confluence in Growth Medium 
containing Dulbecco’s Modified Essential Medium (DMEM) (Invitrogen, UK, 11880-) 
supplemented with 10% v/v heat inactivated foetal bovine serum (FBS) (Invitrogen, UK, 10270) 
(heat inactivated by incubation at 56°C for 30 minutes), 2mM glutamine (Invitrogen, UK 25030) 
1% v/v penicillin-strepomycin (Invitrogen, UK 15140) and 10mg/L phenol red (Sigma, Dorset, 
UK, P5530).  
Hep G2 cells were grown to confluence in Growth Medium containing Minimum Essential 
Medium (MEM) (Invitrogen, UK, 21090) supplemented with 10% v/v FBS, 2mM glutamine, 1% 
v/v penicillin-strepomycin (Invitrogen, UK, 15140) and 1% v/v non-essential amino acids 
(Invitrogen, UK, 11140).  
 
5.2.1.2 Routine cell passaging 
L6-G8C5 cells on 9cm diameter Petri dishes were routinely sub-cultured every 4 days to prevent 
them becoming more than 75% confluent. Growth Medium was aspirated and cells were rinsed 
with 5ml Hanks Balanced Salt Solution (HBSS) (Invitrogen, UK, 24020) to remove serum. 
Trypsin- EDTA (2ml) (Invitrogen, UK, 25300) was added to the cells which were then incubated 
at 37°C for 10 minutes until detached from the bottom of the plate. Growth medium was added 
to inactivate the Trypsin-EDTA and this cell suspension was centrifuged at 200g for 5 minutes at 
room temperature. The cells were resuspended in Growth Medium seeded at a density of 16 X 
104 per 9cm Petri and cultured at 37°C under humidified 95% air and 5% CO2. 
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Hep G2 cells in 25cm2 flasks were routinely sub-cultured every 4 days to prevent becoming 
more than 75% confluent. Growth Medium was aspirated and cells were rinsed with 5ml HBSS 
(Invitrogen, UK, 24020) to remove serum. Trypsin- EDTA (2ml) (Invitrogen, UK, 25300) was 
added to the cells which were then incubated at 37°C for 10 minutes until detached from the 
bottom of the plate. Growth medium was added to inactivate the Trypsin-EDTA and this cell 
suspension was centrifuged at 200g for 5 minutes at room temperature, The cells were 
resuspended in 6ml Growth Medium. 1ml of cell suspension and 4ml Growth Medium was 
added to a 25cm2 flask and cultured at 37°C under humidified 95% air and 5% CO2. 
 
5.2.1.3 Differentiation of myoblasts into myotubes for experiments 
Cells were seeded on 35mm diameter 6-well plates at 43 X 104 cells/well in Growth Medium. 
When the L6-G8C5 cells had reached confluence, which occurred after 3 days, the Growth  
Medium was replaced with MEM (Invitrogen, UK, 21090) supplemented with 2% v/v heat 
inactivated FBS (Invitrogen, UK, 10270), 2mM glutamine, and 1% v/v penicillin-streptomycin 
(Invitrogen, UK, 15140), which was replenished every 2 days. By 8 days after seeding, the cells 
had differentiated into fused myotubes suitable for experimental incubations. 
 
5.2.1.4 Experimentation 
Confluent myotubes were rinsed with HBSS (Invitrogen, UK, 24020) and incubated at 37°C, 
under humidified 95% air / 5% CO2 in the relevant test medium. Test medium consisted of MEM 
supplemented with 2%v/v Dialysed Foetal Bovine Serum (DFBS) (Invitrogen, UK, 26400) and 
1% v/v Penicillin-Streptomycin (Invitrogen, UK, 15140) at pH 7.4 unless otherwise stated. Other 
components of the test media varied depending upon the experimental conditions and are 
detailed in figure legends in this chapter. Test media for amino acid free conditions contained 
Earls Balanced Salts Solution (Sigma, Dorset, UK, E2888) supplemented with 1% v/v Penicillin-
Streptomycin with MEM vitamins (Invitrogen, UK, 11120037) at pH 7.4. unless otherwise 
stated. 
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5.2.1.5 Passive stretch technique 
Adapted from that described in Rauch and Loughna, (2008). L6-G8C5 cells were seeded on type 
I collagen coated Bio-flex six well plates (Flexcell International Corporation, NC, USA, BF-
3001C). Once the cells were confluent and fused, a glass marble (15mm diameter) was placed 
centrally under each well with a 3kg weight on top of the culture plate to create approximately an 
18% linear stretch of the culture surface. Myotubes were stretched for 17 or 48h in media 
containing 2mM glutamine. The % linear stretch was calculated using trigonometry from the 
measured vertical movement shown in Figure 2.1A as described by Rauch and Loughna (2008). 
 
5.2.1.6 Cyclic stretch technique 
L6-G8C5 cells were seeded on type I collagen coated Bio-flex six well Flexcell plates and 
stretched using Flexercell Strain Unit Fx-3000 (Flexcell International Coproration, NC, USA). 
Cells were cyclically stretched using the same protocol as Goto et al. (2003), a 2 second sine 
wave stretch with a 4 second release that resulted in an 18% maximum stretch. In each 
experiment a second plate of cells was cultured under the same conditions, but was not stretched 
and so acted as a control. Stretch pattern is depicted in Figure 2.2. 
    
Figure 5.1. Graphs indicating (A) the measured vertical displacement of the highest point 
on the culture surface on applying various loads to the top of the culture plate. (B) the 
accompanying calculated linear stretch of the L6-G8C5 myotubes. 
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Figure 5.2. Stretch applied to L6-G8C5 myotubes during cyclic stretch, a 2 second sine 
wave stretch with a 4 second release resulting in an 18% stretch. 
 
5.2.2 Radio-isotope techniques 
5.2.2.1 Detection of 35Sulphate production by L6 and Hep G2 cells by 35S-methionine 
labelling 
Confluent cultures on 35mm wells were incubated in sulphate-free MEM (Invitrogen, UK, 
51200) with L-35S-Met at 10.25µCi/ml; 1175µCi/µmol for 24h. Following incubation, 800μl of 
medium was sampled and placed into a 1.5ml Eppendorf tube on ice. 20% w/v TCA (267μl) was 
added to the samples, vortexed and incubated on ice for 10 minutes to precipitate the protein. 
The tubes were microcentrifuged at 13,000rpm for 10 minutes at 4˚C and 700μl of the 
supernatant was transferred to a new tube. To this, 100mM Na2SO4 (100μl) was added followed 
by 1% w/v BaCl2 (200μl) and vortexed. The tubes were microcentrifuged at 13,000rpm for 10 
minutes at 4˚C to spin down the 35S-labelled barium sulphate. The supernatant was aspirated and 
the pellet was vortexed to help break it up and washed twice in 100mM Na2SO4 (1ml), by 
vortexing and microcentrifugation at 13,000rpm for 10 minutes at 4˚C. To the pellet, 1ml 
Ecoscint A Scintillant (National Diagnostics, Hesssle, UK) was added and the tubes vortexed 
thoroughly and immediately transferred to scintillantion vials containing 3ml of Ecoscint A 
Scintillant and counted on an LKB 1219 liquid scintillation counter. 
 
 Recovery measurements using fresh culture medium spiked with 35SO42- demonstrated that 
approximately 70% of the radioactive sulphate was detected in the scintillation vial and this 
recovery was essentially constant over a wide range of sulphate concentrations (Table 2.6).  
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Table 5.1. 35SO42- Recovery Measurements 
(Pooled data from two experiments each performed in triplicate) 
 
 Nominal Dilution Factor 
 101 102 103 104 105  106
Mean added 
35SO42- 
 (cpm) 
1330000   135000  16200  1773  380  124  
% Recovery 67 ± 3 70 ± 4 66 ± 5 71 ± 4 73 ± 4 71 ±4 
 
When culture medium was incubated with L-35S-Met in the absence of cells, 35SO42- radioactivity was 
almost indistinguishable from background in the final Barium Sulphate pellet (data not shown). 
 
5.2.2.2 14C MeAIB uptake measurements 
SNAT2 (System A) transport activity was measured by the incorporation of 14C MeAIB from 
extracellular medium into the intracellular space of L6 cells cultured on 22mm diameter plates.  
Following incubation of cultures on 35mm wells with test media, medium was aspirated and the 
cells were washed twice with 2ml Hepes Buffered Saline (HBS) (see Appendix A). HBS (1ml) 
was added to all the wells, and to the wells to be used as transport blanks, unlabelled MeAIB was 
added (10μl) to give a final concentration of 10mM. 14C-MeAIB (20μl) containing 0.5mCi 
(18.5MBq/L) was added to all the wells and incubated for 5 minutes at room temperature. The 
14C –labelled medium was aspirated and the cells washed 3 times with 2ml ice cold 0.9% NaCl 
followed by storage at -20˚C. 
 
5.2.2.3 Processing plates to assess 14C-MeAIB incorporation into cells 
Plates were thawed and each well scraped in 0.05M NaOH (400μl) and transferred to a 1.5ml 
Eppendorf tube. The tubes were incubated at 70˚C for 30 minutes in a water bath to digest the 
cells. Cell digests (110μl) were mixed with 4ml Ecoscint A Scintillant (National Diagnostics, 
Hessle, UK) in a scintillation vial and left in the dark overnight to allow chemiluminesence to 
decay before counting on a LKB 1219 liquid scintillation counter with quench correction. 
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5.2.2.4 Northern Blotting 
For cell culture experiments in which plentiful RNA was available, expression of SNAT2 mRNA 
was quantified by Northern blotting. RNA (30µg) extracted following the procedure described in 
Section 2.9.1 was resolved by denaturing gel electrophoresis on a 1% w/v agarose 1.9% 
formaldehyde gel in MOPS/EDTA/sodium acetate. RNA was loaded using RNA gel loading 
sample buffer (see Appendix A) with Ethidium Bromide (0.5µg/ml) to visualise the bands and 
the gel was run at 80V for approximately 1 hour. The integrity of the RNA was checked using a 
transilluminator and the gel was washed in DEPC water to remove the formaldehyde. The gel 
was blotted overnight onto nylon membrane (GE Health Care Life Sciences, Little Chalfont, 
UK), which was then cross linked by UV illumination the following morning. The membranes 
were then incubated with pre-hybridisation solution (see Appendix A) for 4 hours at 42˚C. 
Membranes were hybridised overnight with 32P labelled cDNA probes using a Prime-a-gene kit, 
(Promega, Hampshire, UK, TB049) for SNAT2 and cyclophilin. The probe templates were a full 
length cDNA for rat SNAT2 (a kind gift from Professor J. Erickson as described in Yao et al. 
2000) and for cyclophilin (a kind gift from Dr Izabella Pawluczyk from SmithKlein, Beecham, 
UK). After the incubation, the membrane was washed twice in a low stringency wash containing 
2X SSPE and 0.2% SDS for 10 minutes at room temperature followed by two more washes in 
high stringency wash containing 0.2X SSPE and 0.2% SDS for 30 minutes at 65˚C. The 
hybridisation signal was visualised using autoradiography. The membrane was placed on top of a 
Kodak X-OMAT XAR-5 film and a Kodak X-OMAT LS film (Sigma, Dorset, UK) and exposed 
for 8-24h. The LS film was developed first, and the exposure time for the XAR-5 film was 
adjusted according to the signal obtained on the LS film. 
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5.3 Results 
Part A 
In vitro modelling of the factors controlling the production of sulphuric acid (35SO42-) in 
cultured L6 skeletal muscle cells and HepG2 hepatocytes 
 
5.3.1 Characterisation of 35SO42- output 
The time course of the accumulation of (35SO42-) in the culture medium when the cells were 
incubated with 35S-L-Methionine is shown for L6-G8C5 myotubes in Figure 5.1 and for HepG2 
cells in Figure 5.2. As a positive control, flux through the pathway from L-Methionine to 
sulphuric acid was stimulated in some cultures by increasing the L-Methionine concentration in 
the medium from 100 to 1100µM (- the specific radio-activity of the 35S-L-Methionine in the 
medium in those cultures was kept constant by also increasing the amount of 35S-L-Methionine 
added).  
As expected, 35SO42- production was strongly stimulated in the positive control cultures in both 
L6-G8C5 and HepG2 cells (P<0.001). The basal rate of production of sulphate was 
approximately 10 times faster in HepG2 cells than in L6-G8C5 myotubes, consistent with the 
more rapid rate of sulphuric acid production reported in liver compared with skeletal muscle 
(Garcia and Stipanuk, 1992). Both cell types exhibited a time-dependent generation of 35SO42- 
from 35S-L-Methionine. Sulphate generated from L6-G8C5 cells continued to accumulate over 
72h (P<0.05) (Figure 5.1). In HepG2 cells a paradoxical fall in the concentration of 35SO42- was 
observed in the medium at 72h (Figure 5.2) (implying re-incorporation of the 35SO42- into a pool 
not precipitated by barium) and this was accompanied by loss of cell viability owing to 
exhaustion of the medium. For that reason all incubations in subsequent experiments were 
restricted to 24h or less.  It would be important in future experiements to perform measurements 
of protein breakdown to see if sulphate generation does actually cause increases in protein 
degradation that is implied from the correlations seen in Chapter 4. 
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Figure 5.3. Time course of 35SO42- production from L6-G8C5 myotubes and the effect of L- 
Methionine (Met) loading of the medium. Media contained sulphate-free MEM with 100µM 
L-Methionine, 2mM L-Gln and 2% dialysed foetal bovine serum. “+ Met” cultures were 
incubated with 1100µM L-Methionine. Data are from a representative experiment (with at least 3 
replicate culture wells per treatment). *denotes significant difference from corresponding control 
condition for that time point (P<0.001), adenotes significant difference from 24h + Met condition 
(P<0.05) and bdenotes significant difference from 48h + Met condition (P<0.05). 
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Figure 5.4. Time course of 35SO42- production from HepG2 cells and the effect of L- 
Methionine (Met) loading of the medium. Media contained sulphate-free MEM with 100µM 
L-Methionine, 2mM L-Gln and 2% dialysed foetal bovine serum. “+ Met” cultures were 
incubated with 1100µM L-Methionine. Data are from a representative experiment (with at least 3 
replicate culture wells per treatment). *denotes a significant difference from corresponding 
control condition (P<0.001), adenotes significant difference from 24h + Met condition (P<0.05) 
and b denotes significant difference from 72h + Met condition (P<0.05). 
 
5.3.2 Effect of inhibitors of protein metabolism on 35SO42- output 
Incubation with the proteasome inhibitor MG132 (to block protein degradation) and with 
cycloheximide (CYC) (to inhibit protein synthesis) had no significant effect on sulphate 
generation in L6-G8C5 myotubes (Figure 5.3). However, with these treatments some effect was 
observed in HepG2 cells. MG132 appeared to reduce sulphate generation when used at a 
concentration of 10µM, but this fell just short of statistical significance (P = 0.064; Figure 5.4). 
When CYC was administered at a concentration of 50µM there was also a significant reduction 
in sulphate production compared to the control condition (P = 0.023). 
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Figure 5.5. The effect of incubation with MG132 or Cycloheximide on35SO42- production in 
L6-G8C5 myotubes. To maintain cell viability, incubations were restricted to 7h. Media 
contained sulphate-free MEM with 100µM L-Methionine, 2mM L-Gln and 2% dialysed foetal 
bovine serum. Condition C served as the control, whilst M1 contained MG132 (1µM) M10, 
MG132 (10µM), C0.5, Cycloheximide (0.5µM), C5, Cycloheximide (5µM) and C50 contained 
Cycloheximide (50µM). Data are from a representative experiment (with at least 3 replicate 
culture wells per treatment). 
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Figure 5.6. The effect of incubation with MG132 or Cycloheximide on 35SO42- production in 
HepG2 cells. To maintain cell viability, incubations were restricted to 7h. Media contained 
sulphate-free MEM with 100µM L-Methionine, 2mM L-Gln and 2% dialysed foetal bovine 
serum. Condition C served as the control, whilst M1 contained MG132 (1µM) M10, MG132 
(10µM), C0.5, Cycloheximide (0.5µM), C5, Cycloheximide (5µM) and C50 contained 
Cycloheximide (50µM). Data are from a representative experiment (with at least 3 replicate 
culture wells per treatment). *denotes a significant difference from condition C (P<0.05). 
 
5.3.3 Effect of non-sulphur amino acids on 35SO42- output 
Both in L6-G8C5 myotubes and HepG2 cells, L-Glutamine starvation significantly increased 
sulphate production compared with control cultures with 2mM L-Glutamine, but this effect was 
less marked in HepG2 (Figures 5.5 and 5.6). Increasing L-Glutamine to a supraphysiological 
concentration (8mM) had no further suppressive effect. Addition of L-Glutamate (a potential 
method for reversing the aspartate aminotransferase step in the sulphuric acid production 
pathway (Chapter 1, Figure 1.5); or competitive inhibition of System A transporters with a 
saturating dose of their non-metabolisable substrate MeAIB (a potential method for blocking L-
Methionine influx)  also had no further suppressive effect in the presence of 2mM L-Glutamine.   
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Figure 5.7. The effect of possible therapeutic agents on 35SO42- production in L6-G8C5 
myotubes. Media contained sulphate-free MEM with 100µM L-Methionine, 2% dialysed foetal 
bovine serum, and the specified amino acid concentrations. Data are from a representative 
experiment (with at least 3 replicate culture wells per treatment). Cells were incubated for 24h 
with these media. *denotes a significant difference from L-Glutamine starved condition 
(P<0.05). 
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Figure 5.8. The effect of possible therapeutic agents on 35SO42- production in HepG2 cells. 
Media contained sulphate-free MEM with 100µM L-Methionine, 2% dialysed foetal bovine 
serum, and the specified amino acid concentrations. Data are pooled from 2 experiments (with at 
least 3 replicate culture wells in each experiment). Cells were incubated for 24h with these 
media. *denotes a significant difference from L-Glutamine starved condition (P<0.05). 
 
Part B 
5.3.4 The effect of glucocorticoid on the activity and expression of the SNAT2 amino acid 
transporter 
As previously demonstrated by Evans et al. (2008), these results show acidosis (pH 7.1) 
significantly reduced SNAT2 transport activity in L6-G8C5 myotubes compared to that in 
control incubations at pH 7.4  (by approximately 42%, P<0.001; Figure 5.7). Following a 7 hour 
incubation with 500nM dexamethasone at pH 7.4, SNAT2 transport activity was also reduced by 
approximately 40% (P<0.001). The effects of a reduction in pH and the addition of 500nM 
dexamethasone on transport activity were found to be approximately additive (Figure 5.7).                            
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Figure 5.9. Effect on SNAT2 transport activity of 7h incubations at the specified pH with 
and without 500nM dexamethasone (Dex) in L6-G8C5 myotubes. Media were based on 
MEM and contained 2mM L-Gln with 2% dialysed foetal bovine serum. Pooled data from 3 
experiments are shown with 4 replicate culture wells in each experiment. The pH of the medium 
during the transport assay (Chapter 2.11.1) was maintained at the same value as that in the 
preceding 7h incubation in culture medium. *denotes a significant difference from the pH 7.4 
control value without Dex (P<0.05). adenotes a significant difference from 500mM Dex pH 7.1 
(P<0.05). 
 
The time course of the effect of glucocorticoid on SNAT2 transporter activity was biphasic 
(Figure 5.8). A significant reduction in transport activity was observed in the first 7h of 
incubation with Dexamethasone but, following this initial decrease, a gradual recovery was 
observed, with net stimulation of the transport activity relative to the control condition after 48h, 
(P = 0.009). 
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Figure 5.10. Time course of the effect of 500nM dexamethasone (Dex) on SNAT2 transport 
activity at pH 7.4 expressed as a percentage of the corresponding control value measured 
without Dex. Media were based on MEM and contained 2mM L-Gln with 2% dialysed foetal 
bovine serum. Pooled data from at least 3 independent experiments are shown. *denotes a 
significant difference relative to the control value at the corresponding time point (P<0.05). 
 
Consistent with changes in transport rates, there were also changes observed in the intracellular 
amino acid concentrations, especially L-Glutamine a major SNAT2 substrate. After 7h 
incubation with 500nM Dexamethasone at pH 7.4, the intracellular L-Glutamine concentration 
had declined by approximately 22%, just short of statistical significance (P = 0.053). Lowering 
the pH of the media from 7.4 to 7.1 also reduced L-Glutamine concentrations (P = 0.044) and, as 
observed in the effects on transport activity, the effects of acidosis and glucocorticoid on 
intracellular L-Glutamine concentration were additive (Figure 5.9A). However, after 48h (Figure 
5.9B), the effect of Dex was no longer detectable, consistent with the recovery in SNAT2 
transport activity that was seen at this time point (Figure 5.8). 
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Figure 5.11. Effect of pH and 500nM dexamethasone (Dex) on intracellular L-Glutamine 
concentration in L6-G8C5 myotubes after 4h (A) and 48h (B) incubation. Pooled data from 
3 experiments. *denotes significant difference from pH 7.4 control condition without Dex 
(P<0.05). a denotes significant difference from pH 7.1 condition without Dex (P<0.05). 
The inhibition of transporter activity following incubation with Dexamethasone was abolished 
both by RU38486, a specific glucocorticoid receptor antagonist; and by Actinomycin D, an 
inhibitor of transcription (Figure 5.10), indicating that Dexamethasone was acting through a 
classical transcription-dependent pathway mediated by glucocorticoid receptors. However, by 
Northern blotting no change was detected in the expression of the SNAT2 transporter in response 
to Dexamethasone even after 17h (Figure 5.11). An apparent increase in SNAT2 expression was 
observed followed incubation with acidified media, but due to the wide scatter in the results, this 
failed to reach statistical significance (P = 0.151). 
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 Figure 5.12. Effect of inhibition of the glucocorticoid receptor with RU38486 (A) and of 
transcription with Actinomycin D (B) on SNAT2 transport activity in L6-G8C5 myotubes 
with or without 500mM Dexamethasone (Dex). Media were based on MEM and contained 
2mM L-Gln with 2% dialysed foetal bovine serum. Pooled data from 2 experiments are shown 
with 4 replicate culture wells for each treatment. Cultures were incubated with relevant test 
media for 4h. *denotes significant difference from treatment with 500nM Dex alone (P<0.05). 
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Figure 5.13. Effect on SNAT2 expression in L6-G8C5 myotubes of 17h incubations at the 
specified pH with or without 500mM dexamethasone (dex) measured by Northern blotting. 
Media were based on MEM and contained 2mM glutamine with 2% dialysed foetal bovine 
serum. (A) Representative Northern blot autoradiograph. (B) Pooled quantification data by 
densitometry from three experiments are shown with at least four replicate cultures for each 
treatment.   
 
In contrast, assessment of SNAT2 protein expression in membrane preparations obtained by 
ultracentrifugation from L6-G8C5 myotubes showed a clear down-regulation of the protein in 
response to 4h of incubation with 500nM Dexamethasone (Figure 5.12A) and this was confirmed 
by quantification using densitometry (P = 0.005; Figure 5.12B). No corresponding effects were 
seen with the α-Na, K ATPase (P = 0.509) or Annexin II (P = 0.080) that acted as control 
proteins. (Figures 5.12C and D). As reported previously (Evans et al. 2008) low pH had no 
reproducible effect on SNAT2 protein expression. 
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Figure 5.14. Effect of pH, 500nM Dexamethasone and positive controls (amino acid 
starvation and hyperosmolality (200mM Sucrose)) on the expression of SNAT2 protein in 
cell membranes prepared as described in Chapter 2.5.1. Media were based on MEM and 
contained 2mM L-Gln with 2% dialysed foetal bovine serum. L6-G8C5 myotubes were 
incubated with the relevant test media for 4h. In the amino acid starved condition myotubes were 
incubated in amino acid free media, as described in Section 5.2.1.4. Immunoblot (A) shows 
proteins that were separated by SDS-PAGE from a 170,000g membrane preparation, probed with 
antibodies specific for SNAT2 or α1-Na,K-ATPase or Annexin II as loading controls. 
Densitometry results for (B) SNAT2 (C) α1-Na,K-ATPase and (D) Annexin II are results of 5 
pooled experiments. *denotes significant difference from pH 7.4 control value (P<0.01).  
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Part C  
5.3.5 The effect of mechanical stretch on SNAT2 transporter activity 
It was observed that 48h of continuous passive stretch resulted in a significant increase in the 
transport activity of SNAT2 (P = 0.028), but only a small and statistically insignificant effect 
was obtained after 17h (P>0.05; Figure 5.13). However, under conditions of cyclic intermittent 
stretch (Figure 5.14), 17h was sufficient to observe an up-regulation in activity and this effect 
was even more apparent after 48h (P<0.05) (Figure 5.14). This was accompanied by an apparent 
increase in the expression of the transporter after both 17h and 48h (Figure 5.15), but at both 
time points, this failed to reach statistical significance. 
 
Figure 5.15. Effect of 17h or 48h of passive continuous stretch on SNAT2 transporter 
activity. Media were based on MEM and contained 2mM L-Gln with 2% dialysed foetal bovine 
serum. Pooled data from 2 experiments are shown with at least 4 replicate culture wells in each 
experiment. L6-G8C5 myotubes were cultured on Collagen-coated Flexcell silicon-based culture 
wells that, upon initiation of the experiment, were placed on glass spheres and stretched by 
loading with a 3kg weight placed on the top of the culture plate as described in Chapter 2.1.5 to 
maintain a constant passive stretch (Rauch and Loughna, 2008). *denotes significant difference 
compared with 48h control condition (P<0.05). 
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Figure 5.16. Effect of 17h (A) and 48h (B) of cyclic stretch on SNAT2 transport activity in 
L6-G8C5 myotubes. The culture medium was based on MEM at pH 7.4 and contained 2mM 
glutamine with 2% dialysed foetal bovine serum. Myotubes were cultured on Collagen-coated 
Flexcell silicon-based culture wells stretched using a Flexcell Fx3000 system set to 2 second sine 
wave stretch with 4 second release as described in Section 2.1.5. * denotes significant difference 
from control value (P<0.05). Pooled data from 2 experiments. 
 
Figure 5.17. Effect of cyclic stretch on expression of SNAT2 in L6-G8C5 myotubes assessed 
by Q-PCR as described in Chapter 2.9.7. SNAT2 expression was related to Cyclophilin 
expression using the Pfaffl equation (Pfaffl, 2001). Myotubes were cultured and stretched exactly 
as described in Figure 5.14. The culture medium was based on MEM at pH 7.4 and contained 
2mM glutamine with 2% dialysed foetal bovine serum. Pooled data from 2 experiments are 
shown with 3 replicate culture wells in each experiment. 
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5.4 Discussion 
5.4.1 In vitro modelling of the factors controlling the production of sulphuric acid (35SO42-) 
in cultured L6 skeletal muscle cells and HepG2 hepatocytes 
Characterisation of 35SO42- output from cells incubated with 35S-L-Methionine (Figures 5.1 to 
5.6) indicate that this is a sensitive assay for sulphuric acid production in vitro, which detects (as 
expected) a high production rate in a hepatocyte cell line, a significantly lower rate in a skeletal 
muscle cell line, stimulation by L-Methionine loading, and no output in the absence of cells 
(Chapter 2.10.2). Recent data from this laboratory (L. Tooley and J.R. Brown, unpublished 
observations) have also confirmed that it is inhibited by amino-oxyacetate an inhibitor of 
aspartate aminotransferase in the sulphuric acid pathway (Figure 1.5). The detection here of 
sulphur amino acid catabolism to sulphuric acid in the L6-G8C5 skeletal muscle cell line is 
unlikely to be simply a cell culture artefact: sulphuric acid production has not been extensively 
documented in muscle, but has nevertheless been clearly demonstrated in rat skeletal muscle 
(Garcia and Stipanuk, 1992) and there are reports that it is stimulated under conditions of 
cachexia in vivo (Hack et al. 1996). It would be important in future experiments to perform 
measurements of proteolysis alongside measurements of sulphate production to investigate if 
sulphate generation is causally related to 3-MH excretion that is implied from the correlations 
seen in Chapter 4. 
 
5.4.2 Effect of inhibitors of protein metabolism on 35SO42- output 
The correlation between sulphate excretion and 3-MH excretion in Chapter 4 (Figure 4.4A) 
could have arisen as a result of stimulation of protein degradation by acidosis, or through the 
release of sulphur amino acids by protein degradation. If the second explanation is true, near 
complete inhibition of proteolysis in vitro with a high concentration of the proteasome inhibitor 
MG132 should strongly impair sulphate output. Conversely abolishing protein synthesis with a 
high dose of cycloheximide (an inhibitor of the elongation process in translation) should result in 
enhanced generation of sulphate due to increased availability of L-Cysteine and L-Methionine 
(Stipanuk, 2004).  In practice, little effect of either of these treatments was seen in the L6-G8C5 
myotubes and only modest effects in HepG2 cells, suggesting that, at least in vitro, sulphuric 
acid production is not strongly responsive to changes in protein metabolism. Ideally this result 
should be confirmed by a non-radio-isotopic method to guard against the possibility that sulphate 
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output from degraded protein has been missed because of incomplete labelling of sulphur in the 
protein pools.  
 
5.4.3 Effect of non-sulphur amino acids on 35SO42- output 
The observation that feeding L-Glutamine in vivo may divert sulphur catabolism from sulphuric 
acid towards taurine (Boelens et al. 2003) implies that L-Glutamine might be of therapeutic 
value in suppressing sulphuric acid production. The data from L6-G8C5 myotubes and HepG2 
hepatocytes in Figures 5.5 and 5.6 suggest that this may be the case, but as intracellular taurine 
concentrations were not measured in the present study, the mechanism of the suppression of 
sulphate output by L-Glutamine is currently unknown. With the relatively high L-Glutamine 
concentrations tested here, it is possible that L-Glutamine also acted partly by competing with L-
Methionine and L-Cysteine at plasma membrane transporters such as SNAT2, resulting in a 
lower intracellular availability of these substrates for sulphate metabolism. L-Methionine is an 
effective substrate for SNAT2 (Yao et al. 2000) and inhibition or silencing of SNAT2 in L6-
G8C5 myotubes significantly depletes intracellular L-Methionine (Evans et al. 2007). However, 
competitive inhibition of SNAT2 with a saturating concentration of its substrate MeAIB (Figures 
5.5 and 5.6) failed to suppress sulphate output any further than was the case with 2mM L-
Glutamine, suggesting that competitive effects of L-Glutamine on SNAT2 are not the full 
explanation. 
The effect of L-Glutamate  (L-Glu) was also tested in Figures 5.5 and 5.6. In principle L-Glu 
could exert a mass-action effect on the aspartate aminotransferase equilibrium:  
 
L-Glu + beta-sulphinylpyruvate (BSP) <--> alphaketoglutarate + cysteinsulphinate (CSA);  
 
thus depleting BSP (the precursor of sulphuric acid) (Yang and Brunengraber, 2000), and 
expanding the CSA pool (the main determinant of Taurine production through the regulatory 
enzyme CSA decarboxylase). In practice this exerted no effect beyond that observed with 2mM 
L-Glutamine, possibly because L-Glutamate generated from L-Glutamine was already exerting a 
maximal effect on this equilibrium. 
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5.4.4 The effect of glucocorticoid on the activity and expression of the SNAT2 amino acid 
transporter 
Metabolic acidosis is reported to increase circulating glucocorticoid concentrations (May et al. 
1986) and elevated concentrations are seen in CKD (Rosman et al. 1982; McDonald et al. 1979). 
Therefore the aim of the second part of this chapter was to investigate whether glucocorticoid 
might mediate a persistent inhibitory effect of acidosis on SNAT2 which could have contributed 
to the sustained collapse of muscle amino acid gradients in the acidotic exercising patients in 
Chapter 3. 
Dexamethasone administered at a concentration of 500nM did significantly reduce the transport 
activity of SNAT2 by approximately 40% and, in combination with acidified media, resulted in 
an additive inhibitory effect of approximately 70%.  The effect of glucocorticoid persisted for 
several hours suggesting that this is indeed a feasible mediator of longer term inhibitory effects 
on active transport of amino acids into muscle in acidotic CKD patients and warrants further 
investigation. Although a high dose of dexamethasone was used here this was because it appears 
this cell line is relatively insensitive. In order for effects of insulin on protein degradation to be 
seen in vitro, an insulin concentration that is approximately 100 times greater than that seen to 
produce an effect in vivo has to be used. This problem was also encountered in selecting a 
glucocorticoid dose to be used, doses lower than 500nM failed to produce an effect and so a 
relatively high non-physiological dose had to be used. 
 
These changes in transport activity were mirrored by changes in the intracellular L-Glutamine 
concentration, one of the main substrates for this transporter (Hyde et al. 2003; Yao et al. 2000). 
It has previously been reported that reducing the pH of the medium to 7.1 causes significant 
decreases in intracellular L-Glutamine concentrations (Evans et al. 2007). Incubation at pH 7.1 
for 4h in the present study resulted in a 22% reduction in the intracellular L-Glutamine 
concentration confirming this earlier report. Glucocorticoids were also seen to produce a 
comparable effect: 4h incubation with 500nM dexamethasone decreased glutamine levels by 
25% and when dexamethasone and acid were combined, the effect was additive, resulting in a 
43% decline, comparable with the decline in the L-Glutamine gradient observed in the STD 
bicarbonate group in Chapter 3, Table 3.16. 
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The effects on transport activity and intracellular L-Glutamine depletion appeared to show a 
biphasic time course, with inhibition in the first 7h, but after this time there was a rebound of 
SNAT2 activity which was actually significantly above baseline after 48h with Dexamethasone. 
Biphasic effects of glucocorticoid have been reported previously by Pickering et al. (2003) who 
observed a biphasic effect of Dexamethasone on the time course of protein degradation in L6-
G8C5 myotubes. Kayali et al. (1990) also observed that in normal and diabetic rats, the daily 
administration of corticosterone resulted in an increase in protein degradation rates measured by 
3-MH release from the hindquarters in the first four days. After this time, a fall in degradation 
rate back to baseline was seen, an effect that appeared to be independent of insulin and could not 
be explained by the authors. 
The additive effect of glucocorticoids and acid that was observed on SNAT2 transport activity, 
and subsequent changes on the intracellular L-Glutamine concentration, suggests that these two 
effects are occurring through distinct mechanisms. Previous reports of the effect of low pH on 
SNAT2 transport activity (Bevington et al. 2002) have shown that this effect is rapidly reversed 
when the acidified medium is washed away consistent with acid exerting a direct effect upon the 
SNAT2 transporter protein (reviewed in Chapter 1.14.1) Consequently, to observe the effect of 
low pH on SNAT2 activity, the transport assay must also be performed at a low pH. This is not 
the case for Dexamethasone, which exerts a more persistent effect on SNAT2 activity that is 
detectable even when the Dexamethasone has been removed from the medium. This persisting 
effect is consistent with glucocorticoid acting upon gene expression through a classical steroid 
receptor-mediated transcription dependent pathway (Figure 5.10). This pathway is activated by 
ligand binding to the glucocorticoid receptor resulting in the ligand-receptor complex 
translocating to the nucleus and binding to glucocorticoid response elements that are found on 
the promoter region of target genes (Granner, 1996).  
The data in Figure 5.10 suggest that Dexamethasone inhibits SNAT2 through effects on gene 
expression, but not on expression of the SNAT2 gene. Northern blotting detected no change in 
the expression of the transporter after 17h incubation with Dexamethasone (although a short-
lived effect may have been missed). It is possible that glucocorticoid acts by increasing the 
expression of a protein which leads to the down-regulation of the SNAT2 protein observed in 
Figure 5.12. 
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5.4.5 The effect of mechanical stretch on SNAT2 transporter activity 
The principal conclusion from this part of the study was that prolonged mechanical stress for up 
to 48h stimulates SNAT2 activity in L6-G8C5 myotubes, consistent with the stimulation of 
System A activity reported in rats following acute exercise (Henriksen at al 1992, 1993; King, 
1994). Under none of the conditions tested did mechanical stress inhibit SNAT2 activity. 
Therefore there is no evidence at this stage that the patients’ exercise regime in Chapter 3 led 
directly to the observed collapse of the muscle amino acid gradients.  
However, the observations that both continuous and cyclic stretch were able to activate SNAT2, 
and that SNAT2 is apparently able to regulate phosphorylation of rpS6 and 4E-BP1 and hence 
translation initiation (Evans et al. 2007) are of interest. Atherton et al. (2009) have shown that 
cyclic stretch of L6-G8C5 myotubes also increases the phosphorylation of these proteins, and 
previous research by Vandenburgh (1987) found that passive stretching of cells in vitro resulted 
in a large increase in protein synthesis and a small decrease in protein degradation. This may 
mean that SNAT2 serves as a sensor of mechanical stretch, mediating anabolic signals to protein 
metabolism and increasing protein synthesis rates (Vandenburgh, 1987). It will now be 
interesting to determine whether inhibition or silencing of SNAT2 leads to inhibition of stretch-
induced increases in phosphorylation of proteins downstream of mTOR. 
 
5.4.6 Conclusions 
Part A of this Chapter confirms that skeletal muscle does play a role in sulphate metabolism as 
previously suggested (Garcia and Stipanuk, 1992). Although its involvement is to a lesser degree 
than hepatocytes, it may be of importance as this source of sulphuric acid will be the most 
readily available one to myocytes. At least in vitro, the potential for L-Glutamine to be used as a 
therapy to reduce sulphuric acid production looks promising, and warrants further investigation. 
The results from part B of this chapter demonstrate a chronic inhibition by glucocorticoids of the 
SNAT2/slc38a2 transporter that appears to act via a separate mechanism to that of acidosis. This 
presents a possible line of enquiry to be investigated that may explain the collapse of the 
intracellular/extracellular amino acid gradients observed in the exercising patients in Chapter 3, 
but as these results were obtained in vitro, caution is needed in translating these conclusions 
directly to the effects seen in humans. 
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The results from part C of this chapter lead to the hypothesis that SNAT2/slc38a2 may be a 
sensor of mechanical stress, which may be able to up-regulate transport activity rates and, 
making use of the results from Evans et al. (2007), increase signalling through mTOR. 
Therefore, if acidosis and raised glucocorticoid levels in CKD are capable of inhibiting this 
transporter, this implies a role for SNAT2 in the regulation of protein metabolism under 
conditions relevant to uraemia. Whether this inhibition can be relieved by resistance exercise (i.e. 
mechanical stress) remains to be seen. 
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6.1 Aerobic exercise training in CKD patients and the effect of sodium 
bicarbonate 
There are many reports now published that demonstrate exercise in haemodialysis patients, both 
aerobic and resistance, improves exercise capacity (Painter et al. 1986; Kouidi et al. 1997; 
Molsted et al. 2004; Sakkas et al. 2003) and the results from Chapter 3 show this is also the case 
following aerobic exercise training in pre-dialysis patients. One of the most important findings 
from this chapter was the effect that additional sodium bicarbonate imposed on adaptations to the 
exercise training. A reduced lactate response to the same absolute workload was seen with 
modest increases in lean body mass (LBM) and reduced expression of the ubiquitin E3 ligases, 
none of which were seen in the exercising patients who received only their standard bicarbonate 
treatment. A possible interpretation is that XS bicarbonate allowed patients to exercise for longer 
by buffering acid that was produced during the exercise bout. The results presented in Chapter 3 
suggest that in these patients acidosis is not beneficial, but actually appears to be detrimental 
preventing the exercise-induced adaptations seen in the patients in the XS bicarbonate group. 
Acidification of skeletal muscle may be a limiting factor to exercise in this patient population, 
Nishida et al. (1991) observed a greater decline in sarcosolic pH during exercise in uraemic 
patients compared to healthy controls, and it is possible that the addition of XS bicarbonate 
helped to prevent such a fall. This beneficial effect of bicarbonate is in line with results from 
Stein et al. (1997) who observed that additional alkali therapy resulted in an increase in body 
weight and mid-arm circumference and reduced morbidity, and Szeto et al. (2003) who saw 
increases in free fat mass and LBM with reduced morbidity in peritoneal dialysis patients.  
Surprisingly, those patients who exercised while receiving only their standard bicarbonate 
therapy exhibited striking declines in intramuscular amino acid pools and a collapse of the 
intracellular/extracellular amino acid gradients. This was an effect that was apparent after one 
month of exercise, but was much larger after six months, and may have the potential to limit 
protein synthesis. Importantly, the administration of extra bicarbonate to exercising patients was 
able to prevent this collapse and maintain intramuscular amino acid concentrations. Amino acid 
gradients are usually maintained by active transporters, with the pH sensitive SNAT2/slc38a 
transporter apparently being the main active amino acid transporter in skeletal muscle cells. 
Previous evidence from our laboratory has shown that inhibition of this transporter by acidosis in 
vitro results in the depletion of L-Glutamine and other amino acids whose intracellular 
concentrations are maintained by the L-Glutamine concentration gradient set up by SNAT2 
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(Evans et al. 2007). Therefore, it was hypothesised that as this effect on amino acids was only 
seen in the exercising patients on STD bicarbonate therapy and not in the non-exercising controls 
also receiving only their STD bicarbonate therapy, it was an effect that was mediated by the 
exacerbation of acidosis by exercise. However, this gradient disruption was observed in the 
resting state, after any exercise-induced acidosis and therefore amino acid disruption may have 
dissipated.  
The results from the in vitro experiments in chapter 5 provide interesting speculation on a second 
factor that might be involved in the observed collapse in amino acid gradients. Acidosis results in 
an increase in circulating glucocorticoid levels (May et al. 1986) which have been reported in 
CKD (Rosman et al. 1982; McDonald et al. 1979) and appear to be a permissive factor for the 
catabolic effect of acid. For this reason, it seemed plausible that, like acid (Evans et al. 2007), 
glucocorticoids may also be exerting an effect on protein metabolism through SNAT2. In vitro, 
glucocorticoids (Dexamethasone) did suppress SNAT2 transport activity and reduce intracellular 
glutamine concentrations and, when applied in conjunction with acid, the effect was additive 
suggesting that these factors are working through distinct mechanisms. Caution is required when 
applying conclusions drawn from in vitro experiements to in vivo data, however, it is possible 
that glucocorticoids mediate a persistent inhibitory effect of acidosis on SNAT2 which could 
have contributed to the sustained collapse of muscle amino acid gradients seen in the acidotic 
exercising patients in Chapter 3. Whether the circulating glucocorticoid concentration in acidotic 
CKD patients is sufficient to exert such an effect in vivo, and whether exercise further increases 
this concentration, remains to be determined. 
Owing to the positive results seen in this aerobic training pilot study, further investigation is 
warranted into the effects of a resistance training programme, where much larger effects on net 
muscle mass might be expected. It would be important to continue to compare the effect of extra 
bicarbonate therapy, which if the current results are correct, may be a crucial supplement to 
make to exercise therapy in pre-dialysis CKD patients.  
 
6.2 Exercise and measures of myofibrillar proteolysis 
Despite the observation that exercise and XS bicarbonate therapy reduced E3 ligase expression, 
other markers of myofibrillar proteolysis showed no consistent beneficial effect and reduced 
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levels of the 14kDa actin fragment and 3-MH excretion were not observed together under the 
same condition that suppressed E3 ligase expression. There was no statistically significant 
decline in 14kDa actin levels in any group, contrary to the decline previously reported in 
combined aerobic and resistance exercise in haemodialysis patients (Workeneh et al. 2006). 
Similarly no change was observed in 3-MH excretion rates in any group, and although a decrease 
was seen in the muscle protein:DNA ratio in the XS group which appeared to be induced through 
technical error, no changes were seen in muscle: DNA ratio in the remaining groups, and this 
resulted in only very small effects on LBM observed by DEXA. This inability to reduce 3-MH 
excretion and therefore muscle proteolysis possibly resulted from a failure of the treatments to 
increase PKB phosphorylation sufficiently (although the importance of this is human muscle 
now seems to be unkown) and reduce caspase-3 activity, and, in the case of STD bicarbonate 
therapy, to effectively buffer the acid generated by exercise. Endurance exercise traditionally 
does not result in the accretion of skeletal muscle protein and the fact some small increases in 
LBM following aerobic exercise were seen here may be a reflection of how cachectic these 
patients were. In future studies, larger gains might be expected with resistance exercise training.  
When interpreting the results from Chapter 3, there are some limitations that should be taken into 
account. Firstly, sample sizes were not equal in all the groups and some groups were left with 
small numbers owing to a significant drop-out rate which has previously been reported in 
exercise studies with CKD patients (Koufaki et al. 2000; Malagoni et al. 2008). Such problems 
are difficult to avoid when performing a six month exercise training study in a disease 
population. Secondly, as the exercise programme was unsupervised, there was no way to 
quantify exactly how much exercise the patients actually performed. They were asked to fill in 
exercise diaries, but a digitalized method of assessing this would have been more accurate, for 
example an accelerometer. Finally, the allocation of patients to either an exercise or control 
group was not randomized. This means that the result may have been influenced by comparing 
an intervention group who were willing to exercise, with a control group who were unwilling.  In 
future studies it would be helpful to recruit a large number of patients all willing to exercise, and 
then randomly allocate them to exercising and non-exercising groups, but the large patient 
population required would probably need a multi-centre study. Unfortunately, due to logistical 
problems, it was necessary in the present study to limit recruitment to Leicester General 
Hospital. 
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6.3 Production of sulphuric acid and links to protein breakdown 
As the results from Chapter 3 showed the importance of limiting acidosis, sources of acid 
generation were investigated in Chapter 4. Sulphur containing amino acids that are consumed in 
the diet are ultimately catabolised to either sulphuric acid (sulphate plus hydrogen ions) or the 
non-acidic end product taurine. Interestingly, there was no relationship observed between venous 
bicarbonate concentration (the conventional measure of acidosis) and 3-MH excretion. There 
was however, a strong correlation between sulphate excretion and 3-MH excretion in the 
patients, but not in healthy controls. This suggests that in this patient population, sulphuric acid 
production is functionally significant and might be a better indicator of those patients at risk of 
acid-induced muscle wasting. However, it is important to bear in mind this conclusion has been 
made from only a correlation and is required to be confirmed using more robust experiments.  
Whether glutamine supplementation, possibly by trapping sulphur in the form of taurine 
(Boelens et al. 2003), can significantly limit the production of sulphuric acid in vivo and exert 
beneficial effects under conditions of uraemia warrants further investigation.  
 
6.4 Summary 
In conclusion, aerobic exercise in pre-dialysis CKD patients was a relatively un-researched area 
and this study has demonstrated that aerobic exercise is also able to confer some benefits to pre-
dialysis patients, as well as the haemodialysis population as previously documented, but only 
when applied in combination with additional bicarbonate therapy. Indeed, the evidence presented 
suggests that exercise with standard bicarbonate therapy, and therefore lower serum bicarbonate 
levels, might even be detrimental in the long-term. The conventional measure of acidosis, serum 
bicarbonate seems to be an insensitive marker of protein wasting in this population and this study 
tentatively proposes sulphate excretion rates as a putative indicator of those patients at high risk 
of skeletal muscle wasting. Glutamine therapy has been observed in vitro as a potential means by 
which to decrease sulphuric acid production. Finally, based on evidence in vitro, the pH sensitive 
SNAT2 transporter has been identified as a possible sensor of acidosis and mechanical stress, but 
much more work is required to demonstrate that it has an important role in protein metabolism in 
vivo following exercise and under conditions relevant to uraemia. 
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Appendix A 
Solutions and Reagents 
 
Folin Reagent A (1 Litre) 
20g Anhydrous Na2CO3 
4g NaOH 
0.2g K,Na-tartrate. 4H2O 
Ultra pure water up to one litre 
 
Folin Reagent B (1 Litre) 
5g CuSO4.5H2O 
Ultra pure water up to one litre 
 
UIC3 Protease Inhibitor Cocktail (100ml) 
8.55g Sucrose 
0.47g Hepes 
0.032g Sodium Azide 
0.076g EGTA 
Adjust to pH 7.4 with 0.5M NaOH 
Ultra pure water up to 100ml  
20 µl PMSF (25mg) 
14.2µl E64 (5mg) 
13.7µl Pepstatin A (5mg) 
9.5µl Leupeptin (10mg) 
 
SDS-PAGE Muscle Lysis Buffer (10ml) 
0.08g NaCl 
0.002g KCl 
0.002g MgCl2 
500µl Tris 1M pH 7.5 
20µl Ethylenediaminetetraacetic acid (EDTA) 0.5M pH 8 
250µl Ethylene glycol tetraacetic acid (EGTA) 40mM 
800µl Glycerol 
1ml 10% Triton X-100 
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100µl β-Glycerophosphate 1M 
1.18ml Sodium Orthovanadate 8.5mM 
1ml Sodium Fluoride 500mM 
10µ β-Mercaptoethanol 
5.09ml ultra pure water 
 
SDS-PAGE L6 Lysis Buffer (10ml) 
500µl Tris 1M pH 7.5 
20µl Ethylenediaminetetraacetic acid (EDTA) 0.5M pH 8 
250µl Ethylene glycol tetraacetic acid (EGTA) 40mM 
1ml 10% Triton X-100 
100µl β-Glycerophosphate 1M 
1.18ml Sodium Orthovanadate 8.5mM 
1ml Sodium Fluoride 500mM 
10µ β-Mercaptoethanol 
5.89ml ultra pure water 
 
Laemelli Reducing Sample Buffer 
4ml Ultra pure H2O 
1ml 0.5M Tric HCL pH 6.8 
0.8ml Glycerol 
1.6ml 10% w/v Sodium Dodecyl Sulphate (SDS) 
0.4ml β-Mercaptoethanol  
0.2ml 0.05% w/v Bromophenol Blue 
 
10X Running Buffer (1 Litre) 
30.3g Trizma Base    
144g Glycine    
100ml 20% SDS   
Ultra pure water to one litre 
 
1X Running Buffer (1 Litre) 
100ml 10X Running buffer   
900ml Ultra pure water   
 
10X Transfer Buffer (1 Litre) 
30.3g Tris-Base  
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144g Glycine    
Ultra pure water to one litre 
 
1X Transfer Buffer (1 Litre) 
100ml 10X Transfer Buffer    
200ml Methanol    
100ml 10% SDS 
Ultra pure water to one litre  
Blue 
 
10X TBS 
60.55g Trizma base   
87.66g NaCl    
Ultra pure water to 700ml 
pH to 7.6 using 6M HCl 
Ultra pure water to one Litre 
 
1X TTBS + 0.1% tween (1 Litre) 
100ml 10X TBS   
Ultra pure water to one litre 
1ml Tween 20 
 
RNA Gel Loading Sample Buffer 
50% Glycerol 
10mM Tris 
1mM EDTA 
Bromophenol blue 0.05% w/v to give a readily detectable colour 
DNA Sample Buffer 
0.25% Bromophenol Blue 
15% Ficoll (Type 400) in Water 
 
HBS 
140mM BaCl 
20mM Hepes Acid 
2.5mM MgSO4. 7H2O 
5mM KCl 
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1mM CaCl2. 2H2O 
10mg/l Phenol red 
Adjust to pH 7.4 with 0.5M NaOH 
 
Pre-hybridisation Solution 
5 ml Formamide   
2.5ml 20X SSPE   
1ml 50X Denhardt’s solution 
0.5ml 20% SDS w/v   
1ml DEPC Water   
200μg/ml Salmon sperm DNA  
Warm to 42˚C prior to use. 
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Appendix B 
Methods Development 
There were no protocols were set up in the Laboratory for working with skeletal muscle, and for 
western blotting in particular, a great deal of methods development had to be done to get the 
assay working effectively. Below is a step by step description of this process. 
1) I started by practicing the protocol described by Karlsoon et al. (2004) on rat skeletal 
muscle to determine the phosphorylation status of P-rpS6, P-PKB, P-P70S6K, and P-4E-
BP1. Westerns were run with 30μg protein, the amount of protein routinely loaded onto 
the gels in our Laboratory when running cell culture lysates. These Westerns worked 
well. 
2) Professor Ron Maughan kindly taught Dr Kosmadakis the biopsy technique and in the 
process provided myself with some human skeletal muscle to continue methods 
development with. Initially, all Westerns were run for P-rpS6 with the aim of setting up 
this western first. I repeated the protocol that had obtained good results in rodent muscle, 
but there was only a very faint signal detectable in healthy human skeletal muscle. 
3) The amount of protein loaded onto the gel was increased to 100μg protein and gave a 
better signal than 30μg. This was then increased to 150μg, which gave no improvement 
over 100μg. 
4) Two patients withdrew very early on in the study, but allowed their baseline samples to 
be used in methods development. The protocol was repeated with 100μg and then 150μg 
protein, but no signal was detectable. As a result of this, 150μg protein was routinely 
loaded onto the gel to maximise the possibility of detecting a signal with further 
modifications. 
5) It was decided to always run a positive control on the same gel as the muscle samples to 
ensure that the lack of a signal was not due to a technical failure of the Western. L6-
G8C5 cells stimulated with insulin served as the positive control and a volume containing 
10μg protein was loaded onto the gel. (A reduced amount of protein was used here 
because the length of time the membrane was exposed to the film meant that anything 
more than 10μg resulted in a very large overexposed band.) 
6) The effect of using a signal enhancer reagent and an antibody extender from Thermo 
Scientific was tested. Due to cost reasons it was decided to use the signal enhancer 
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reagent, but this was later removed from the protocol as it made little difference and 
prevented the membranes from being re-probed with other antibodies. 
7) I tried varying the length of time the membrane was exposed to the film, finally 
increasing to 24h exposures, which did give stronger signals than shorter exposures and 
this exposure time was then routinely used. 
8) I switched from using nitrocellulose to PVDF membranes, as these are sometimes 
suggested to be more sensitive. However, they seemed to make little difference, but 
again, in order to maximise the possibly of detecting a signal, they were continued to be 
used. 
9) I tried increasing the length of time proteins were transferred from the gel to the 
membrane using the wet transfer system from 2 to 3 hours and finally up to 4 hours to 
make sure all the protein was transferred out of the gel successfully. However, coomassie 
blue staining showed there was difference in the amount of protein that remained in the 
gel between the three different transfer times, and no difference in the signals detected, so 
the transfer time remained at 2 hours. 
10)  I started to compare the lysis buffer recipe I was using (which was the same as that used 
in cell culture experiments in our Laboratory) with those in the literature. It was 
essentially the same, except some research groups add salts to help dissolve the protein 
and glycerol to maintain a uniform concentration of the lysate when frozen. Salts and 
glycerol were then routinely added to the lysis buffer. 
11)  I tried using sonication following homogenisation to ensure the biopsy had completely 
gone into solution. This made no difference and was removed from the protocol. 
12) The length of time the muscle homogenate was incubated in the lysis buffer was 
increased from 30 to 60 and finally to 90 minutes, and instead of incubating it on ice, the 
tubes were rotated in the cold room. After this modification and the improved lysis buffer 
recipe, the lysates did appear to be more translucent and to contain less insoluble 
material. 
13)  Some research groups use the semi-dry transfer method, and this was tried following the 
modifications made in point 12. This method did seem to give a better transfer and the 
wet transfer system was no longer used. 
14)  I changed the blocking agent from 5% milk powder to 5% Bovine Serum Albumin 
(BSA), but this resulted in a high background and was no longer used. 
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15)  I then applied to the Loughborough University Ethical Advisory Committee to run a 
healthy volunteer study to obtain muscle biopsies from healthy individuals, in which 
phosphorylation signals should be detectable. If I could see a signal, then I could be sure 
that the lack of a detectable signal in the biopsies from CKD patients was the correct 
result and it was not simply the result of technical difficulties. A signal was detectable, so 
it was concluded that there is simply very little phosphorylation of rpS6 in these patients.  
 
This low phosphorylation signal was also found to be the case for P-4E-BP1 and P-P70SK6, but 
phosphorylation of PKB could be seen. 
The protocol described in Section 2.5 was used in the Western blotting experiments for 
phosphorylated proteins described in this thesis. 
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Appendix A 
Solutions and Reagents 
 
 
Folin Reagent A (1 Litre) 
20g Anhydrous Na2CO3 
4g NaOH 
0.2g K,Na-tartrate. 4H2O 
Ultra pure water up to one litre 
 
Folin Reagent B (1 Litre) 
5g CuSO4.5H2O 
Ultra pure water up to one litre 
 
UIC3 Protease Inhibitor Cocktail (100ml) 
8.55g Sucrose 
0.47g Hepes 
0.032g Sodium Azide 
0.076g EGTA 
Adjust to pH 7.4 with 0.5M NaOH 
Ultra pure water up to 100ml  
20 µl PMSF (25mg) 
14.2µl E64 (5mg) 
13.7µl Pepstatin A (5mg) 
9.5µl Leupeptin (10mg) 
 
SDS-PAGE Muscle Lysis Buffer (10ml) 
0.08g NaCl 
0.002g KCl 
0.002g MgCl2 
500µl Tris 1M pH 7.5 
20µl Ethylenediaminetetraacetic acid (EDTA) 0.5M pH 8 
250µl Ethylene glycol tetraacetic acid (EGTA) 40mM 
800µl Glycerol 
1ml 10% Triton X-100 
100µl β-Glycerophosphate 1M 
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1.18ml Sodium Orthovanadate 8.5mM 
1ml Sodium Fluoride 500mM 
10µ β-Mercaptoethanol 
5.09ml ultra pure water 
 
SDS-PAGE L6 Lysis Buffer (10ml) 
500µl Tris 1M pH 7.5 
20µl Ethylenediaminetetraacetic acid (EDTA) 0.5M pH 8 
250µl Ethylene glycol tetraacetic acid (EGTA) 40mM 
1ml 10% Triton X-100 
100µl β-Glycerophosphate 1M 
1.18ml Sodium Orthovanadate 8.5mM 
1ml Sodium Fluoride 500mM 
10µ β-Mercaptoethanol 
5.89ml ultra pure water 
 
Laemelli Reducing Sample Buffer 
4ml Ultra pure H2O 
1ml 0.5M Tric HCL pH 6.8 
0.8ml Glycerol 
1.6ml 10% w/v Sodium Dodecyl Sulphate (SDS) 
0.4ml β-Mercaptoethanol  
0.2ml 0.05% w/v Bromophenol Blue 
 
10X Running Buffer (1 Litre) 
30.3g Trizma Base    
144g Glycine    
100ml 20% SDS   
Ultra pure water to one litre 
 
1X Running Buffer (1 Litre) 
100ml 10X Running buffer   
900ml Ultra pure water   
 
10X Transfer Buffer (1 Litre) 
30.3g Tris-Base  
144g Glycine    
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Ultra pure water to one litre 
 
1X Transfer Buffer (1 Litre) 
100ml 10X Transfer Buffer    
200ml Methanol    
100ml 10% SDS 
Ultra pure water to one litre  
Blue 
 
10X TBS 
60.55g Trizma base   
87.66g NaCl    
Ultra pure water to 700ml 
pH to 7.6 using 6M HCl 
Ultra pure water to one Litre 
 
1X TTBS + 0.1% tween (1 Litre) 
100ml 10X TBS   
Ultra pure water to one litre 
1ml Tween 20 
 
RNA Gel Loading Sample Buffer 
50% Glycerol 
10mM Tris 
1mM EDTA 
Bromophenol blue 0.05% w/v to give a readily detectable colour 
DNA Sample Buffer 
0.25% Bromophenol Blue 
15% Ficoll (Type 400) in Water 
 
 
HBS 
140mM BaCl 
20mM Hepes Acid 
2.5mM MgSO4. 7H2O 
5mM KCl 
1mM CaCl2. 2H2O 
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10mg/l Phenol red 
Adjust to pH 7.4 with 0.5M NaOH 
 
Pre-hybridisation Solution 
5 ml Formamide   
2.5ml 20X SSPE   
1ml 50X Denhardt’s solution 
0.5ml 20% SDS w/v   
1ml DEPC Water   
200μg/ml Salmon sperm DNA  
Warm to 42˚C prior to use. 
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Appendix B 
Methods Development 
No protocols were set up in the Laboratory for working with skeletal, and for western blotting in 
particular, a great deal of methods development had to be done to get the assay working 
effectively. Below is a step by step description of this process. 
1) I started by practicing the protocol described by Karlsoon et al. (2004) on rat skeletal 
muscle to determine the phosphorylation status of P-rpS6, P-PKB, P-P70S6K, and P-4E-
BP1. Westerns were run with 30μg protein, the amount of protein routinely loaded onto 
the gels in our Laboratory when running cell culture lysates. These Westerns worked 
well. 
2) Professor Ron Maughan kindly taught Dr Kosmadakis the biopsy technique and in the 
process provided myself with some human skeletal muscle to continue methods 
development with. Initially, all Westerns were run for P-rpS6 with the aim of setting up 
this western first. I repeated the protocol that had obtained good results in rodent muscle, 
but there was only a very faint signal detectable in healthy human skeletal muscle. 
3) The amount of protein loaded onto the gel was increased to 100μg protein and gave a 
better signal than 30μg. This was then increased to 150μg, which gave no improvement 
over 100μg. 
4) Two patients withdrew very early on in the study, but allowed their baseline samples to 
be used in methods development. The protocol was repeated with 100μg and then 150μg 
protein, but no signal was detectable. As a result of this, 150μg protein was routinely 
loaded onto the gel to maximise the possibility of detecting a signal with further 
modifications. 
5) It was decided to always run a positive control on the same gel as the muscle samples to 
ensure that the lack of a signal was not due to a technical failure of the Western. L6-
G8C5 cells stimulated with insulin served as the positive control and a volume containing 
10μg protein was loaded onto the gel. (A reduced amount of protein was used here 
because the length of time the membrane was exposed to the film meant that anything 
more than 10μg resulted in a very large overexposed band.) 
6) The effect of using a signal enhancer reagent and an antibody extender from Thermo 
Scientific was tested. Due to cost reasons it was decided to use the signal enhancer 
reagent, but this was later removed from the protocol as it made little difference and 
prevented the membranes from being re-probed with other antibodies. 
7) I tried varying the length of time the membrane was exposed to the film, finally 
increasing to 24h exposures, which did give stronger signals than shorter exposures and 
this exposure time was then routinely used. 
8) I switched from using nitrocellulose to PVDF membranes, as these are sometimes 
suggested to be more sensitive. However, they seemed to make little difference, but 
again, in order to maximise the possibly of detecting a signal, they were continued to be 
used. 
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9) I tried increasing the length of time proteins were transferred from the gel to the 
membrane using the wet transfer system from 2 to 3 hours and finally up to 4 hours to 
make sure all the protein was transferred out of the gel successfully. However, coomassie 
blue staining showed there was difference in the amount of protein that remained in the 
gel between the three different transfer times, and no difference in the signals detected, so 
the transfer time remained at 2 hours. 
10)  I started to compare the lysis buffer recipe I was using (which was the same as that used 
in cell culture experiments in our Laboratory) with those in the literature. It was 
essentially the same, except some research groups add salts to help dissolve the protein 
and glycerol to maintain a uniform concentration of the lysate when frozen. Salts and 
glycerol were then routinely added to the lysis buffer. 
11)  I tried using sonication following homogenisation to ensure the biopsy had completely 
gone into solution. This made no difference and was removed from the protocol. 
12) The length of time the muscle homogenate was incubated in the lysis buffer was 
increased from 30 to 60 and finally to 90 minutes, and instead of incubating it on ice, the 
tubes were rotated in the cold room. After this modification and the improved lysis buffer 
recipe, the lysates did appear to be more translucent and to contain less insoluble 
material. 
13)  Some research groups use the semi-dry transfer method, and this was tried following the 
modifications made in point 12. This method did seem to give a better transfer and the 
wet transfer system was no longer used. 
14)  I changed the blocking agent from 5% milk powder to 5% Bovine Serum Albumin 
(BSA), but this resulted in a high background and was no longer used. 
15)  I then applied to the Loughborough University Ethical Advisory Committee to run a 
healthy volunteer study to obtain muscle biopsies from healthy individuals, in which 
phosphorylation signals should be detectable. If I could see a signal, then I could be sure 
that the lack of a detectable signal in the biopsies from CKD patients was the correct 
result and it was not simply the result of technical difficulties. A signal was detectable, so 
it was concluded that there is simply very little phosphorylation of rpS6 in these patients.  
 
This low phosphorylation signal was also found to be the case for P-4E-BP1 and P-P70SK6, but 
phosphorylation of PKB could be seen. 
The protocol described in Section 2.5 was used in the Western blotting experiments for 
phosphorylated proteins described in this thesis. 
 
 
